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ABSTRACT

ABSTRACT
Food poisoning incidences relating to marine biotoxins are a global phenomenon and have
the potential to severely impact the aquaculture industry. As a result, and as a legislative
requirement in the European Union (EU), many countries have implemented monitoring
programmes for these compounds but their success relies on the availability of certain quality
assurance tools, two of which are reference materials (RMs) and proficiency testing. The
limited amounts of RMs, in particular matrix certified reference materials (CRMs) for
paralytic shellfish poisoning (PSP) toxins has been a limiting factor in the implementation of
alternatives to the mouse bioassay for routine monitoring programmes. Various stabilisation
procedures were investigated to ascertain the applicability of each for preparing RMs for
various uses including internal QA/QC, proficiency testing and as candidates for certification.
The beginning of these studies coincided with a large PSP toxic event in Icelandic waters.
During that period mussels from two production sites on the north and north-west coasts of
Iceland accumulated PSP toxins to levels many times over the EU regulatory limit. Mussels
sampled during this period were characterised and presented along with phytoplankton data
from the same period and presented as a first report of PSP toxins from Icelandic waters.
Large quantities of naturally contaminated mussel tissues were harvested during this period
for use in these studies.
Various stabilisation procedures were investigated, such as thermal treatment, the use of
preserving additives, high pressure processing (HPP) and freeze drying, for their applicability
in preparing RMs for PSP toxins. Extensive characterisation of the materials was performed
through homogeneity and short and long-term stability studies using two LC-FLD methods to
evaluate each technique in reducing levels of degradation, biotransformations or
epimerization. Freeze drying proved the most effective technique evaluated and this
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procedure was used to prepare RMs in two shellfish species, Pacific oyster (Crassostrea
gigas) and blue mussels (Mytilus edulis). The technique improved the stability of all toxins
assessed compared to untreated controls. A successful feasibility study was carried out in a C.
gigas matrix which resulted in the production of a medium scale RM as a candidate CRM.
Certification of this material was not carried out during the course of these studies however.
Although freeze drying proved the most effective in stabilising both the tissue matrix and the
PSP toxins themselves, the labour intensive nature of the procedure as well as the significant
per unit production costs led to alternative RM techniques being investigated. HPP of a C.
gigas tissue matrix was performed and it provided an extremely effective technique for
stabilising the toxins through a reduction of microbial activity. Stability studies showed the
technique reduces or eliminates toxin degradation and epimerisation compared to untreated
control materials with the technique potentially having applications in CRM development,
although a full feasibility study was not conducted.
The use of heat treatment and preserving additives provided the simplest and most cost
effective stabilisation procedure investigated with both techniques, particularly when
combined, improving toxin and matrix stability compared to untreated controls. Each
technique was evaluated separately and combined in one tissue matrix, M. edulis and
applications for materials prepared by this procedure were examined. Combining the use of
preserving additives with a thermal pre-treatment step provided sufficiently stable and
homogenous RMs which were used as an internal QA/QC tool in the Irish National
Monitoring Programme (NMP) and in proficiency testing (PT) schemes operated by
QUASIMEME and VEREFIN.
Data from a RM prepared by the combined techniques above and used in the Irish NMP over
a two year period provided evidence for the long-term stability of the material using a
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classical stability model and was used to calculate an expanded uncertainty of measurement
for the method used for official control purposes at the Marine Institute.
Materials prepared by these combined techniques were also used to develop the first
commercially available PT scheme for PSP toxins. Data is presented from the first six years
of this development exercise from participants using a wide array of methodologies. Data
showed the improvement of participants over this period but found statistical differences in
the datasets of both LC-FLD methods employed by some subscribers in determining dcSTX
and GTX2,3. A material was also prepared for use in a separate PT scheme operated by
VEREFIN which highlights the wide applicability of these RMs.
The techniques investigated during these studies have multiple applications in method
development, as QA/QC tools, in CRM preparation and in proficiency testing schemes.
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Chapter 1
BACKGROUND AND OBJECTIVES
1.1

HARMFUL ALGAL BLOOMS, BIOTOXINS AND SHELLFISH POISONING

Phytoplankton are microscopic, single-celled plants that can grow in both marine and
freshwater environments, providing a critical food supply for filter feeding bivalve shellfish
such as mussels, oysters, clams and scallops. There are approximately 5000 known species of
marine phytoplankton, a small proportion of which, less than 2%, can produce toxins that can
find their way through the food chain to humans [1]. Dense concentrations of these cells can
manifest as Harmful Algal Blooms (HABs), frequently referred to as “red tides”.

Accumulation
Production

Marine biotoxins
Filter-feeding bivalves
Food
poisoning

Processing,
cooking etc.

Phytoplanctonic cells

Figure 1-1: From phytoplankton to food poisoning.

Phytoplankton are a vital food source for filter feeding bivalve shellfish such as mussels,
oysters, clams and scallops. Biotoxins can accumulate in the flesh of shellfish through filter
feeding of toxin producing phytoplankton species, with the highest toxin concentrations
generally found in the digestive gland (hepatopancreas) of the shellfish (Figure 1-2) [2].
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Figure 1-2: Internal anatomy of a mussel.

There are approximately 2000 cases of human poisoning reported each year through the
consumption of fish and shellfish and results in an approximate 15% mortality rate. Impacts
on public health and potential economic damage through reduced consumption and
exportation can therefore be extensive [3]. Whilst the shellfish generally remain unaffected
following accumulation of these phycotoxins, human consumption of contaminated seafood
products can lead to a variety of symptoms experienced after as little as 30 minutes, and can
include nausea, vomiting, abdominal pain, diarrhoea, memory loss, paralysis and in extreme
cases death.
There are 5 internationally recognised syndromes of shellfish poisoning, namely:


Paralytic Shellfish Poisoning (PSP)



Amnesiac Shellfish Poisoning (ASP)



Diarrhetic Shellfish Poisoning (DSP)



Azaspiracid Shellfish Poisoning (AZP) and



Neurotoxic Shellfish Poisoning (NSP)

The research undertaken in these studies was on the PSP group of biotoxins.
2

Chapter 1

1.2

HYDROPHILIC BIOTOXINS

1.2.1 PARALYTIC SHELLFISH POISONING (PSP)
PSP is caused by a group of closely related compounds all based on a tetrahydropurine
skeleton (Figure 1-3), with saxitoxin (STX) being the parent toxin and the first to be isolated
in this group [4,5].

OCONH2:
6
7

1

8
2

9

3

OCONHSO3-:

12
11

Figure 1-3: Structure of the principal PSP toxins.
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These potent neurotoxins are mainly produced by marine dinoflagellates, in particular,
Alexandrium spp. (Figure 1-4), Gymnodinium catenatum and Pyrodinium bahamense var.
compressum [6] but have also been found to be produced by some freshwater cyanobacteria
[7,8].
Saxitoxin and its congeners differ substantially in their toxicity (Table 1-1) and can be
categorised into several subgroups based on their substituent sidechains, the most important
of which are the carbamoyl, decarbamoyl and N-sulfo-carbamoyl groups (Figure 1-3).
Saxitoxin is an inhibitory neurotoxin which has a high affinity for binding site 1 of the
voltage-gated sodium ion channel in mammalian nerve cells, thus inhibiting conductance of
signals along the neuron [9].

Depending on the dose, symptoms can include tingling

sensation or numbness around the lips, face, neck and extremities, headache, dizziness,
nausea, vomiting, diarrhoea, muscular paralysis, respiratory difficulties and in severe cases
death through respiratory paralysis [10]. Shellfish contaminated with PSP toxins pose severe
risks to human consumers and numerous accounts of intoxications leading to illness or death
have been recorded from around the world [11–15].

10µm l

20µm

Figure 1-4: Alexandrium tamarense using a) fluorescence in situ hybridisation (FISH) probes and b) calcofluor white
staining using a compound microscope with epi-flourescence microscopy (Olympus BX53, 100Mag).
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STX comprises a 3,4-propinoperhydropurine tricyclic system together with two guanidino
functional groups, which account for its high polarity and is soluble in water, methanol and
ethanol but not in other organic solvents [4]. Paralytic Shellfish Toxins (PSTs) are prone to
pH dependent conversions, are heat stable under mildly acidic conditions with the exception
of the N-sulfo-carbamoyl toxins and are readily oxidised under alkaline conditions [16]. The
N-sulfo-carbamoyl toxins such as GTX5 and C1,2 may be partially converted to the
corresponding carbamate group toxins through hydrolysis if heated at low pH. These
conversions can take place when PSTs are boiled with a strong acid such as HCl and can
result in STX analogues with lower toxicity factors being chemically converted into ones
with higher toxicities. Conversions do not take place in weak acids such as acetic acid even
under boiling conditions [6].

Table 1-1: Toxicity equivalency factors (TEFs) of the principal PSP toxins.

Toxin
STX
GTX2
GTX3
NEO
GTX1
GTX4
GTX5
C1
C2
C3
C4
GTX6
dcSTX
dcGTX2
dcGTX3
dcNEO
11-hydroxy-STX

Toxicity Equivalency Factors
Oshimaa
EFSAb
1.00
1.00
0.36
0.40
0.64
0.60
0.92
1.00
0.99
1.00
0.73
0.70
0.06
0.10
0.01
0.10
0.10
0.01
0.06
0.10
0.06
0.10
0.51
1.00
0.15
0.20
0.38
0.40
0.40
0.30

a TEFs calculated based on relative potency data by Oshima et al. [17].
b TEFs proposed by the CONTAM panel (EFSA) [6].
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STX-group toxins, also referred to as PSTs are not detectable by either UV or fluorescence
owing to the lack of a chromophore. They therefore require alkaline oxidation into
fluorescent imino purine derivatives for detection [6].
The first recorded fatal incidence of shellfish poisoning occurred in 1793 during Captain
George Vancouver’s expedition into British Columbia. Upon landing in an area now known
as Poison Cove, shellfish were collected by some of his crew for breakfast. This toxic
banquet resulted in the death of one crew member five and a half hours after ingestion and
severe PSP like symptoms experienced by four others; although they subsequently made a
full recovery [18]. STX producing algae have been found to occur worldwide in both tropical
and moderate climate zones [6], with detection of phytoplankton and contaminated shellfish
tissues confirmed throughout regions of Europe, the Americas, Asia, Africa and Australasia.
The EU regulatory limit for PSTs is set at 800 micrograms per kilogram (800 µg/kg) [19] and
the reference method is the mouse bioassay (MBA) [20]. A named alternative to the MBA,
the so called “Lawrence method”, was first cited in EU legislation in 2006 [21] which is
based on high performance liquid chromatography with fluorescence detection (LC-FLD).

1.2.2 AMNESIC SHELLFISH POISONING (ASP)
Domoic acid (DA) (Figure 1-5), the amnesic shellfish poisoning toxin, belongs to a group of
amino acids called the kainoids. They are classified as neuroexcitants or excitotoxins as they
interfere with neurotransmission mechanisms in the brain [22].

Figure 1-5: Structure of domoic acid.
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The toxin can be accumulated in shellfish feeding on a number of toxic Pseudo-nitzschia
diatom species. Consumption of shellfish contaminated with ASP toxins can lead to
intoxication with symptoms including, abdominal cramps, nausea, vomiting, diarrhoea,
decreased reaction to deep pain, disorientation, hallucinations, confusion, short-term memory
loss (amnesia) and seizures [23].
The EU regulatory limit is set at 20 milligrams of domoic acid per kilogram (20 mg/kg) [19]
and the reference method [20] is based on that published by Quilliam et. al., in 1995 for the
quantitative determination of domoic acid in unsalted seafood [24].

1.3

LIPOPHILIC BIOTOXINS

1.3.1 DIARRHETIC SHELLFISH POISONING (DSP)
The class of toxins causing DSP includes okadaic acid (OA) and the dinophysistoxins DTX1,
DTX2 and DTX3 (Figure 1-6). The first documented occurrence of DSP was in 1976 in
Japan where numerous intoxications were reported [25].

Toxin

R1

R2

R3

OA

CH3

H

H

DTX1

CH3

CH3

H

DTX2

H

H

CH3

Figure 1-6: Structure of the OA group toxins.

DSP is caused by certain Dinophysis and Prorocentrum species and has a worldwide
geographical distribution [2]. No deaths have ever been attributed to DSP with patients
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generally recovering within three days from symptoms which may include nausea, vomiting,
diarrhoea and abdominal cramps [3]. In addition the polyether toxins OA and DTX1 may
promote stomach tumours [26].
For many years, the EU reference method for the regulatory testing of DSP toxins was a
qualitative rodent-based assay [19,20], usually implemented as a mouse bioassay (MBA). As
of the 1st January 2015 the EU reference method was changed from the MBA to a liquid
chromatography-mass spectrometry (LC-MS/MS) method as described by the EU- reference
laboratory for marine biotoxins (EU-RLMB) [27]. The method must be capable of detecting
at least OA, DTX1, DTX2, DTX3 and their esters and the EU regulatory limit is set at 160
micrograms of okadaic acid equivalents per kilogram (160 µg/kg) [19].

1.3.2 AZASPIRACID SHELLFISH POISONING (AZP)
Azaspiracids (AZAs)(Figure 1-7) are a recently discovered class of shellfish toxin, first
implicated in human poisoning in 1995 in the Netherlands through consumption of mussels
originating from Killary Harbour, Ireland [28]. Seven official poisoning incidents attributed
to AZP have been reported to date with all originating from shellfish harvested in Ireland
[29].
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Figure 1-7: Structure of the AZA group toxins.

The first causative organism of AZP was only recently discovered in 2009 and named
Azadinium spinosum [30], with many more Azadinium and related species being subsequently
discovered [31]. Symptoms are similar to those described for DSP and include nausea,
vomiting, abdominal cramps and diarrhoea and no deaths have been attributed to AZP [28].
As in the case of the DSP group toxins described above, the reference method in the EU for
AZAs is the EU-RLMB LC-MS/MS method which must be capable of detecting at least
AZA1, AZA2 and AZA3 [27]. The regulatory limit in the EU is 160 micrograms of
azaspiracid equivalents per kilogram (160 µg/kg) [19].

1.3.3 YESSOTOXINS (YTXS) AND PECTENOTOXINS (PTXS)
Neither YTX nor PTX toxins have been implicated in shellfish poisoning in humans to date
and there has been much debate on the toxicity of both groups with evidence showing PTXs
(Figure 1-8) to be of no risk to humans [32] and the oral toxicity of YTXs (Figure 1-9) to be
extremely low compared to its intraperitoneal toxicity [33].
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Toxin

R1

PTX1

CH2OH

PTX2

CH3

Figure 1-8: Structure of the PTX group toxins.

Both groups are named after the genus of scallop they were first isolated from, Patinopecten
yessoensis [34,35] and the reference method in the EU for their detection is the EU-RLMB
LC-MS/MS method described above [27].

Figure 1-9: Structure of yessotoxin.

The regulatory limit in the EU is set at 160 micrograms of okadaic acid equivalents per
kilogram for PTXs (160 µg/kg) [19]; owing to their general co-occurrence with DSP group
toxins, and at 3.75 milligrams of YTX equivalents per kilogram (3.75 mg/kg) [36]. The
causative organisms of PTXs are Dinophysis and Protoperidinium species and YTXs are
caused by Lingulodinium polyedrum and Protoceratium reticulatum [34,35].
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1.4

IRISH SHELLFISH INDUSTRY AND IMPACTS OF HABS

Azaspiracids are the most problematic toxin group in terms of farm closures for the Irish
shellfish industry and they have been detected every year since the inception of the biotoxin
monitoring programme in 2001 (Figure 1-10) [31]. Shellfish farm closures have occurred
every year except 2004, due to AZP toxicity over the EU regulatory limit. Toxicity typically
occurs in the mid to late summer months with those sites affected sometimes remaining
closed for long periods due to the apparent slow depuration rates of these toxins from
shellfish [37]. Ireland is the worst affected country for AZAs with Norway and the UK being
the only other countries to report AZA levels over the EU regulatory limit. There have been
seven official poisoning incidents associated with AZA toxins reported to date but numerous
others have also been linked to this toxin group, with the source of all incidents traced back to
shellfish harvested in Ireland [29].
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Figure 1-10: Shellfish farm closures from 2012-2014 caused by DSP and AZP toxins.
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DSP is caused by the OA-group toxins and they represent the next most problematic for the
Irish shellfish industry causing significant economic hardship to shellfish farmers due to toxin
related farm closures. They have been detected in various shellfish species in Ireland since
2002. Toxicity typically occurs during the early to mid-summer months from Dinophysis
acuta or Dinophysis acuminata blooms producing OA and DTX2 predominantly [38].
Depuration rates of OA-group toxins are faster than AZAs but both toxin groups regularly cooccur in Irish shellfish which compounds the problem for farmers [38]. PTXs have only
recently been detected in Irish shellfish (since 2014), although regular monitoring of this
toxin group has only been in effect since 2011. YTXs have never been detected in any Irish
shellfish species to date.
Another problematic toxin group, although impacting far less is ASP caused by DA. Until
recently scallops were the only species to be monitored year round for DA with levels in the
main edible parts (posterior adductor muscle and gonad) rarely rising above the regulatory
limit of 20 mg/kg, although it takes a long time for DA to depurate from scallops [39].
During large blooms of the causative organism, Pseudo-nitzchias, other species are regularly
tested for this toxin group. Levels in these other species, mainly mussels can rise many times
above the regulatory limit within a couple of weeks but fortunately toxicity quickly subsides
due to apparently quick depuration rates.
PSP toxins have not been problematic for the Irish shellfish industry to date with only one
location in the South of the country, Cork Harbour experiencing shellfish harvesting area
closures as a result of PSTs over the EU regulatory limit of 800 µg/kg STX equivalents.
Monitoring of PSP was carried out using the MBA [40] until 2011 at the Marine Institute
(MI), after which a pre-column oxidation (preCOX) liquid chromatography with fluorescence
detection (LC-FLD) method also called the “Lawrence method” resulting in AOAC Official
Method (OM) 2005.06 was used [41].
13
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2012
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Figure 1-11: Locations where PSP toxins have been detected in shellfish 2012-2014.

Since the implementation of this method PSTs have been detected, albeit at low levels, in
other locations along the west coast of Ireland (Figure 1-11). It is unclear whether the
occurrence of these toxins in other locations is due to the spread of the toxin producing algal
14
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species or, as is more likely, their detection is due to the improved sensitivity the preCOX
LC-FLD method provides in comparison with the PSP MBA. The causative organism for
PSP toxins in Irish waters are the Alexandrium species tamarense and minutum, which
produce a toxin profile consisting predominantly of the gonyautoxins 2 & 3 (GTX2,3) as well
as saxitoxin (STX). In samples close to or above the regulatory limit the gonyautoxins 1 & 4
(GTX1,4) are also typically detected. Toxin accumulation in shellfish from Cork Harbour is
very predictable with the onset of toxin uptake typically taking place during the first two
weeks of June each year. Toxin levels quickly rise to concentrations around the regulatory
limit or above but drop within a couple of weeks, although very low levels of GTX2,3 can
typically be detected for many months thereafter. Although Alexandrium species are detected
in phytoplankton samples all along the West coast of Ireland, particularly during the summer
months, toxin levels in shellfish remain low. This is thought to be because both toxic and
non-toxic variants of Alexandrium exist in Irish waters with the non-toxic variant
predominating outside Cork Harbour at present [42].

1.5

EU REGULATORY FRAMEWORK

There have been a number of EU Directives and Regulations relating to the production and
placing on the market of live bivalve molluscs for human consumption. Two underlying
Council Directives played an important role in setting out the goals to be achieved by a
Member State (MS). First, Council Directive 91/492/EEC, last amended by Council Directive
97/79/EC, which laid down the health conditions for the production and the placing on the
market of live bivalve molluscs and second, Council Directive 86/609/EEC which related to
the protection of animals used for experimental or other scientific purposes [43–45].
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In 2004 Council Regulations (EC) 853/2004 and 854/2004 were passed into law which
brought together and replaced the existing hygiene regulations for the food sector [19,46].
Regulation (EC) No. 853/2004 lays down the maximum permissible levels of marine
biotoxins in shellfish with PSP toxins for example set at a limit of 800 micrograms (µg) per
kilogram (kg). Regulation (EC) No. 854/2004 gives the monitoring authorities in each MS
the mandate to examine live molluscs for the presence of biotoxins.
Council Regulation (EC) No. 2074/2005 amended by Regulation (EC) No. 1664/2006
indicates the recognised testing methods for marine biotoxins for the purposes of Regulations
(EC) No. 853/2004 and No. 854/2004 [20,21]. With regard to PSP toxins it follows previous
directives in establishing the biological testing method as the reference method in the EU but
for the first time lays down an alternative method that can be used for official control
purposes. The so called “Lawrence Method”, as published in the Journal of the AOAC as OM
2005.06 may also be used by MSs [41].

1.6

REFERENCE MATERIALS

The need for and use of reference materials (RMs) in the analysis of foodstuffs is necessitated
by the quality assurance requirements of official control laboratories in order to demonstrate
the adequacy of their testing methods. The definition of a RM as set down in the International
Standards Organisation (ISO) 2008 guide on the definitions of reference materials and
certified reference materials is stated as [47]:
“A material, sufficiently homogeneous and stable with respect to one or more specified
properties, which has been established to be fit for its intended use in a measurement
process.”
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The nomenclature used in the area of RM production varies, with organisations and authors
of literature using an assortment of different terms. Arguably the most important in terms of
analytical capabilities are Certified Reference Materials (CRM). The characteristics of these
materials allows the determination of the accuracy or trueness of a method providing valuable
information on the performance of methods to both laboratories and accreditation bodies.
Their effective use is highly dependent on the long-term stability of the material, so detailed
feasibility studies on candidate CRMs must be undertaken to determine any potential
degradation issues associated with the material through long-term or accelerated stability
studies. The ISO 2008 guide further defines a CRM as [47]:
“Reference material characterised by a metrologically valid procedure for one or more
specified properties, accompanied by a certificate that provides the value of the specified
property, its associated uncertainty, and a statement of metrological traceability.”

1.6.1 REFERENCE MATERIAL TYPES AND CLASSIFICATION
RMs may be categorised in a number of different ways with two distinct types described as
calibrant RMs and matrix RMs, the latter of which is dealt with in these studies [48,49]. The
primary uses of these categories of RM are for analytical instrument calibration and the
validation of entire analytical methods respectively, although they can be interchangeable.
RMs can also be categorised based on their intended use and this will form the basis for how
materials are defined herein.
These categories are described as follows [50]:
1.

Certified Reference Material (CRM):

As detailed in the definition above, a CRM must be accompanied by or be traceable to a
certificate or other piece of documentation issued by a certifying body. The material will
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have one or more property values certified by a technically valid procedure together with
uncertainty and traceability to the primary unit or standard [51].
Certification and the statistical principles involved in this process are detailed in various ISO
documents.
2.

Laboratory Reference Materials (LRMs):

These materials are generally used in the day-to-day quality control (QC) of official control
sample testing. They are extracted and analysed alongside routine samples and thereby form
one of the primary tools for the acceptance or rejection of a batch of samples. LRMs can also
serve as a powerful and significantly cheaper tool, compared to the sole use of CRMs, in the
in-house validation of a test method, particularly for parameters such as precision and
ruggedness. As these materials are typically not transported to other laboratories,
confirmation of stability under frozen conditions is usually sufficient for demonstration of
fitness for purpose, in addition to homogeneity being adequately proven [50].
3.

Interlaboratory Reference Materials (ILRMS):

The last category of matrix RMs were first defined by Hess et al. in 2007 [50] and are
intended to check the comparability of testing methods through interlaboratory exercises,
such as collaborative trials and proficiency testing. The stability of these materials during
transportation internationally to participant laboratories can be demonstrated through stability
studies using elevated temperatures to mimic adverse conditions potentially encountered
during transit. This requirement typically necessitates the use of stabilising techniques in the
preparation of these materials as well as adequate homogenisation techniques, a requirement
of any RM production procedure.
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1.6.2 PRODUCTION
The production of any RM requires a level of technical and organisational competence to
ensure the key requirements of homogeneity and stability are adequately fulfilled [52].
Chapters 4 and 5 detail the various RM preparation techniques investigated in these studies
but generically any RM procedure follows the basic key steps detailed in ISO guide 80:2014
and illustrated in Figure 1-12 [52]. This document gives guidance for the in-house
preparation of what are termed quality control materials (QCMs), a category defined by ISO
to encompass both LRMs and ILRMs.

Material
Specification

Material
Sourcing

Material
Processing

Sub-division &
Packaging

Homogeneity
Assessment

Characterisation
/ Value
Assignment

Stability
Assessment

Documentation
/ Information

Storage

Figure 1-12: Key steps in the preparation of RMs (reproduced from ISO guide 80 [52].

The specification of the RM in general is that the materials prepared should be as close as
possible to real life samples and be available in sufficient quantities. In the area of biotoxin
monitoring the large variety of shellfish species covered in these programmes means, in
general, choosing the species most frequently analysed; which in the case of the Irish NMP
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blue mussels (Mytilus edulis) are. In the area of ILRM production (described in Chapter 6) a
systematic approach was followed which sought to prepare materials from as many shellfish
species as possible, although this was dictated by the authors’ access to large enough
quantities of naturally contaminated material. Other factors to consider in the material
specification are the unit size required, an estimate of the total units required and the
preparation yield [52]. Materials can then be sourced through various means including
purchase from another organisation, collection of contaminated shellfish during toxic events,
through toxin spiking or even shellfish feeding experiments [53].
One of the most important steps in this procedure is material processing which can involve a
number of different steps aimed at ensuring appropriate homogeneity and stability for the
final materials. Stabilising the material is discussed in detail in further chapters but the
processing techniques for the wet tissue RMs, aimed at improving homogeneity, were
developed and refined by McCarron in 2007 [54]. These techniques involved the use of
various industrial blenders and grinders purchased during this period and further used during
the course of these studies.
Sub-division and particularly packaging is another important factor to consider, with
appropriate techniques having been shown to improve toxin stability. Sealing the final
product under an inert gas, for example, prevents or minimises oxidative reactions from
taking place as well as creating an environment inhospitable for microbial growth [54].
Once the material is prepared and dispensed, an assessment of its homogeneity and stability
must be undertaken in addition to RM characterisation and value assignment. Homogeneity is
determined by analysing a representative quantity of RMs from the entire production batch
with a statistical evaluation of the data. For the RMs described in this thesis this involved
calculating the coefficient of variation from the homogeneity data with comparison to
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expected levels of method variability determined through validation of the test method, below
which the RM was deemed sufficiently homogenous.
Depending on the final use of the materials, an assessment of stability in the short and/or
long-term must also be undertaken. The stability studies contained in this thesis followed a
reverse isochronous design which negates day-to-day instrumental variations through the
analysis of all samples at the end of the study in one chromatographic sequence [55]. Material
characterisation and value assignment are also important in establishing toxin profiles in the
final product, as changes can occur during the processing steps. This is particularly important
for ILRM preparation where PT organisers require the information to assess which toxins or
toxin profiles are covered by their schemes and for the preparation of LRMs under private
contract.
The last steps involve the preparation of accompanying documentation which generally
include homogeneity and stability results, material characterisation and a description of the
preparation techniques employed and the recommended storage conditions of the product
determined through stability studies.

1.6.3 STABILISATION TECHNIQUES
In terms of the stability of biological matrices, microbial or biological activity is the most
important influence to consider during preparation. Chemical activity and physical effects
from, for example light and temperature are also important influences to consider, but
microbial activity presents the biggest potential problem in RM preparation [56]. Various
procedures to stabilise the matrix and therefore the analyte(s) have been described in the
literature and the techniques used to prepare the RMs contained in this thesis are briefly
described below.
21

Chapter 1
1.6.3.1 PRESERVING ADDITIVES
The use of preserving additives to stabilise the biological matrix is a relatively easy and cost
effective technique to employ in RM production. The use of the antioxidant ethoxyquin has
been used previously in the preparation of CRMs for marine biotoxins [57–59] and its
combined use with antibiotics in the preparation of marine biotoxin RMs [54]. Their
combined use was shown to improve the stability of DA [60] and to a lesser extent AZA3
[54]. To date the combined use of these additives has not been reported for their stabilising
effects on PSTs in shellfish matrices.
As in the case of most stabilisation techniques for biological matrices the use of preserving
additives aims to reduce or eliminate biological activity and oxidative degradation from
taking place in the final product. This is particularly important given the fact that processing
and dispensing steps are not carried out aseptically in the procedures described in this thesis
so any technique aimed at reducing or eliminating bacterially induced reactions in the final
product may be beneficial.

1.6.3.2 THERMAL TREATMENT
Another relatively simple stabilisation technique is sterilization through heat treatment which
aims to destroy bacteria present in the source tissues. As this step is usually performed prior
to material processing and dispensing bacteria may still play a part in toxin stability due to
the septic nature of further processing steps. The heat treatment step should however,
significantly reduce bacteria colony numbers in the source tissues. Although the thermal
stability of the analytes must be sufficient to withstand the high temperatures applied, to
minimise degradation during this step [52].
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1.6.3.3 FREEZE DRYING
Removal of water through drying is another technique to stabilise, in particular biological
tissue matrices, improving both short and long-term stability as well as making the material
easier to handle [52]. Freeze drying is a technique ideally suited to the preparation of
thermally sensitive analytes owing to the relatively gentle freeze drying process. The process
involves the removal of water from the matrix through a process called sublimation, which is
the transition of a substance directly from the solid to the gas phase without going through the
intermediate liquid phase [61]. This transition takes place at temperatures and pressures
below the triple point of a substance, which is the temperature and pressure point where all
three phases (solid, liquid and gas) exist in thermodynamic equilibrium [61]. The process
involves reducing the pressure inside the freeze drying chamber while simultaneously
increasing the temperature slowly through a series of ramp steps, typically 96 hours in the
case of materials described herein. The removal of water reduces the likelihood of microbial
growth formation [52].
This technique has been used for many years in the area of preservation in the food industry
[56], as well as in the preparation of RMs for DA and some lipophilic toxins [62–65]. It has
also been investigated for the preparation of a CRM containing two PSTs, STX and dcSTX
[66–68]. This PST freeze dried CRM was not made commercially available and could not be
distributed by the Institute for Reference Materials and Measurement (IRMM).

1.6.3.4 HIGH PRESSURE PROCESSING
High Pressure Processing (HPP) or High Hydrostatic Pressure Processing (HHP) is a nonthermal pasteurisation technique which has been used to produce food products free from
microbial contamination for over a century [69]. The process is desirable not only for the
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potential of decontaminating the food product but also because it minimises the impact on the
nutritional and physical characteristics of the final product (Figure 1-13).

Figure 1-13: Picture of a strawberry after HPP treatment

The process generally involves subjecting the food product to pressures of between 150-600
MPa for times of 1-15 min [70]. Pressure is applied through water which surrounds the
product and allows an even distribution of pressure throughout the product.
This process applied in the area of RM preparation has the potential advantage of leaving the
final material and matrix practically intact and very close to real life samples generally
analysed in a laboratory. However, prior to the work described in this thesis, such an
approach has yet to be reported for RMs of any type.

1.6.4 HOMOGENEITY TESTING
Homogeneity is defined by ISO as the “uniformity of a specified property value throughout a
defined portion of a reference material” [47]. The level of inhomogeneity of the material
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should result in a smaller effect on the measurement result than the expected variation of the
measurement process or should be below an established criterion value [52].
In general homogeneity testing requires the selection of a sufficient number of units, which
are representative of the entire batch and the analysis of selected properties within those
units. There are two aspects to homogeneity testing, between-unit and within-unit. Withinunit homogeneity is only a requirement where the RM has been dispensed with more than
one portion, and it is essential that each portion taken yields similar results. Between-unit
homogeneity seeks to determine if differences between the various units of a batch exist and
if those differences are within acceptable limits. The RMs described in these studies were
dispensed as single portions so within-unit homogeneity was not assessed.
The number of samples taken for homogeneity testing has recently been covered in ISO guide
80:2014 [52] and two sampling guidelines are described in the document. The first approach
is to select samples from a stock comprising “n” individuals using the formula:
3(n)1/3
This approach can be excessive in the number of samples chosen, particularly when
dispensing large quantities of RMs (>1000) and therefore represents a significant analytical
effort including the associated costs involved.
The second approach which is based on studies to determine the effects of reducing the
number of units selected, concluded that in certain circumstances 10 units analysed in
duplicate was sufficient in assessing homogeneity [51]. This approach, where ≥10 units are
selected is deemed appropriate by ISO for materials used in proficiency testing schemes [71].
The use of either approach in selecting the number of units to be assessed is highly dependent
upon the sampling approach taken, i.e. the selections are representative of the entire
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production batch. The best way of ensuring representativeness is through stratified random
sampling. This involves dividing the total population into smaller groups known as strata,
from which simple random sampling or systematic sampling is applied to each stratum.

1.6.5 STABILITY TESTING
Stability is defined in ISO guide 30:2015 as the “characteristic of a reference material, when
stored under specified conditions, to maintain a specified property value within specified
limits for a specified period of time”.
The stability and homogeneity of a RM are arguably the two most important factors to
consider when preparing these materials. Depending on the final use of the material, different
approaches to stability testing can be performed. For example if transportation of the RM is
not required, such as an LRM for sole internal use at one site, then short-term stability testing
would not be necessary and an assessment of its long-term stability would be sufficient.
Where international dispatch of the materials may be required, such as the preparation of
ILRMs, an assessment of the short-term stability is necessary as these materials need to be
stable during potentially adverse transportation conditions. As RMs are often prepared in
large enough quantities to enable their use over a number of years, a long-term stability
assessment is necessary to determine storage conditions.
There are two main approaches in assessing the stability of the RM, classical and isochronous
stability studies [55]. The “classical” model involves the analysis of materials, stored at
various temperatures, and at pre-defined times during the course of the study. As analysis is
carried out on different days, this model is highly dependent upon the long-term
reproducibility of the method as well as its repeatability.
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An alternative approach described by Lamberty et al. in 1998 [55] sought to negate these
reproducibility issues through an isochronous experimental design, which can be used when
the total duration of the study is known. This design can have two main formats, isochronous
and reverse isochronous measurements. In the standard isochronous design the required
amount of materials are transferred to the various storage conditions at the beginning of the
study. After specific time periods during the study, materials are transferred from the storage
conditions to a reference storage temperature where stability is assumed. This format relies
on the assumption that the degradation process ceases once materials are removed from the
temperature condition being investigated and stored at the reference temperature.
A reverse isochronous stability study involves transferring the required amount of materials
to the reference temperature at the beginning of the study. At specific time periods during the
study, materials are removed from the reference storage temperature and transferred to the
storage conditions being investigated.
In the case of both the isochronous and reverse isochronous stability studies, all materials are
removed from the storage conditions at the end of the study and analysed immediately. The
long-term method reproducibility is therefore inconsequential following this approach and
only method repeatability is a factor in the analysis.

1.6.6 CERTIFICATION
There are a number of technically valid approaches to certifying a reference material,
including measurement by one or more methods involving one or many laboratories. The
requirements for a CRM are that it is “characterised by a metrologically valid procedure for
one or more specified properties, accompanied by a certificate that provides the value of the
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specified property, its associated uncertainty, and a statement of metrological traceability”
[51].
Accuracy and the uncertainty of the values determined are two important aspects in the
certification process. The certified value(s) of the material presents the best estimate of the
“true” value and is not expected to differ by more than the measurement uncertainty. The
uncertainty of the measurement value should take into account errors associated with the
measurement process, such as systematic or random errors. All components of the uncertainty
should be evaluated and taken into account when calculating this value, with data generated
through the measurement process, as well as homogeneity and stability study data being used
to produce the final uncertainty of the CRM.
Measurement of the value can be carried out using a single definitive method, by two or more
independent reference methods or by a network of qualified laboratories using one or more
methods of demonstrated accuracy [51].
Certification of the RMs prepared during these studies was not carried out so the statistical
approaches involved are not discussed further.

1.7

PROFICIENCY TESTING

The use of RMs is becoming increasingly important in the area of quality assurance (QA),
particularly given the global nature of the shellfish industry. Implementing and running a
robust quality system is of the upmost importance to any monitoring system in giving
confidence to the analyst and industry as a whole. The use of proficiency testing (PT) as well
as being a legislative requirement in the EU [72,73] is a powerful QA tool at the analyst’s
disposal enabling laboratories to evaluate their results against a designated consensus.
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QUASIMEME was founded in 1992 and initially funded by the EU under a three year quality
assurance project [74]. The aim was to establish a comprehensive network of laboratories
producing demonstrably reliable chemical information while providing a holistic approach to
quality assurance.
The determination of PSP toxins was added to the QUASIMEME scope in 2009 as a
development exercise, and has been running each year since with one round organised
annually. The wide array of methods available for determining PSP toxins gives choice to the
analyst but does pose a problem to organisers of PT schemes in including as many of these
methods as possible. The most widely used methods internationally for PSP analysis are the
mouse bioassay (MBA) [40], liquid chromatography-fluorescence detection (LC-FLD) based
on pre-column oxidation (preCOX) [41] and post-column oxidation (PCOX) [75], immunobased assays (ELISA) and liquid chromatography with tandem mass spectrometry (LCMS/MS).
The Finnish Institute for Verification of the Chemicals Weapons Convention (VEREFIN),
located in the University of Helsinki was established in 1994 continuing a research project on
Chemical Weapons (CW) which had been operating since 1973. VEREFIN supports CW
disarmament, of which STX is listed in schedule 1 of the Chemical Weapons Convention
(CWC), through the development of analytical methodologies used to identify Chemical
Warfare Agents (CWA). Under the 7th EU Framework Programme for Research VEREFIN
co-ordinated the EQuATox (Establishment of Quality Assurance for the Detection of
Biological Toxins of Potential Bioterrorism Risk) project. As part of this project a PT scheme
was organised which sought to evaluate existing methodologies for the determination of STX
in real samples. A shellfish tissue RM prepared using one of the techniques described in
chapter 4 was used in this PT scheme.
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1.8

EVOLUTION OF METHODOLOGIES FOR PSP DETERMINATION

As previously stated the MBA is the reference method in EU legislation for the determination
of PSP toxins in Europe. It was first applied in the determination of PSP toxicity by Sommer
and Meyer in 1937 [76]. Subsequently the procedure underwent standardisation, culminating
in AOAC official method (OMA) 959.08 [40]. This is the reference method specified in EU
legislation [21] and involves the extraction of the shellfish homogenate tissue in dilute
hydrochloric acid followed by intraperitoneal injection of filtered extracts into replicate mice.
The time taken from injection to mouse death is recorded and the toxicity determined from a
conversion table developed by Sommer and Meyer [76]. Reported drawbacks of the method
include underestimations of total toxicity caused by high salt concentrations or the presence
of some metals in samples [10,77]. The presence of other metals, such as zinc, particularly
evidenced in oyster tissues has been reported to increase the threat of false positives [78]. The
method is also controversial in its use of large numbers of mice and in stipulating death as an
endpoint. A further drawback of the MBA is that it only provides a total toxicity value and no
information about the specific toxin profile of a sample. However, the method has been used
globally for many years and has provided an excellent preventative method for the significant
reduction of PSP intoxications worldwide.
Due to method performance concerns, ethical issues regarding animal welfare, and as a
legislative requirement to reduce, refine or replace animal based assays, an alternative
method was written into EU legislation in 2011 which is based on the oxidation of extracts
before separation and determination by LC-FLD [21]. PSP toxins do not exhibit natural
ultraviolet absorption or fluorescence and must therefore be oxidised into iminopurine
derivatives before analysis using fluorescence detection [79]. The method cited in legislation
was developed by Lawrence & Ménard, 1991 [80] and underwent international validation in
2004 before being approved as an AOAC official method in 2005 [41]. This method is based
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on a two-step acetic acid extraction followed by solid phase extraction (SPE) cleanup using
C18 reverse-phase cartridges to remove hydrophobic shellfish matrix interferences. Cleaned
extracts are then oxidised using peroxide and/or periodate reagents before separation and
analysis by LC-FLD (preCOX) to determine the qualitative or semi-quantitative presence of
toxins. Full quantitation of samples containing N-hydroxylated toxins normally requires
further sample extract clean-up using carboxylic acid ion-exchange SPE cartridges. This step
separates the samples into three fractions each containing toxins in a different overall charge
state, thereby enabling more accurate detection and quantitation of each toxin or epimeric
pair [41].
The main drawbacks of the method relate to the complex chromatographic output as well as
the lack of separation of epimeric pairs (GTX1 & GTX4, GTX2 & GTX3, C1 & C2, dcGTX2
& dcGTX3 and C3 & C4) characteristic of this toxin group. Users of this method calculate
summed toxin concentrations for each epimeric pair. Sample toxicities are estimated from the
sum of toxin concentrations, which leads to a slight overestimation as the more toxic
analogue for each epimeric pair is used to calculate total toxicity. This is in spite of the fact
that the epimer ratio in bivalve tissues typically reaches an equilibrium of 3:1 predominated
by the less toxic α-epimers (GTX1, 2) compared to the more toxic β-epimers (GTX3, 4) [81].
Pre-column derivatization can produce one to three oxidation product peaks per toxin,
leading to difficulties in determining toxin profiles and accurate quantitation. This is
particularly pertinent for samples often used in PT schemes that have either a complex toxin
profile or a profile not routinely seen by the participant’s laboratory. Another drawback of
using this method and all chemical based methods of analysis is the lack of certified reference
standards for all the PSP toxins, most notably GTX6, C3, C4, dcGTX1 and dcGTX4.
Although complex, the method has been refined and standardised since acceptance as a first
action AOAC method, and in recent years has been implemented into routine official control
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testing of shellfish in a number of countries including Ireland, UK, Portugal and New
Zealand.
Methods based on post-column derivatization were first utilised for shellfish monitoring by
Sullivan and Wekell in 1984 [82]. Further developments were described by Oshima et al. in
1989 [83] where the separation of the full suite of known PSP toxins was achieved using
three separate chromatographic conditions. A method modified from those of Oshima, 1995
[17] and Thomas et al. 2006 [84] was first published by Rourke et al., 2008 [85]. This
method underwent international validation under the protocol of the AOAC in 2010 and was
subsequently accepted as AOAC official method 2011.02 [75]. The extraction technique is
based on that of the MBA, specifically involving boiling in HCl. Partial hydrolysis of certain
PSP toxins into more toxic analogues occurs with the PCOX/MBA extraction method which,
some argue, mimics the process of digestion in the stomach thereby more accurately
reflecting sample potential toxicity [86]. The milder conditions of the preCOX extraction
method do not cause hydrolysis of the toxins, with toxin profile consequently remaining
unaffected.
A distinct advantage the PCOX method has over the preCOX is the formers ability to
separate the PSP epimers contained in this group [87]. One disadvantage with the PCOX
methods are its inability to separate certain PSP toxins (dcNEO/NEO and GTX6/GTX4)
unless a very long runtime is used [85]. OMA 2011.02 also requires two chromatographic
runs in order to separate the full suite of PSP toxins. The method has recently been adopted
into US legislation and has been implemented into official control monitoring programs
within Canada, Norway and some US states.
The use of mass spectrometry (MS) as a detection system for determining PSP toxins is
desirable, based on the high sensitivity and selectivity this technique potentially gives the
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user. Early LC-MS methods required the use of ion-pairing reagents in the mobile phase in
order to ensure adequate retention of the charged PSP species [88,89]. This, along with the
aqueous mobile phase these methods employed, led to poor ionization and signal suppression.
Dell’Aversano et al., 2005 [90] developed an LC-MS/MS method based on hydrophilic
interaction liquid chromatography (HILIC) which increased detection sensitivity compared to
previous LC-MSMS methods. Despite comparable sensitivities for the majority of toxins to
the other methods described above, the use of LC-MS/MS methods in routine monitoring and
therefore PT schemes is limited, mainly due to matrix effects problems. Recent advances in
this area were made by Boundy et al. 2015 [91] where the application of solid phase
extraction using graphitised carbon prior to LC-MS/MS analysis eliminates or significantly
reduces these matrix related issues.
A number of functional and immunological assays have been developed for PSP toxins over
the last 20 years although their use for routine monitoring purposes has been limited. This is
mainly due to the lack of information these methods provide on the toxin profile of samples,
the use and handling of radioisotopes or cross reactivity issues which may lead to false
positives or false negatives.
A receptor binding assay (RBA) was developed by Vieytes et al., in the early 90’s [92] and
was further optimised by Doucette et al. [93]. This binding competition assay uses sodium
channels isolated from rat brain membranes coated on to microtitre plates. Tritiated saxitoxin
[3H]STX competes with unlabelled STX and its derivatives for binding to the available
sodium channel receptor sites. Unbound tritiated STX is removed by filtration and bound
triated STX is quantified by liquid scintillation counting. This method has undergone
extensive single laboratory validation (SLV) and a collaborative study [94,95] and has been
accepted as an official AOAC method of analysis (OMA AOAC 2011.27) [96].
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Several cytotoxicity assays have been developed and are based on the combined effect they
exert in the presence of veratridine and ouabain on neuroblastoma cells [6]. The method,
further developed by Jellet et al. in 1992 [97] yielded unsatisfactory results in an AOAC
International collaborative study in 1999 however. A radioligand binding assay using a STX
specific receptor, saxiphilin was developed by Llewellyn et al., in the late 90’s but has not
been subjected to formal SLV or collaborative studies to date [98].
Immunological assays use antibodies to detect the toxin of concern which are raised either in
animal or cell cultures. Two formats of immunological assays have been developed for PSPs,
ELISA (Enzyme-Linked ImmunoSorbent Assays) and LFA (Lateral Flow Assays). These
methods are based on the antibodies ability to recognise and bind the toxin of interest. The
most common immunoassay technique in use for PSP testing is that of ELISA. A number of
commercial testing kits are available with one utilised within the Quasimeme PT rounds sold
under the name Ridascreen™ (R-Biopharm, Darmstadt, Germany). The high number of STX
analogues has however posed problems for developers of this and other similar ELISA
methods, with NEO and GTX-1,4 in particular exhibiting poor cross reactivity with the
Ridascreen assay [99].
The development of biosensors using biological components, such as antibodies to recognise
and bind the toxins, has advanced over the last number of years. These sensors use antibodies
as the bio-recognition component and surface plasmon resonance (SPR) as the detection
component. These methods involve the immobilisation of the toxin onto a chip. Samples are
then mixed with the bio-recognition component and are injected over the surface of the chip.
Toxins present in the sample compete with toxins on the chip for binding to the antibody
which if present change the resonance angle of the light [100]. An SPR based immunoassay
developed for PSP toxins was subjected to various validation studies but, as in the case of the
ELISA above, showed poor cross reactivity for some analogues, in particular GTX1,4 and
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dcNEO [101–104]. A multiplex SPR method has also been developed for the ASP, DSP and
PSP groups which has the advantage of detecting three toxin groups in a single test, although
their development is still at an early stage [105].
Alternative methods for PSP determination include capillary electrophoresis coupled to
ultraviolet (UV) or MS detection, although limited research has been carried out in this area
[106–111].
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1.9

RESEARCH AIMS AND OBJECTIVES

The primary aims and objectives of this research were to investigate techniques aimed at
stabilising PSTs in various shellfish tissue matrices. Each technique was evaluated for its
applicability in preparing RMs for different uses including official control monitoring in the
Irish NMP, for PT schemes operated by QUASIMEME and VEREFIN and feasibility studies
into the production of a CRM.
A further aim of this research was to characterise and present a first report of PSP toxins from
shellfish harvested in Iceland. This toxic event occurred during the initial search for PSP
contaminated materials for use in these studies.
Using one of the techniques developed during these studies, multiple materials were prepared
and used in the first commercially available PSP PT scheme operated by Quasimeme and in a
separate PT exercise organised by VEREFIN.
The major aims and objectives can be outlined as follows:


Characterise materials harvested during a large PSP toxin event in Iceland during the
summer of 2009 and present a first report including toxin profile determination
together with associated phytoplankton data.



Collect and characterise PSP contaminated material for use in these development
exercises.



Investigate various stabilisation techniques and their effects on PSTs and shellfish
tissue matrices including their applicability for RM production for various uses. The
techniques investigated included:
o Heat treatment
o Use of preserving additives (antioxidant and antibiotics)
o High Pressure Processing (HPP)
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o Freeze drying
o Combinations of the above


Assess data generated over six years of PT exercises operated by QUASIMEME to
investigate potential method dependency issues and if they relate to the analysis of
particular PSP analogues.
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MATERIALS AND METHODS
2.1

SOURCE OF TISSUES

With the levels of PSP toxins in Irish shellfish rarely rising above the EU regulatory limit (MI
unpublished data), coupled with a relatively simple toxin profile, it was necessary to source
contaminated materials from collaborators of the MI for use in the RM investigations
described in this thesis.
Table 2-1: Description of whole flesh (WF) source tissues used in the preparation of materials for the studies contained in
this thesis, including country of origin, species and toxins present as determined by preCOX LC-FLD (AOAC 2005.06).

Country
Spain
Portugal
UK
Canada
Ireland
Iceland
Norway

Species

Predominant Toxin(s) Present

Trace Toxin(s)
Present

dcSTX

GTX5 + STX

Mussel
(Mytilus galloprovancialis)
Clam
(Spisula solida)
Oyster
(Crassostrea gigas)
Mussel
(Mytilus edulis)
Mussel
(Mytilus edulis)
Mussel
(Mytilus edulis)
Mussel
(Mytilus edulis)

dcGTX2,3, dcSTX + dcNEO
GTX2,3, STX, GTX-1,4, NEO, C1,2
GTX2,3, STX, GTX1,4 + NEO
GTX2,3 + STX

GTX1,4

GTX2,3, STX + GTX-1,4
GTX2,3, STX, GTX1,4 + NEO

The beginning of this research coincided with a large PSP event in Iceland, as detailed in
Chapter 3, and a large quantity of contaminated blue mussels (Mytilus edulis) were harvested
and transported on ice to the MI. Large amounts of Mediterranean mussels (Mytilus
galloprovancialis) were harvested in Spain in 2009, after which it was discovered that PST
levels were above the EU regulatory limit. A sub-sample of the tissue material was also sent
to the MI on ice.
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The Norwegian Veterinary Institute (NVI), Canadian Food Inspection Agency (CFIA),
Centre for Environment Fisheries and Aquaculture Science (CEFAS), UK also all provided
PST contaminated shellfish with various toxin profiles as detailed in Table 2-1.

2.2

CONSUMABLES

2.2.1 CHEMICALS
All chemicals and solvents used were of analytical or HPLC grade. The deionised (DI) water
was supplied from a reverse osmosis system (Barnstead Int., Dubuque, IA, USA). Acetic acid
(HOAc), hydrochloric acid (HCl), nitric acid (HNO3), ortho-phosphoric acid (H3PO4)
ammonium formate, ammonium acetate, sodium chloride (NaCl), sodium hydroxide (NaOH),
ammonium hydroxide (NH4OH), hydrogen peroxide (H2O2), disodium hydrogenphosphate,
1M tetrabutyl ammonium phosphate, erythromycin, ethoxyquin, trichloroacetic acid (TCA)
and periodic acid (H5IO6) were purchased from Sigma-Aldrich (Steinheim, Germany).
Ampicillin and oxytetracycline were purchased from Fisher Scientific (Waltham, MA, USA).
Methanol (MeOH) and acetonitrile (MeCN) were purchased from Labscan (Stillorgan,
Ireland).

2.2.2 STANDARDS
Certified reference toxins: gonyautoxin 1 and 4 (GTX1,4), neosaxitoxin (NEO),
decarbamoylsaxitoxin (dcSTX), gonyautoxin 2 and 3 (GTX2,3), gonyautoxin 5 (GTX5), Nsulfocarbamoyl-gonyautoxin

2

and

3

(C1,2),

decarbamoylneosaxitoxin

(dcNEO),

decarbamoylgonyautoxin 2 and 3 (dcGTX2,3) and saxitoxin (STX) were obtained from the
Institute of Biotoxin Metrology, National Research Council Canada (IMB, NRCC, Halifax,
Nova Scotia, Canada).
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For preCOX analysis, the CRMs were first diluted in water (adjusted to pH 4.0 ± 0.1 with
0.1M HOAc) to prepare primary stock solutions. Further dilutions were performed in 0.1 mM
HOAc to prepare working calibration solutions. Primary and working standards were stored
following NRCC recommendations [112]. Standards were prepared in three separate mixes as
the oxidation products of some toxins co-elute. The concentration ranges and toxins
contained in each mix are detailed in Table 2-2.
For PCOX analysis, the working standards were prepared as dilutions of NRC-CRMs, in
0.003M HCl for the GTX/STX toxins and in de-ionised water (pH 5.0 ± 0.1) for the C-toxins
as described in AOAC OM 2011.02 [75]. The concentration ranges used in PCOX analysis
are detailed in Table 2-3.

2.3

METHODS OF ANALYSIS

2.3.1 AOAC OFFICIAL METHOD 2005.06

Figure 2-1: Schematic diagram of AOAC OM 2005.06 procedure.
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EXTRACTION
Tissue samples (5.0 g ± 0.1 g) were extracted twice in 50 mL polypropylene (PP) centrifuge
tubes with 3.0 mL volumes of 1% HOAc. The first extraction step was performed using a
multi-tube vortex mixer (V400 Alpha Labs, UK) for 1 min on high power, before being
placed into a boiling water bath (Grant SBB Aqua 26 plus) for 5 min. Sample tubes were
removed from the boiling water bath and placed into a basin of cold water for 5 min. Sample
tubes were then centrifuged (CR4-22 Jouan, Thermo Electron Corp., CA, USA) at 4500 rpm
for 10 min, collecting the resultant supernatant in 15 mL PP test tubes. The remaining pellet
was re-extracted using a multi-tube vortex mixer, as described above, before re-centrifugation
at 4500rpm for 10 min. The supernatants from both extraction steps were combined in the
graduated 15 mL PP test tubes and made up to 10 mL with de-ionised water.

SOLID PHASE EXTRACTION (SPE) C18
Sample clean-up was performed using Supelclean (Supelcosil, Bellefonte, PA, USA) C-18
cartridges (500 mg/3 mL), following the method described by [41]. The cartridges were
conditioned with 6.0 mL MeOH before being washed with 6.0 mL DI water. 1.0 mL of the
crude extract was loaded onto the cartridge and eluted with 2.0 mL de-ionised water into 4.0
mL PP collection tubes. The extract was then adjusted to pH 6.5 ± 0.1 (Orion pH meter,
Thermo Scientific Inc., Waltham, MA, USA) using 1M NaOH (3.99 g ± 0.01 g made up to
100 mL with DI water) before the total volume was made up to 4 mL with de-ionised water.
Aliquots were then taken for oxidation with either peroxide or periodate reagent depending
on the toxins present. The clean-up procedure was performed on an automated SPE unit
(Gilson ASPEC XL4, UK), which was previously in-house validated (data not shown) unless
otherwise stated in the analysis sections of each chapter.
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SOLID PHASE EXTRACTION (SPE) CARBOXYLIC ACID
Ion exchange clean-up was performed to fractionate the C18-cleaned extracts using
Bakerbond (J.T. Baker, Phillipsburg, NJ, USA) COOH cartridges (500 mg/3 mL) [41]. The
COOH SPE cartridges were conditioned with 10.0 mL 0.01M ammonium acetate (0.77 g ±
0.01 g ammonium acetate made up to 1 L with DI water) before loading a 2.0 mL aliquot of
the C18 SPE cleaned extract. Fraction 1 containing the neutrally charged C toxins was eluted
with 4.0 mL water and collected in a 12 mL PP tube, adjusting the final volume to 6.0 mL
with DI water. 4 mL of 0.05M NaCl (0.29 g ± 0.01 g NaCl made up to 100 mL with DI
water) were then passed through the cartridge, collecting the eluant containing the singlycharged gonyautoxins in a 4 mL PP tube, adjusting the final volume to 4 mL with DI water.
Fraction 3, containing the double-charged carbamates, was collected by eluting 5 mL of 0.3M
NaCl (1.75 g ± 0.01 g NaCl made up to 100 mL with DI water) through the cartridge and
collecting in a 12 mL PP tube, ensuring the final volume was 5 mL through adjustment with
DI water. The clean-up procedure was performed manually using a SPE manifold and pump
from Sigma-Aldrich (Steinheim, Germany).

MATRIX MODIFIER
The matrix modifier, used in the periodate oxidation of standard and sample extracts as
described in section 2.3.1 was prepared weekly. An oyster (Crassostrea gigas) WF tissue,
confirmed to be <LOD for all EU regulated biotoxins by LC-MS/MS (for lipophilic toxins),
LC-UV (for DA and epi-DA) and LC-FLD OM AOAC 2005.06 (for PSTs), was dispensed in
5 g aliquots into PP tubes before being hermetically sealed and stored at -20°C. An aliquot
was taken weekly, defrosted before being extracted, SPE C18 cleaned and adjusted to pH 6.5
according to section 2.3.1. This solution was stored at +4°C and used in the periodate
oxidations described below.
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OXIDATION
PSP toxins are not naturally fluorescent and must therefore be oxidised into a fluorescent
form prior to analysis. Two oxidation reactions could be performed on the cleaned extracts
depending on the toxin profile present in the tissue. Non-hydroxylated PSP toxins were
oxidised using H2O2 while the N-hydroxylated toxins were oxidised using a periodate
reagent. Oxidations were performed in 1.5 mL PP HPLC vials (Fisher Scientific, Waltham,
MA, USA) using calibrated pipettes and multichannel timers (Fisher Scientific, Waltham,
MA, USA).

PEROXIDE OXIDATION
250 µL of 1M NaOH was added to 25 µL 10% H2O2 in a 1.5 mL PP HPLC vial and vortex
mixed. 100 µL of the standard solution or test extract, after C18 or COOH SPE clean-up, were
added to the vial, mixed, and allowed to react at room temperature for 2 min. The reaction
was stopped by adding 20 µL glacial HOAc. 50 µL of the oxidised solution were injected
onto the HPLC system.

PERIODATE OXIDATION
The periodate oxidant was prepared daily by combining equal quantities of 0.03M H5IO6
(0.68 g ± 0.01 g H5IO6 made up to 100 mL with DI water), 0.3M ammonium formate (1.89 g
± 0.01 g ammonium formate made up to 100 mL with DI water) and 0.3M disodium
hydrogen phosphate (4.26 ± 0.01 g disodium hydrogen phosphate) made up to 100 mL with
DI water) and adjusted to pH 8.2 with 0.2M NaOH (0.79 g ± 0.01 g NaOH made up to 100
mL with DI water).
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100 µL of matrix modifier (blank toxin free C-18 cleaned oyster tissue extract) were added to
100 µL of standard or test extract, after C18 or COOH SPE clean-up, in a 1.5 mL PP HPLC
vial. 500 µL of periodate oxidant was added to the vial, mixed and allowed to react at room
temperature for 1 min. The reaction was stopped through the addition of 5 µL glacial HOAc.
50 µL of the oxidised solution was injected onto the HPLC system.

LC-FLD ANALYSIS

Figure 2-2: LC-FLD setup used for OMA AOAC 2005.06.

A Shimadzu (Kyoto, Japan) HPLC system with a fluorescence (FLD) detector (ex 340 nm,
em 395 nm) (Shimadzu RF-10AXL), cooled autosampler set to +4°C (Shimadzu SIL-20A)
and a degasser was used. The HPLC column was a reverse phase C-18 Supelcosil (150 mm x
4.6 mm, 5 µm) fitted with a C-18 Supelguard cartridge (20 mm) as recommended in the
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official method [41]. The HPLC programme followed was a slightly modified gradient
elution based on that published in AOAC 2005.06 [41] using a flow rate of 1.5 mL/min. MP
A was prepared by dissolving ammonium formate (12.62 g ± 0.01 g) in DI water before
making up to the mark with DI water in a 2L volumetric flask. MP B was prepared by
dissolving ammonium formate (6.31 g ± 0.01 g) in DI water, adding 100 mL MeCN before
making up to the mark with DI water in a 1 L volumetric flask. Both MPA and B were
adjusted to pH6.0 ± 0.1 with 0.1M HOAc (572 µL glacial HOAc made up to 100 mL with DI
water) before filtering through a 0.45 µm nylon filter.
The gradient followed was 0 - 5% MP B over 5 min, 5 - 70% B over the next 4 min, back to
0% B over 2 min, then keeping at this condition for 7 min before the next injection. PST
concentrations in sample extracts were quantified against a five-point calibration for each
toxin and were expressed in µmol/kg. The concentration range of the standards used during
these studies are contained in Table 2-2.
Table 2-2: Concentration range of standards used for OMA AOAC 2005.06 analysis.

Mix

Mix 1

Mix 2
Mix 3

Toxin
STX
dcSTX
GTX2,3
GTX5
dcGTX2,3
C1,2
NEO
GTX1,4
dcNEO

0.005
0.003
0.003
0.003
0.008
0.013
0.009
0.027
0.009

Concentration Range (µmol/L)
→
→
→
→
→
→
→
→
→

0.417
0.399
0.973
0.295
0.819
0.859
0.349
0.423
0.334

CALCULATIONS
PSTs produce between 1 – 3 oxidation products after peroxide or periodate oxidation, some
of which co-elute. Identifying toxins present in samples and therefore quantification is
complex, particularly when certain toxins are present in samples. The toxin dcSTX co-elutes
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with both dcNEO and NEO and dcGTX2,3 co-elutes with the toxins GTX1,4 so a back
calculation is required when these toxins are present in a sample together. Materials described
in these studies only contained a combination of dcSTX and dcNEO so only this back
calculation is described below.
The toxin dcSTX produces two oxidation products after both peroxide and periodate
oxidation, with the first peak after peroxide oxidation used for quantification. The toxin
dcNEO produces two oxidation products after periodate oxidation with the first peak used for
quantification. In a sample containing both toxins the first dcNEO peak also has a
contribution of dcSTX present in the sample. A set of dcSTX standards are periodate
oxidised and a calibration curve generated from the area of the first peak of dcSTX versus
dcSTX concentration. The amount of dcSTX present in the sample is known from the
peroxide oxidation of the SPE C18 cleaned extract. This value can then be used to estimate the
area of the dcSTX peak to be subtracted from the first dcNEO peak. The net area of dcNEO
is then used to calculate its concentration.
PST concentrations in samples, as described in the following chapters were calculated as
follows:
-

Response (toxin) / slope = µmol/L

-

Concentration (µmol/L) / Tissue weight x 10 (Final volume of extract) x Dilution
Factor SPE = µmol/kg
Dilution Factors:

C18 cleaned extracts - 4
COOH fraction 1 – 12
COOH fraction 2 – 8
COOH fraction 3 – 10

-

µmol/kg x 372.2 g/mol (STX Mol. Wt. HCl form) x TEF = µgSTXdiHCl-eq/kg
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The total toxicity of a sample was calculated by combining individual analogue
concentrations and is expressed in µgSTXdiHCl-eq/kg.

UNCERTAINTY OF MEASUREMENT
An expanded uncertainty of measurement (U) was calculated for OMA AOAC 2005.06
during validation studies. Data was generated through the use of an LRM (internal MI code
LRM-09-02) using OMA AOAC 2005.06 as part of the Irish National Monitoring
Programme (NMP) for marine biotoxins. An aliquot of LRM-09-02 was extracted and
analysed per batch over a two year period and the mean (996 µgSTXdiHCl-eq/kg) and
relative standard deviation (8.7%) of the total toxicity data was generated.
The uncertainty of measurement was calculated as follows:
UCM = k x C x RSD
K = Coverage Factor = 2 (@ 95% confidence assuming a normal distribution)
C = 996 µgSTXdiHCl-eq/kg
RSD = 8.7%
UCM = 2 x 996 µgSTXdiHCl-eq/kg x 0.087
UCM = 173 µgSTXdiHCl-eq/kg
UCM at 996 µgSTXdiHCl-eq/kg ± 173 µgSTXdiHCl-eq/kg
UCM at 996 µgSTXdiHCl-eq/kg ± 17.4%
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2.3.2 AOAC OFFICIAL METHOD 2011.02

Figure 2-3: Schematic diagram of AOAC OM 2011.02 procedure.

EXTRACTION
Tissue samples (5.0 ± 0.1 g) were extracted in 50 mL PP centrifuge tubes with 5 mL of 0.1M
HCl (40.0 mL of 5M HCl made up to 2.0 L with DI water. 5M HCl prepared as 413.2 mL
HCl made up to 1.0 L with DI water). The mixture was vortex mixed for 1.0 min ± 0.1 min
and the pH adjusted to pH 2-4 if necessary. The mixture was placed in a boiling water bath
for 5.0 ± 0.1 min, before being cooled in a basin of cold water for 5.0 ± 0.1 min, rechecking
the pH and adjusting if necessary. The tubes containing the material were then centrifuged at
4500 rpm for 10 min. 500 µL of the resultant supernatant were transferred to a micro
centrifuge tube, adding 25 µL 30% TCA (15.00 g ± 0.01 g TCA made up to 50.0 mL with DI
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water) to deproteinate the extract, mixed well before centrifuging at 16000 x g for 5 min.
Protein precipitation is induced by adding TCA which exposes more of the proteins
hydrophobic structure, resulting in increased precipitation. This step is necessary as proteins
could precipitate out in the reaction coil of the oxidation unit causing blockages. 20.0 ± 0.1
µL 1M NaOH were added to the supernatant, mixed well and centrifuged at 16000 x g for 5
min, before filtering through a 0.2 µm nylon disc filter into a PP HPLC vial.

LC-FLD ANALYSIS
The same LC-FLD system described in section 2.3.1 above was used for the PCOX analysis
with fluorescence detector set to ex 330 nm, em 390 nm and fitted with an automated postcolumn derivatisation unit (Pickering Laboratories Inc., CA, USA) (Figure 2-4).

Figure 2-4: LC-FLD and post column derivatisation unit setup for OMA AOAC 2011.02.
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The system was setup by connecting the LC tubing, just after the analytical column, into the
derivatisation unit. Samples pass through the unit via two mixing chambers, the first used to
oxidise the sample and the second to stop the reaction. The reactor coil (5 metres in length) is
situated between both mixing chambers and this heats the sample to 85°C. After the reaction
is stopped in mixing chamber 2 the LC tubing is plumbed back to the fluorescence detector.
The materials were analysed using two chromatographic runs as per [75], the first to
determine GTX/STX toxins and the second for the C-toxins. The HPLC columns used were a
Zorbax Bonus RP (150mm x 4.6mm, 3.5µm) fitted with a Zorbax guard cartridge (20mm) for
the GTX/STX separation and a Thermo Betabasic 8 (250mm x 4.6mm, 5µm), fitted with a
Thermo Betabasic guard cartridge (20mm) for the C-toxins. The HPLC programmes followed
were as published in AOAC Official Method 2011.02 [75].
GTX/STX analysis: MP A was prepared by adding 44.0 mL 0.5M heptane sulphonate (11.01
g ± 0.01 g heptane sulphonate made up to 100 mL with DI water) to ~ 1.8 L DI water. This
solution was mixed before adding 22.0 mL 0.5M H3PO4 (33.9 mL H3PO4 made up to 1.0 L
with DI water), adjusting the pH of the combined solution to pH7.1 ± 0.1 with concentrated
NH4OH. The solution was transferred to a 2.0 L volumetric flask, made up to the mark with
DI water before filtering through a 0.45 µm nylon filter. MP B was prepared by adding 22.0
mL 0.5M heptane sulphonate to ~ 0.8 L DI water. This solution was mixed before adding
33.0 mL 0.5M H3PO4, adjusting the pH of the combined solution to pH7.1 ± 0.1 with
concentrated NH4OH. 115 mL MeCN was added before transferring the solution to a 1.0 L
volumetric flask, making the final volume up with DI water before filtering through a 0.45
µm nylon filter.
C-toxin analysis: MP A was prepared by adding 4.0 mL 1.0M tetrabutyl ammonium
phosphate to ~ 1.8 L DI water. The pH of the solution was adjusted to pH5.8 ± 0.1 through
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the addition of 1% NH4OH before transferring to a 2.0 L volumetric flask, making up to the
mark with DI water before filtering through a 0.45 µm nylon filter.
For the GTX/STX run a flow rate of 0.8 mL/min was used and the step gradient followed was
0 – 7.9 min, 0% MP B, 8.0 – 18.5 min, 100% MP B and back to 0% MP B for 5.4 min to reequilibrate the column.
For the C-toxin analysis, a flow rate of 0.8 mL/min was used and the system was operated in
isocratic mode.

POST-COLUMN DERIVITISATION
The PCOX unit was operated at 0.4 mL/min for both the oxidant and acid solutions with the
reactor coil set to 85°C (reaction coil 5m x 0.5mm id). The oxidant solution was prepared by
adding 400.0 mL 0.5M H3PO4 to ~1.2 L DI water. 200 mL 0.05M H5IO6 (11.40 g ± 0.01 g
H5IO6 made up to 1.0 L with DI water) was added before adjusting to pH 7.8 ± 0.1 with 5M
NaOH (20.0 g ± 0.01 g NaOH made up to 100 mL with DI water). The combined solution
was transferred to a 2.0 L volumetric flask making up to volume with DI water, before
filtering through a 0.45 µm nylon filter.
The acid solution was prepared by making 101.2 mL HNO3 up to 2.0 L with DI water and
filtering through a 0.45 µm nylon filter.
PST concentrations in sample extracts were quantified against a four-point calibration for
each toxin and were expressed in µmol/kg. Total saxitoxin equivalents were calculated for
each sample as an estimation of total toxicity using the guidance described in the AOAC
official method [75].
The concentration range of the standards used during these studies are contained in Table 2-3.
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Table 2-3: Concentration range of standards used for OMA AOAC 2011.02 analysis.

Toxin
STX
dcSTX
GTX2
GTX3
GTX5
dcGTX2
dcGTX3
C1
C2
NEO
GTX1
GTX4

Concentration Range (µmol/L)
0.019
→
0.195
0.032
→
0.390
0.029
→
0.503
0.011
→
0.191
0.104
→
0.262
0.061
→
1.713
0.014
→
0.386
0.031
→
2.706
0.009
→
0.831
0.052
→
0.291
0.142
→
0.733
0.046
→
0.239

2.3.3 AOAC OFFICIAL METHOD 959.08
The method involves the acidic aqueous extraction of shellfish tissue in 0.1M HCl. Aliquots
(1 mL) were injected intraperitoneally into male albino CD1 strain mice in triplicate and
toxicity (µgSTXdiHCl-eq/kg) was calculated from median death times using Sommer’s
tables [76]. The method was standardised using an STX certified reference standard obtained
from the Institute of Marine Biosciences, National Research Council Canada (IMB, NRCC,
Halifax, Nova Scotia, Canada).

2.4

MOISTURE CONTENT DETERMINATION

2.4.1 ROTARY VACUUM METHOD
Empty 50 mL PP centrifuge tubes were weighed using a 4-place balance before adding a 1.0
± 0.1 g tissue sample into the pre-weighed tube, noting the weight of the tube and tissue
combined. The tubes were then placed into a rotary drier (Jouan, Saint Herblain, France),
dried under vacuum for 950 min on #4 heat setting. After completion of the run, the weights
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of the dried centrifuge tubes were taken and the moisture content determined by the loss
through drying as follows:
% Moisture Content = (

𝑳𝒐𝒔𝒔 𝒕𝒉𝒓𝒐𝒖𝒈𝒉 𝒅𝒓𝒚𝒊𝒏𝒈
𝑨𝒍𝒊𝒒𝒖𝒐𝒕 𝒘𝒆𝒊𝒈𝒉𝒕

) 𝒙𝟏𝟎𝟎

2.4.2 KARL FISCHER TITRATION (KFT)
Volumetric KFT measurements were carried out using an Aquamax KF Volumetric (GR
Scientific, Bedford, UK) on some of the freeze dried materials described in Chapter 5. The
method was standardised using a Fluka hydranal water standard (Sigma Aldrich, Steinheim,
Germany) with a certified water content of 10.02 mg/g ± 0.03 mg/g. The solid matrix samples
were directly added to the vessel after standardisation with Hi-Dry KF Methanol (Sigma
Aldrich, Steinheim, Germany) and titrated with a Romia one-component pyridine free KF
reagent VC5 (Sigma Aldrich, Steinheim, Germany). The solvent was changed after each
triplicate measurement.

2.5

QUASIMEME

All materials were prepared by the author and designed to test participants over a range of
concentration levels and different complexities in toxin profile composition. The materials
used were naturally contaminated with a range of PSTs and prepared following in-house
procedures to ensure homogeneity. Stabilisation of the toxins and matrices was achieved
using a combination of heat treatment and the addition of antibiotics and an antioxidant [113]
with short-term stability and homogeneity studies performed on all materials before
distribution to participants.
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Table 2-4: Materials used in QUASIMEME rounds 2009-2014 with assigned codes, predominant toxins present and
matrices.

Tissue

Rounds Used

Year

Codes Used

57

2009

QST075BT

61

2010

QST093BT

69

2012

QST132BT

2014-1

2014

Sample 1

57

2009

QST076BT

61

2010

QST095BT

69

2012

QST133BT

61

2010

QST094BT

65

2011

QST111BT

69

2012

QST134BT

2014-1

2014

Sample 2

65

2011

QST113BT

72

2013

QST152BT

2014-1

2014

Sample 3

65

2011

QST114BT

72

2013

QST154BT

F

69

2012

QST135BT

G

72

2013

QST155BT

H

2014-1

2014

Sample 4

A

B

C

D

E

Predominant Toxins Present

Matrix

dcSTX, STX, GTX5

Mytilus galloprovincialis

dcSTX, GTX2,3, GTX1,4, STX,
GTX5 & C1,2

Mytilus edulis & Mytilus
galloprovincialis

dcGTX2,3, dcSTX & dcNEO

Spisula solida

GTX2,3 & STX

Mytilus edulis

GTX2,3, STX & dcSTX

Mytilus edulis

GTX2,3, STX, GTX1,4 & NEO
GTX2,3, STX, GTX1,4 &
dcSTX
GTX2,3, STX, GTX1,4 &
dcSTX

Crassostrea gigas
Mytilus edulis
Crassostrea gigas

A total of six materials were used over the six exercises 2009-2014, with Tissues A & C
being used in four rounds (R) apiece, Tissues B & D being used in three rounds, Tissue E
used in two rounds and Tissues F, G & H used in one round only. Table 2-4 lists each of the
materials used over the 6 year period.
No standardised method protocol was provided by QUASIMEME, apart from requesting
TEFs to be used in total toxicity calculations, so participants were allowed to use either the
analytical method routinely employed at their laboratories or any other method applicable to
PST testing. In 2009 (R57) and 2010 (R61), the TEFs included in the protocol for use by
participants in calculating total toxicity were those determined by Oshima et al. [17], while in
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subsequent rounds 2011 (R65), 2012 (R69), 2013 (R72) and 2014 (R2014-1) TEFs
recommended by the EFSA [6] were prescribed in the protocol (see Table 1-1).
Data submitted by participants depended on which method was employed at their laboratory,
with all submitting a total toxicity result such that all methods could be assessed together
(Table 2-5). Participants using either the preCOX, PCOX or LC-MS/MS methods of analysis,
where individual analogue concentrations can be determined, could additionally submit these
results, such that a data assessment and therefore z-scores could be calculated in addition to
the total toxicity results. This allowed participants receiving less than satisfactory z-scores to
pinpoint potential causes if they related to the determination of a particular analogue.
Table 2-5: Breakdown of methods used by participants in each of the rounds 2009-2014.

Methods Used
preCOX

PCOX

MBA

ELISA

LC-MS/MS

Total Number of
Participants

57

8

2

4

-

-

14

2010

61

9

5

2

-

-

16

2011

65

8

5

4

2

-

19

2012

69

9

5

2

-

-

16

2013

72

13

6

2

-

1

22

2014

2014-1

13

5

2

-

3

23

Year

Round

2009

2.6

ICELANDIC SAMPLING

2.6.1 PHYTOPLANKTON SAMPLING
Samples were taken from two sites in Iceland: Eyjafjordur on the north coast and
Breidafjordur on the west coast (Figure 3-1). There were two sampling sites in Breidafjordur:
Flatey in the north of the fjord and Stykkisholmur in the south and one location in
Eyjafjordur, Hrisey Island, located in the middle of the fjord. Phytoplankton sampling was
carried out weekly from spring to autumn 2009. Toxic species were screened by net sampling
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using a 20 µm mesh. The net was hauled from a depth of 5 metres to the surface several
times. All samples were fixed in hexamine buffered formalin and examined under a
microscope. If toxic species were detected in these net samples then 50 mL water samples
were allowed to settle in a sediment chamber for 24 hours according to the Utermöhl method
[114] and examined in an inverted microscope where toxic species were identified and
counted [115]. Phytoplankton sampling, identification and counting was carried out by Dr.
Karl Gunnarsson and his team at the Icelandic Research Institute who supplied results
described in Chapter 3 (Table 3-2).

2.6.2 SHELLFISH SAMPLES
Samples were collected from two sites: Eyjafjordur (Hrisey Isalnd) on the north coast and
Breidafjordur (Stykkisholmur) on the west coast between June and August 2009. Mussels at
both harvesting locations are grown in mesh sleeves attached to suspended long lines.
Samples were stored in their shells at <-20°C until frozen samples were dispatched in one
batch to the Marine Institute on ice.
The samples were thawed and prepared by dissecting and removing the whole flesh from the
shell, removing byssus threads and any fragments of shell before being homogenised using a
Waring™ blender (Hartford, CT, USA). Aliquots of the homogenised tissues were then
extracted and analysed, with the bulk tissues stored in PP containers frozen at -20°C.
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FIRST REPORT AND CHARACTERISATION OF PSP TOXINS FROM
ICELAND

This chapter details work described by Burrell et al. 2013.
S. Burrell, T. Gunnarsson, K. Gunnarsson, D. Clarke, & A.D. Turner, (2013). First detection
of paralytic shellfish poisoning (PSP) toxins in Icelandic mussels (Mytilus edulis): Links to
causative phytoplankton species. J. Food Con. 31: 295-301
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3.1

BACKGROUND AND AIMS

The marine sector is hugely important to the Icelandic economy. In 2009 alone marine
products accounted for 42% of Iceland’s total export value with the industry employing
approximately 7300 people, representing nearly 4% of the overall Icelandic workforce [116].
Shellfish have been harvested commercially in Iceland over the last 40 years with Icelandic
scallop (Clamys islandica) and ocean quahog (Artica islandica) being the main species
harvested. Mussel farming is relatively new however, with investigations into its feasibility
being carried out in 1973 and later in 1985-87 [117]. Since these initial investigations blue
mussels (Mytilus edulis) have been grown experimentally around the coast of Iceland with
harvesting figures contained in Table 3-1.
Table 3-1: Quantities of blue mussel harvested from Icelandic waters since 2009 (Results provided by the Icelandic Food
and Veterinary Authority).

Year
2009
2010
2011
2012
2013
2014

Harvest Figures (tonnes)
12
32
94
63
163
48

With nearly 5000km of coastline, the Icelandic aquaculture industry has huge growth
potential, making the implementation of an effective biotoxin monitoring program a necessity
if the European and world shellfish markets are to be exploited.
HABs are a variable yet worldwide phenomenon and can pose severe economic risks
especially to fledgling shellfish markets such as Iceland’s. For human protection and as a
statutory requirement, Iceland is obliged to conduct routine analysis of shellfish for regulated
shellfish toxins from these harvesting sites. Due to the lack of biotoxin testing facilities in
Iceland, shellfish samples have been transported to Ireland for biotoxin testing over the last
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decade. Since 2005 toxic species of phytoplankton have been monitored in three fjords
around the coast of Iceland, Eyjafjordur on the central north coast, Breidafjordur on the
northwest coast and Hvalfjordur on the southwest coast (Figure 3-1) [115]. Phytoplankton
sampling is carried out weekly from spring to autumn and closure of these sites for harvesting
shellfish is recommended when cell numbers exceed 500 cells/L of Alexandrium spp.

Figure 3-1: Map of Iceland showing shellfish production sites Hvalfjordur, Breidafjordur and Eyjafjordur.

In order to prepare the RMs for the studies described in this thesis, it was necessary to source
relatively large quantities of shellfish tissues containing high levels of PSTs. The lack of
facilities at the MI for conducting shellfish feeding experiments coupled to the fact that PSP
toxins rarely rise above the EU regulatory limit in Irish samples necessitated sourcing these
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toxins outside of Ireland. Shortly after commencing the research for this thesis in 2009,
routine PSP testing by MBA confirmed very high PST levels never seen before in Icelandic
samples.
The research contained in this chapter therefore, had two main aims. Firstly to collect and
characterise M. edulis samples from fjords commercially producing this species and present
the data as a first time report of PST profiles in Icelandic waters. Secondly to obtain and
characterise large quantities of naturally contaminated shellfish tissues for the development
work described in later chapters.
Data is presented from the analysis of whole flesh M. edulis samples collected from two of
these fjords Breidafjordur located on the west coast and Eyjafjordur on the north coast during
a bloom of Alexandrium spp. in 2009. Samples were analysed for PSP toxicity by MBA with
additional confirmatory analysis carried out by LC-FLD to determine toxin profiles and total
saxitoxin equivalents.
During this period a request was submitted to the Icelandic Food and Veterinary Authority by
the author to harvest M. edulis samples in order to build-up stocks of contaminated shellfish
at the MI. Consequently approximately 30 kg of shellfish meat in the shell was harvested and
sent to the author under frozen conditions.
The contamination of blue mussels with PSTs in Iceland in 2009 represents a new and unique
geographical location for the occurrence of these toxins, and one which may potentially result
in a serious impact upon the livelihood of Icelandic shellfish producers and exporters.

60

Chapter 3

3.2

RESULTS

3.2.1 TOXIC PHYTOPLANKTON SPECIES
Results obtained from the Icelandic phytoplankton monitoring program have shown variable
levels of toxic species present since 2005.

3.2.1.1 BREIDAFJORDUR
Between the years 2005-2007, in Breidafjordur (Flatey), no Alexandrium spp. were found in
any samples taken. In 2008 cell numbers exceeded 500 cells/L only once in late May of that
year [115] but in June and July 2009 however, cell numbers of over 3500 cells/L were
recorded at this site (data not shown).
Alexandrium spp. from the other sampling location in Breidafjordur, Stykkisholmur, have
been found infrequently and in very low numbers in the years 2005-2008. In 2009 however
high densities of cells were found, starting in late June and persisting until the middle of July,
peaking at over 16,000 cells/L (Table 3-2).

3.2.1.2 EYJAFJORDUR
At Hrisey Island in Eyjafjordur, Alexandrium spp. have been observed each year from 2005 –
2008 with cell densities >6000cells/L found in 2005 (data not shown). In 2009 Alexandrium
spp. peaked twice, firstly at over 8,000 cells/L in June and secondly at over 10,000 cells/L in
July (Table 3-2).The Alexandrium populations detected in phytoplankton samples from both
fjords were mainly composed of A. tamarense with small numbers of A. ostenfeldii being
found in samples with very high cell counts overall.
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Table 3-2: Phytoplankton cell counts taken during May to September 2009 from Eyjafjordur and Breidafjordur, Iceland.

Sample

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Sampling
Date
25/05/2009
02/06/2009
08/06/2009
14/06/2009
15/06/2009
18/06/2009
21/06/2009
25/06/2009
26/06/2009
28/06/2009
30/06/2009
09/07/2009
13/07/2009
17/07/2009
20/07/2009
23/07/2009
28/07/2009
31/07/2009
05/08/2009
08/08/2009
10/08/2009
12/08/2009
18/08/2009
23/08/2009
26/08/2009
31/08/2009
06/09/2009
13/09/2009

Cell Counts (Alexandrium spp.) cells/L
Eyjafjordur

Breidafjordur

0
0
620
1,000
1,300
1,520
2,200
8,750
360
1,540
2,160
10,920
6,400
80
20
120
40
60
20
0
0

260
4,208
16,680
6,500
1,880
160
0
0
-

3.2.2 MBA AND LC-FLD TOXICITY DATA
3.2.2.1 BREIDAFJORDUR
The MBA and LC-FLD toxicity data from Breidafjordur is presented in Table 3-3. The first
mussel sample was collected on the 30/06/09 when toxicity was already over three times the
regulatory limit. The toxicity rose to over 4 times this limit by the second sample taken on the
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10/07/09 before dropping over the next 4 weeks to levels below this regulatory action level.
The highest total toxicity result was observed in sample 2, with an MBA result of over 4500
µgSTXdiHCl-eq/kg.
Table 3-3: MBA and preCOX LC-FLD data of mussel (M.edulis) samples harvested from Breidafjordur, Iceland.

Concentration (µmol/kg)

Total Toxicity µgSTXdiHCl-eq./kg

Sample

Sampling
Date

GTX-2,3

STX

GTX-1,4

HPLC-FLD

MBA

1
2
3
4
5
6

30/06/2009
10/07/2009
16/07/2009
01/08/2009
13/08/2009
26/08/2009

6.06
6.6
2.55
0.41
0.13
0.07

2.25
3.18
1.44
0.24
0.12
0.1

1.24
1.39
0.47
n.d
n.d
n.d

2652
3175
1280
181
74
53

3800
4694
1141
<LOQ
<LOQ
<LOQ

n.d. Toxin not detected
LOQ for MBA 280 µgSTXdiHCl-eq./kg

3.2.2.2 EYJAFJORDUR
The MBA and LC-FLD toxicity data generated from the analysis of the Eyjafjordur mussel
samples collected during 2009 is presented in Table 3-4. Toxicity was found to be below but
close to the regulatory action limit of 800µgSTXdiHCl-eq/kg in early June, seen in sample 1,
but was found to rise quickly to nearly 10 times the limit in sample 2 within the subsequent
two weeks.
Table 3-4: MBA and preCOX LC-FLD data of mussel (M.edulis) samples harvested from Eyjafjordur, Iceland.

Concentration (µmol/kg)

Total Toxicity µgSTXdiHCl-eq./kg

Sample

Sampling
Date

GTX-2,3

STX

GTX-1,4

HPLC-FLD

MBA

1
2
3
4
5
6

08/06/2009
21/06/2009
28/06/2009
08/08/2009
23/08/2009
31/08/2009

0.02
9.05
12.4
2.63
0.45
0.28

1.44
6.18
9.97
0.86
0.7
0.54

n.d
3.39
5.6
0.48
n.d
n.d

540
5583
8564
1086
361
264

720
7460
8510
1050
550
440

n.d. Toxin not detected
LOQ for MBA 280 µgSTXdiHCl-eq./kg

This emphasises the speed with which these toxins can accumulate in shellfish tissue during
toxic phytoplankton blooms and the importance of conducting regular routine flesh
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monitoring. Toxicity levels remained high for a further 6-8 weeks and did not drop below
regulatory limits until the end of August, sample 5. The highest total toxicity result was
observed in sample 3, with results by LC-FLD and MBA of over 8500µgSTXdiHCl-eq/kg.

Figure 3-2: preCOX LC-FLD separation of PSP toxins present in an Icelandic sample from Breidafjordur in 2009 a) after
SPE-C18 cleanup and peroxide oxidation and b) after SPE-ion exchange cleanup and periodate oxidation of fraction 2.
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Chromatograms taken after a) peroxide and b) periodate oxidation of a sample from
Breidafjordur are presented in Figure 3-2. These showed the clear presence of STX, GTX2,3
and GTX1,4 toxins. Results from both fjords showed the absence of any chromatographic
peaks which may relate either to other PSP toxins or metabolic products. Analysis of
unoxidised extracts of the samples revealed no interfering matrix co-extractives (data not
shown) which may have interfered with the qualitative identification of the PSP toxins and
subsequently compromised toxin quantitation.

3.3

DISCUSSION

Conditions within both fjords during the sampling periods were favourable for phytoplankton
growth as confirmed through the data presented in Table 3-2, where cell counts of
Alexandrium spp. reached record levels in both Eyjafjordur and Breidafjordur.
The exact causes of the high cell numbers observed is unknown and could be due to a number
of factors. Temperature and salinity increases along the west and north coasts have been
observed over the last decade due to a stronger inflow of Atlantic waters into these grounds
[115]. It is unclear from results obtained to date whether these trends are related in any way
to the effects of climate change or, as is more probable, relate to natural cyclic variations such
as oscillations to the North Atlantic subpolar gyre [118,119]. Warmer more saline subtropical
waters can spread north and westwards when this gyre weakens, as it controls the flow
trajectory of the North Atlantic Current. A weakening of this gyre has been observed over the
last decade which could explain the temperature and salinity increases observed by
Gudfinnsson et al. [115].
A comparison of the results obtained from both the algal cell counts and the toxicity tests are
illustrated in Figure 3-3. A clear correlation is evident between the high cell counts recorded
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and flesh samples containing higher concentrations of PSTs. Notably, the data from
Breidafjordur indicates a time delay between the highest concentrations of algae and toxin
levels recorded in the flesh.

Eyjafjordur
12000

9000
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8000
7000

8000

6000
5000

6000

4000
4000

3000
2000

2000

Alexandrium Cell Counts (cells/L)

PSP Toxicity (ug STX di-HCl eq./kg)

10000

1000
0
7/5/09

27/5/09

16/6/09

HPLC-FLD

6/7/09

26/7/09

MBA

15/8/09

4/9/09

0
24/9/09

Alexandrium Cell Count

5000

18000

4500

16000

4000

14000

3500

12000

3000

10000

2500
8000

2000

6000

1500
1000

4000

500

2000

Alexandrium Cell Counts (cells/L)

PSP Toxicity (ug STX di-HCl eq./kg)

Breidafjordur

0
0
6/6/09 16/6/09 26/6/09 6/7/09 16/7/09 26/7/09 5/8/09 15/8/09 25/8/09 4/9/09
HPLC-FLD

MBA

Alexandrium Cell Count

Figure 3-3: Comparison of Alexandrium Cell Counts in the water (cells/L) and total sample toxicity of the harvested mussels
(µg STX di-HCl eq./kg) returned by both LC-FLD and MBA in a) Eyjafjordur and b) Breidafjordur.
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There is also a clear relationship between the reduction of algal cells and the total toxicity
determined in the flesh samples. Unfortunately, an absence of flesh samples collected from
Eyjafjordur in July 2009 prevents an actual comparison between the toxicity of the flesh and
the Alexandrium cell count during the second algal bloom at this location.

3.3.1 TOXIN PROFILE DETERMINATION
The preCOX LC-FLD method [41] has been proven as a valuable tool in the qualitative and
quantitative determination of PSP toxins in shellfish [120]. The epimeric pairs (e.g. GTX2
and GTX3, GTX1 and GTX4, C1 and C2 and dcGTX2 and dcGTX3) are not separated
analytically using this LC-FLD method and are therefore presented as a combined sum using
the higher toxicity factor of the two co-eluted epimers to calculate total toxicity. Through
analysis using this method the toxin profile was determined and found to be similar in both
fjords with samples predominated by the carbamate toxins GTX2,3. STX was the next most
abundant toxin present with GTX1,4 observed in half the samples analysed (Figure 3-4).
The toxin profiles determined in these samples are similar to those found in other areas where
Alexandrium spp. predominates such as the UK [121] where the toxins GTX2,3 and STX
predominate with lower levels of GTX1,4, NEO and GTX5 also being found, or in Ireland
where GTX2,3 has been found to predominate [122] with lower relative concentrations of
STX and GTX1,4 being determined (MI internal NMP data).
Interestingly, there is no indication of the presence of any of the N-sulfocarbamoyl toxins
such as C1,2, which have been found to occur in mussels containing PSP toxins in some UK
waters since 2008 [121] and which are associated with a number of different strains of
Alexandrium spp. The Norwegian PSP toxin profile typically observed is slightly different to
that observed in Iceland, being predominated by GTX1,4, with both NEO and STX being
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found at lower relative concentrations [123]. The differences between profiles in the region
and Iceland’s is mainly the absence of the toxins NEO and C1,2 from samples analysed.

Percentage toxin profile (in terms of
umol/kg)

Eyjafjordur
120%
100%
80%

GTX-2,3

60%

STX

40%

GTX-1,4

20%
0%
8/6/09 21/6/09 28/6/09 8/8/09 23/8/09 31/8/09

Percentage toxin profile (in terms of
umol/kg)

Breidafjordur
70%
60%
50%
GTX-2,3

40%

STX

30%

GTX-1,4

20%
10%
0%
8/6/09

21/6/09 28/6/09

8/8/09

23/8/09 31/8/09

Figure 3-4: Percentage PST profiles determined by LC-FLD (in terms of µmol/Kg) from mussel samples collected from a)
Eyjafjordur and b) Breidafjordur.

Profiles of A. tamarense mainly consist of the N-sulfocarbamoyl toxins, C1,2 and the high
potency carbamate toxins GTX1-4, NEO and STX [124,125]. Profiles of A. ostenfeldii can
contain the spirolides as well as the PSTs GTX6, C1,2 and GTX2,3 [126,127] The absence of
the N-sulfocarbamoyl toxins C1,2 from mussel samples taken from both harvesting areas, if
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not relating to the toxin profile in the source algae, could instead be due to the metabolic
conversion of these toxins in shellfish to GTX2,3 via desulfonation and epimerization [128].
This hypothesis could explain the high concentrations of GTX2,3 found in samples as
evidenced in Figure 3-4. The percentage toxin profile presented in this figure shows
similarities between both fjords with GTX2,3 being the predominant toxins present in early
samples taken in June and early August, although a discrepancy is noted in the data set with
STX being the predominant toxin found in the Eyjafjordur sample from the 08/06/09. The
ratio of GTX2,3 to STX changes by late August with STX becoming the predominant toxin
present. Again this could relate either to changes in the toxin ratios present within the algal
food source or alternatively relate to the potential toxin transformation of GTX2,3 to STX via
desulfonation [129]. However it is noted that these in vitro experiments by Fast et al. were
only carried out on clam tissues.
It is interesting to note that although the Alexandrium cell counts found in Breidafjordur
(Figure 3-3) were considerably higher than those found in Eyjafjordur, the same ratio was not
evident in the toxicity results of the mussel samples. The total PSP toxicity found in mussels
from Eyjafjordur was nearly twice that found in mussels from Breidafjordur. This may relate
to slower uptake of PSTs by mussels found in Breidafjordur compared to Eyjafjordur or a
greater composition of non-toxin producing Alexandrium species present in Breidafjordur.
The absence of GTX1,4 in samples taken in early June and late August from Eyjafjordur and
early August onwards from Breidafjordur is likely due to the low overall toxicity of these
samples and the lower relative sensitivity of the N-hydroxylated toxins to their nonhydroxylated counterparts when analysed using OMA AOAC 2005.06 [120].
It is imperative therefore to have adequate knowledge of specific toxin profiles for the
analysis and risk management of this group of potent neurotoxins due to the range of relative
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toxicities exhibited by the various analogues. These results highlight the presence in Iceland
of some of the most toxic PSP toxins as well as levels of toxicity which may provide a
serious risk to the human consumer.

3.3.2 CHEMICAL AND BIOLOGICAL METHOD ANALYSIS
Toxicity results returned by both the reference MBA method and the preCOX LC-FLD
method appear to correlate reasonably well for these samples (Figure 3-3), as observed
previously in this species for mussels sampled from within UK waters [120]. Overall the
MBA method gave slightly higher values compared to the preCOX LC-FLD as evidenced in
Table 3-3 and Table 3-4, although a variability in this ratio is noted.
It is also clear from the results generated from samples 4-6 from Breidafjordur (Table 3-3),
that the preCOX LC-FLD method provides useful data on the toxicity of samples containing
levels of PSTs lower than the MBAs limit of quantitation. This again shows the usefulness of
the preCOX LC-FLD method for the early warning of toxicity, especially important given the
rapid increases in PSP toxin levels observed in these areas (Table 3-4). These results
therefore clearly demonstrate the importance of a regular effective toxicity monitoring
regime, without which there would be a clear potential risk to human consumers to toxic
bloom events.
The level of observed time delay between the peaks in phytoplankton cell presence found in
the water and the maximum levels of toxicity found in shellfish (Figure 3-3) is also of
interest. At Breidafjordur, the peak in toxicity appears approximately two weeks after the
measured maximum of Alexandrium cells. This observation is consistent with those observed
previously from water and flesh samples collected in the St. Lawrence region, Canada [130]
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or from Busta Voe Lee North, Scotland [131] where time delays of over 7 days have been
found.

3.4

CONCLUSIONS

These novel findings represent the first report of PSP toxins in shellfish from Iceland and
furthermore indicate the potential increase in the presence of the toxins and causative
phytoplankton over the past few years. It is difficult to ascertain however, if this increase is
due to the application of phytoplankton monitoring in Icelandic waters or truly represents an
increase in the incidence of these toxic dinoflagellates. With the increasing economic
importance placed upon the shellfish industry in Iceland, this highlights the importance of
continued monitoring of both shellfish toxicity and their causative organisms. A full and
thorough risk assessment can then be produced, for the occurrence of PSP in Icelandic waters
so as to provide the necessary information to ensure an appropriate biotoxin monitoring
programme is continued. Ongoing work will continue with the analysis of both water and
flesh samples from both current and developing shellfish harvesting beds and over time build
up more data on the timing and intensity of the algal blooms and the subsequent shellfish
toxin accumulation. Further data will allow the ongoing assessment of the presence and
variability of PSP toxicity and toxin profiles, ultimately providing an essential resource to
ensure the continued development of the Icelandic shellfish production program.
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STABILISATION TECHNIQUES
4.1

BACKGROUND AND AIMS

As discussed in Chapter 1, homogeneity and stability are two of the most important
parameters to consider in the preparation of RMs. In order for a material to be considered fit
for purpose, the biological matrix and the PSTs themselves must be stable during
transportation and throughout the materials use as well as ensuring uniformity across the
entire production lot. Previous studies have proven the role of bacteria present in the
digestive glands of shellfish in the biotransformation of PSTs [132], a process which may
result in unstable PST concentration over time. Techniques investigated in this chapter, aimed
at reducing or eliminating the bacterial effects, lowering the rates of toxin degradation,
epimerization and biotransformations, should improve PST and matrix stability for RM
production. Although the processing and dispensing procedures for all materials prepared in
this study were not carried out aseptically, reducing or eliminating bacteria present in the
source tissues, through the techniques investigated, significantly improves the stability of
biological matrix RMs [52].
The stabilisation procedures investigated in this chapter include the effects of preserving
additives, specifically antibiotics and an antioxidant spiked into tissue during preparation,
thermal treatment of source tissues and the novel application of HPP. The use of preserving
additives and the application of a thermal treatment step to sterilise source tissues has
previously been shown to improve the stability of certain phycotoxins [54,60] but, along with
HPP have not been investigated for the production of PST RMs. Due to the intended use of
some of the materials prepared in this chapter, specifically in Quasimeme PT schemes where
participants may use MBA, it was also necessary to determine if the preserving additives
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would have any adverse effects on the animal assay, specifically inducing PSP like symptoms
which could affect method interpretation.
The study was broken down into distinct sections which investigated the following:


Spiking tissues with an antioxidant (ethoxyquin)



Spiking tissues with antibiotics (ampicillin, erythromycin and oxytetracycline)



Combined use of the preserving additives described above



Thermal treatment



Combined thermal treatment and spiking with the preserving additives described
above



HPP



Untreated control materials
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4.2

PRESERVING ADDITIVES

This section of the study investigated the separate use of an antioxidant, ethoxyquin and three
antibiotics, ampicillin, erythromycin and oxytetracycline and their effects on biological
matrix stability and the PSTs present (Figure 4-1). These preserving additives have
previously been shown to improve the stability of domoic acid and AZA3 however they
provided no additional stability improvements for the other toxins covered in that study,
AZA1, -2, OA or DTX2 [54,60]. To the author’s knowledge this is the first time these
preserving additives have been investigated and compared directly to untreated control
materials for their stabilisation effects on PSTs.

4.2.1 MATERIALS AND METHODS
4.2.1.1 SOURCE TISSUES
The Canadian, Norwegian, Spanish, Icelandic and blank toxin free Irish tissues as listed in
Table 2-1 were used to prepare the RMs used in this section of the study. The tissues were
naturally contaminated with GTX2,3, STX, GTX1,4, NEO and dcSTX and were diluted with
a blank toxin free mussel tissue due to the high levels of PSTs present in the contaminated
tissues. It was necessary to combine different source tissues in order to gain a more
comprehensive toxin profile than a single tissue alone would provide, therefore the PST
NEO, although present in sufficient quantities in the source tissue, was diluted to levels
below the limit of detection (<LOD) of the preCOX and PCOX LC-FLD methods of analysis.
For this reason stability and homogeneity of this toxin was not investigated.
An initial bulk tissue (>2.0 kg), containing the quantities detailed in Table 4-1 was prepared
and subdivided into four separate lots, sealed in PP containers and stored at -20°C until
further use. The four lots were then used to investigate the separate use of three antibiotics
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combined (Tissue 1), an antioxidant (Tissue 2), and an untreated control material (Tissue 3).
The fourth lot was prepared for use in freeze drying experiments as described in Chapter 5,
Section 5.5.

a) Ethoxyquin

b) Ampicillin

c) Erythromycin

d) Oxytetracycline

Figure 4-1: Chemical structures of the four additives used to stabilise the PSTs.
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The bulk tissue was prepared by combining the proportions of tissues detailed in Table 4-1 in
a 5 L Waring™ goblet. To ensure a good degree of homogeneity of the initial bulk tissue, inhouse RM procedures (Standard Operating Procedure (SOP) No. BCT-058) were followed
which have previously been shown to produce sufficiently homogeneous RMs [54]. This
specifically involved homogenising the tissues on medium power for 5.0 min, scrapping
down the insides of the goblet intermittently to ensure thorough mixing.
Table 4-1: Quantities of source wet frozen tissues used to prepare the bulk homogenate for the additives and freeze drying
studies.

Country
Species
Mytilus edulis
Canada
Mytilus edulis
Norway
Mytilus edulis
Iceland
Mytilus galloprovancialis
Spain
Mytilus edulis
Ireland

Quantity (kg)
0.01
0.18
0.38
0.95
0.63

Aliquots were taken for MC determination (n=3) using the rotary vacuum method and
analysis by preCOX LC-FLD (n=1) as described in the materials and methods sections 2.4.1
and 2.3.1 respectively, to give approximate PST concentrations in the bulk tissue. The bulk
homogenate was immediately subdivided into 3 x ~0.5 kg (Tissues 1-3) and 1 x ~0.7 kg
(freeze drying experiment in Chapter 5) sub-samples by pouring the required amount of
tissue into PP containers, sealing with lids and parafilm before storing at -20°C until required
for use. The PST levels and MC results from this bulk homogenate are presented in Table
4-2.
Table 4-2: Toxin profile, concentrations and moisture content of bulk tissue used to prepare Tissues 1-3.

Concentration (µmol / kg)

Material

Bulk
homogenate

dcSTX

GTX2,3

GTX5

STX

GTX1,4

neoSTX

0.65

3.5

0.05

1.99

1.9

0.71
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4.2.1.2 ADDITIVES MATERIAL PREPARATION
Both the antibiotics (Tissue 1) and antioxidant (Tissue 2) spiked materials were prepared
similarly as follows. The frozen bulk homogenate described in section 4.2.1.1 was removed
from the freezer and allowed to defrost overnight in a fridge at +4°C. The preserving
additives were prepared by dissolving in ethanol (1% w/w) and adding to the tissue
homogenates to give 0.02% w/w as described previously by McCarron et al., for domoic acid
in shellfish [60]. For the antibiotics spike, 0.12 ± 0.01 g each of ampicillin, oxytetracycline
and erythromycin were weighed into a 50 mL PP centrifuge tube using a calibrated 3-place
balance. 6.0 ± 0.1 g ethanol was added to the centrifuge tube, capped and vortex mixed
(Vortex Genie-2, Scientific Industries, NY, USA) for 5.0 min. The antioxidant spike was
prepared in the same way, weighing 0.12 ± 0.01 g ethoxyquin into a 50 mL PP centrifuge
tube with 6.0 ± 0.1 g ethanol and vortex mixing for 5.0 min.
The defrosted tissues were further mixed by hand using a spatula before transferring 464 ± 1
g into a Waring™ goblet. The additives/ethanol solution was then spiked into the tissue,
washing out the centrifuge tube with a small volume of DI water before manually mixing
with a spatula. The antibiotics/ethanol solution was spiked into tissue A and the
antioxidant/ethanol solution spiked into tissue B. The final weights of both tissue A and B
were made up to 600 ± 1 g with DI water in order to obtain a final tissue with a MC of ~85%
to better reflect that found in a natural mussel matrix.
The tissues were homogenised using a Waring™ blender on medium power for 5.0 min,
scrapping down the vessel walls intermittently to ensure thorough homogenisation. The
tissues were transferred to PP beakers and further homogenised using a Polytron™ mixer for
30.0 min using a coarse head attachment and for 20.0 min using a fine head attachment. The
Polytron™ homogenisation steps were carried out with the PP beaker placed in an ice-bath to
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prevent localised heating through friction of the apparatus during homogenisation which
could result in evaporation and an altered final MC.
The materials were dispensed as 5.3 ± 0.1 g aliquots using a calibrated peristaltic pump
(Bernant, IL, USA) into 5 mL PP vials (Teklab Ltd., Durham, UK) to ensure minimum
retrieval amounts of 5.0 g, sufficient for preCOX method extraction. The tubes were
hermetically sealed with aluminium lids under a stream of argon using a manual heat sealer
(MK 1, Seal-it-Systems, Lancashire, UK), before being fitted with wadded (polyethylene
disc) screw caps. A total of 110 aliquots of Tissue 1 and Tissue 2 were dispensed providing a
sufficient quantity for short (n=45) and long-term (n=45) stability studies as well as
homogeneity (n=14) and MC (n=3) determinations. All materials were stored at -80°C until
required.

4.2.1.3 UNTREATED CONTROL MATERIAL PREPARATION
The untreated control material (Tissue 3) was prepared by defrosting the bulk homogenate
described in section 4.2.1.1 overnight in a fridge at +4°C. The defrosted tissue was manually
mixed using a spatula before transferring 464 ± 1 g into a Waring™ goblet. The final weight
of the tissue was made up to 600 ± 1 g with DI water in order to obtain a final tissue with a
MC of ~85% to better reflect that found in a natural mussel matrix.
The tissue was homogenised using a Waring™ blender on medium power for 5.0 min,
scrapping down the vessel walls intermittently to ensure thorough homogenisation. The tissue
was transferred to a PP beaker and further homogenised using a Polytron™ mixer for 30.0
min using a coarse head attachment and for 20.0 min using a fine head attachment. The
Polytron™ homogenisation steps were carried out with the PP beaker placed in an ice-bath.
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The material was dispensed as described in section 4.2.1.2 above. A total of 110 aliquots of
Tissue 3 were dispensed providing a sufficient quantity for short (n=45) and long-term
(n=45) stability studies as well as homogeneity (n=14) and MC (n=3) determinations. All
materials were stored at -80°C until required.

4.2.1.4 STUDIES AND ANALYSIS
The between-bottle homogeneity of the materials prepared in sections 4.2.1.2 and 4.2.1.3
above were assessed through the intra-batch analysis of 14 (3n1/3) aliquots selected through
stratified random sampling of the entire fill series. This involved the division of the
population into smaller groups known as strata, from which simple random sampling or
systematic sampling is applied to each stratum.
All materials were stability tested over a short term (ca. 32 day) and long term (ca. 12 month)
period following a reverse isochronous experimental design [55] to negate day-to-day
instrumental variations. The short term study was conducted with triplicate samples
consisting of five time points (0, 3, 8, 16 and 32 days for Tissue 1; 0, 4, 8, 17 and 32 days for
Tissue 2 and 0, 4, 6, 17 and 31 days for Tissue 3) and three temperature conditions (-20°C,
+4°C and +40°C). The time points used in the study of each material were slightly different
to each other as it was necessary to alter the time models slightly to ensure analysis was
completed within the required time frame. The long term study was conducted with triplicate
samples consisting of five time points (0, 3, 6, 9 and 12 month) and three temperature
conditions (-20°C, +4°C and +20°C). The reference temperature used in both studies was 80°C. A total of 9 aliquots were stored at this temperature for the duration of the study before
being removed and extracted with the other stability study samples. In the case of all the
stability studies aliquots of tissue (n=3), were removed from -80°C storage on the prescribed

79

Chapter 4
day and transferred to the storage conditions being investigated. Table 4-3 is an example of a
stability study data table and can be used to describe the process. On the first day of the study
(Day 30, 12/06/11) 9 aliquots of tissue were removed from the -80°C freezer, transferring 3
tissue aliquots into each of -20°C, +4°C and +40°C storage conditions and recording the
aliquot numbers of each in the table below. Two weeks later on the 26/06/11 another 9 tissue
aliquots were removed from -80°C storage and placed in each of the three storage
temperatures being investigated, recording their aliquot numbers in the same table below.
This process was repeated on the 04/07/11 and the 08/07/11.
Table 4-3: Table used to input data for a short-term stability study.

Time point & Date

Sample
-20°C

+4°C

+40°C

30

16

8

4

0

12/06/11
Sunday

26/06/11
Sunday

04/07/11
Monday

08/07/11
Friday

12/07/11
Tuesday

#1
#2
#3
#1
#2
#3
#1
#2
#3

On the final day of the study, 12/07/11 the 9 remaining tissue aliquots were removed from 80°C storage and their aliquot numbers recorded in the column labelled 0 in Table 4-3. At the
same time all the other tissues were removed from the -20°C, +4°C and +40°C storage
conditions, allowing them to equilibrate to room temperature before being extracted and
analysed by preCOX LC-FLD closely following OMA AOAC 2005.06 [41] as detailed in
section 2.3.1. PCOX LC-FLD [75] analysis was additionally performed on all samples to
specifically investigate the extent of epimerisation, if any, of GTX2,3 in each material. The
epimerisation of GTX1,4 was not determined as the concentration of these toxins in each
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tissue was below the limit of quantification (<LOQ) of the PCOX LC-FLD method. GTX2
and GTX3 are good indicator toxins however for rates of epimerization in tissues as
evidenced from previous studies [133–135]. For PCOX LC-FLD analysis, the crude acetic
acid extracts prepared according to section 2.3.1 were deproteinated and analysed following
AOAC 2011.02 as described in section 2.3.2 [75].
PST concentrations in sample extracts were quantified against a 4 - 5-point calibration for
each toxin and are expressed as µmol/kg with total saxitoxin equivalents calculated as an
estimation of total toxicity.
The MC of each of the Tissues 1-3 was determined using the rotary vacuum method as
described in the materials and methods section 2.4.1. Aliquots (n=3) were selected from the
beginning, middle and end of the fill series in order to determine if any evaporation had taken
place during dispensing.
The organoleptic properties of each of the tissues was also assessed, specifically the odour of
the tissues stored at the elevated temperature conditions was noted during extraction of the
stability study samples.
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4.2.2 RESULTS AND DISCUSSION

4.2.2.1 HOMOGENEITY AND MOISTURE CONTENT
All the materials prepared in this section of the study were suitably homogenous for all the
PSTs detected, as evidenced through the coefficient of variances contained in Table 4-4.
A target %CV of below 8% for each analyte including total toxicity was set. This value is
below expected levels of variability associated with intra-batch repeatability, determined
through in-house validation of the preCOX LC-FLD method. The intra-batch repeatability of
the preCOX LC-FLD method was determined to be >9% for all toxins determined during
validation studies. The homogeneity techniques employed were therefore sufficient and the
materials suitable for the study.
Table 4-4: Homogeneity results for the antibiotic spiked (Tissue 1), antioxidant spiked (Tissue 2) and untreated control
(Tissue 3) materials showing mean toxin concentrations determined by preCOX LC-FLD (n=14).
dcSTX

GTX2,3

GTX5

STX

GTX1,4

Total Toxicity

Material
µg STX diHCl-eq. / kg

Average

Stdev

%CV

Tissue 1

205.4

606.0

2.7

705.8

490.5

2010

Tissue 2

214.5

830.3

1.9

690.1

366.4

2103

Tissue 3

194.0

641.8

2.1

545.8

304.1

1688

Tissue 1

15.2

35.7

0.1

46.3

29.9

152.8

Tissue 2

7.9

54.7

0.1

17.6

26.6

75.7

Tissue 3

9.0

44.5

0.1

19.2

14.1

84.0

Tissue 1

7.4

5.9

3.0

6.6

6.1

7.3

Tissue 2

3.7

6.6

3.9

2.6

7.3

3.5

Tissue 3

4.7

6.9

5.9

3.5

4.7

5.0

Each of the three materials were prepared from a pooled homogenate and adjusted to the
same target value for moisture content of 85%. Despite this fact, a statistical difference in
total toxicity means (P < 0.05; one-way analysis of variance [ANOVA]) was evident between
the three tissues which can be seen from the data contained in Table 4-4. The cause or causes
of these differences remain unclear and may be attributed to day-to-day instrument variations
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as the homogeneity determinations were carried out on separate days. Despite the statistical
differences between the means, the processing techniques employed to make the materials
were suitable to prepare sufficiently homogenous materials for use in these studies.

Total Toxicity (µgSTXdiHCl eq. / kg)

2500

2000

1500

1000

500

0

Tissue 1

Tissue 2

Tissue 3

Figure 4-2: visual comparison of total toxicity homogeneity results for Tissues 1-3 (n=14).

The moisture content of each of the Tissues 1-3 gave reproducible results for the three
materials and is slightly higher than the desired value of 85% (Table 4-5). The coefficient of
variances for each Tissue 1-3 was low which indicates that evaporation during dispensing
was minimal. Each tissue took approximately 1 ½ hours to dispense in total so evaporation
during this short timeframe was not expected, particularly given the precautions that were put
in place such as the use of an ice bath to cool the tissue during dispensing. RMs prepared at
the MI for use in the NMP where >1000 aliquots are generally dispensed can take up to 5-6
hours to complete. Moisture content determinations of these large batches of RMs give
coefficients of variance similar to those found in Table 4-5 (data not shown) which indicate
the steps taken to minimise evaporation are sufficient even for dispensing large numbers of
aliquots. The critical number of aliquots dispensed after which evaporation does present a
problem is unknown but is >1000 if precautions are put in place.
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Table 4-5: Moisture content of Tissues1-3 determined by the rotary vacuum method (n=5).

Material
Tissue 1
Tissue 2
Tissue 3

Moisture
Content
86.0
85.9
85.6

%CV
0.05
0.23
0.07

4.2.2.2 SHORT-TERM STABILITY
PRECOX LC-FLD
Figure 4-3 a-e represents the short-term stability results for the three materials at three
different storage temperatures, -20°C, +4°C and +40°C, determined through preCOX LCFLD analysis. Data for dcSTX, GTX1,4, GTX2,3, GTX5 and STX were generated and
results were normalised to the average of replicate analysis (n=9) of samples stored at the
reference temperature of -80°C for the duration of the study. The limits of stability from
Figure 4-3 were generated from two times the standard deviation of the -80°C replicate
analyses.
Overall toxin stability was excellent in each of the Tissues 1-3 when stored at -20°C and
additionally for Tissues 1 and 2 when stored at +4°C for the duration of the short-term study.
Tissue 3 exhibited a slight increase in GTX2,3 concentration after 17 days at +40°C and after
31 days at +4°C which showed the improvement additives spiking specifically had on the
stability of these toxins. However the stability of the other toxins at +40°C differed between
each stabilisation technique and also the control material.
The stability of all the PSTs were improved in Tissue 2 compared to Tissue 3 when stored at
+40°C which highlights the benefits of using an antioxidant in RM preparation for PSTs. The
use of the antibiotics in Tissue 1 showed varying levels of stability for the PSTs with
improvements made to GTX2,3 and GTX1,4 stability at +40°C compared to Tissue 3.
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Figure 4-3: Short-term stability graphs for the PSTs present in Tissues 1, 2 and 3 determined by preCOX LC-FLD. Results
are normalised to the time zero reference temperature of -80°C (error bars represent ± 2 s.d.).
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Interestingly Tissue 1 appears to show instability issues for dcSTX and STX which are more
pronounced than those observed in either Tissue 2 or 3 materials stored at +40°C, the exact
causes of which remain unclear. Similar levels of instability were observed for GTX5 in all
tissues when stored at +40°C which showed neither stability enhancement nor deterioration
through the use of preserving additives for this toxin.
An increase in GTX2,3 concentration was observed in the antioxidant material after 32 days
storage at +40°C and in the control material after 17 and 31 days storage at +40°C and +4°C
respectively. The cause of this increase is unknown but could be due to biotransformations
taking place in the tissue [132].
The use of the antioxidant ethoxyquin improved the stability of the PSTs overall compared to
the control which proves its inclusion for PST RM production to be beneficial. The use of the
antibiotics however gave different results with their inclusion improving the stability of
GTX1,4 compared to the control. The stability of the other PSTs investigated was apparently
worsened, albeit only at the higher temperature of +40°C; similar levels of stability were
evident at the lower temperatures studied for all three tissues.

PCOX LC-FLD
Further analysis was conducted on the short-term stability study extracts for each of the
stabilisation techniques by PCOX LC-FLD and results are presented in Figure 4-4 a-b. The
PCOX LC-FLD method was used specifically to determine the rate of epimerization of
GTX2 and GTX3, if any, in the materials prepared by each technique compared to those
found in the untreated control. Limits of stability and normalised results were calculated as
per the preCOX LC-FLD analysis above.
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No epimerization or degradation was observed in any materials when stored at -20°C for the
duration of the study with results falling within the limits of stability set. Tissue 1 showed
some slight signs of epimerization at +4°C after 32 days storage. At +40°C epimerization of
GTX2,3 in Tissue 1 was evident after 3 days storage which highlights the speed this reaction
can occur when samples are stored at an elevated temperature.
Tissue 2, while similarly stable at -20°C as in the case of Tissue 1, showed slightly more
instability issues at the higher temperatures investigated. Epimerization was evident after 4
days storage at +40°C and after 17 days storage at +4°C in the Tissue 2 samples.
The untreated control, Tissue 3 showed the epimerization of GTX2,3 at temperatures above 20°C. This was evident after 4 days storage at +40°C and after 17 days storage at +4°C.
Further instability issues of GTX3 were evident in the Tissue 3 samples, not seen in either of
the other tissues. The total reduction of GTX3 in Tissue 3 at +40°C as seen in Figure 4-4 a
could not be attributed solely to epimerization as the increase in GTX2 concentration (Figure
4-4 b) does not occur to the same level. GTX3 concentration in Tissue 3 therefore reduces by
~50% most likely through a combination of epimerization to GTX2 and some degradation of
the toxin itself. The reduction of GTX3 in Tissues 1 and 2 however is only ~20-25% and is
accompanied by an increase in GTX2 levels of the same magnitude ~20-25%, which
indicates epimerization is the predominant reaction taking place and very little if any toxin
degradation is occurring in these tissues. Although spiking with additives does not
significantly reduce epimerization rates compared to untreated materials, inclusion of
antibiotics or an antioxidant does improve the stability of GTX3 by approximately 25%
which highlights their advantage in RM preparation, particularly for PCOX LC-FLD analysis
where individual epimers can be quantified.
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Figure 4-4: Stability graphs for the PST epimers GTX2,3 determined by PCOX LC-FLD for the short-term data (a-b) and
the long-term data (c-d) Results are normalised to the time zero reference temperature of -80°C (error bars represent ± 2
s.d.).

The results from both the preCOX and PCOX analysis of the short-term stability samples
provide useful information on the conditions required for transportation of materials
stabilised using both techniques. Although transportation of matrix RMs ideally should be
made under frozen conditions, results indicate materials would also be stable at +4°C for up
to 32 days if spiked with antibiotics and up to 17 days if spiked with the antioxidant,
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ethoxyquin. These findings indicate that if adverse conditions were experienced during
transportation, PSTs would remain stable up to temperatures of +4°C for over two weeks.

4.2.2.3 LONG-TERM STABILITY
PRECOX LC-FLD
Figure 4-5 a-e represents the long-term stability results for the three materials at three
different storage temperatures, -20°C, +4°C and +20°C, determined through preCOX LCFLD analysis. Data for dcSTX, GTX1,4, GTX2,3, GTX5 and STX were generated and
results were normalised to the average of replicate analysis (n=9) of samples stored at the
reference temperature of -80°C for the duration of the study. The limits of stability from
Figure 4-5 were generated from two times the standard deviation of the -80°C replicate
analyses.
All three Tissues 1-3 exhibited excellent stability for all the PSTs throughout the duration of
the yearlong study when stored at -20°C. Differing levels of stability were exhibited under
the other storage conditions however.
At the elevated storage temperatures of +4°C and +20°C the use of preserving additives in
Tissues 1 and 2 did not significantly improve PST stability compared to Tissue 3. GTX5
showed the greatest differences in stability across the three materials with Tissues 2 and 3
exhibiting apparent increases in toxin concentration at +20°C (Tissues 2 and 3) and +4°C
(Tissue 3), the causes of which are unclear. Tissue 1 showed no increase in GTX5
concentration at this storage condition, in fact this tissue showed no signs of degradation until
after 9 months of the study at +20°C and remained stable at +4°C over the course of the 12
months.
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Figure 4-5: Long-term stability graphs for the PSTs present in Tissues 1, 2 and 3 determined by preCOX LC-FLD. Results
are normalised to the time zero reference temperature of -80°C (error bars represent ± 2 s.d.).
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As in the case of the short-term stability studies, but significantly more pronounced, were
increases in GTX2,3 concentrations observed at both +20°C and +4°C storage. Similar
increased GTX2,3 concentrations were observed in all three tissues at +4°C but Tissue 2
exhibited a greater increase at +40°C compared to either Tissues 1 or 3 which exhibited
increases of a similar level.
The results prove that whilst some benefits were obtained following additive pre-treatment,
long-term storage conditions for the materials stabilised with either antibiotics or the
antioxidant should still be at -20°C or below.

PCOX LC-FLD
Further analysis was conducted by PCOX LC-FLD on the long-term stability study extracts
of each of the materials and results are presented in Figure 4-4 c-d. Limits of stability and
normalised results were calculated as per the preCOX LC-FLD analysis above. Data for the
toxins GTX1 and GTX4 were not generated as the concentration of these toxins in each
material was <LOD of the PCOX LC-FLD method.
No epimerization or degradation was observed in any materials when stored at -20°C for the
duration of the study with results falling within the limits of stability set. Tissue 1 showed no
visual evidence of epimerization at +4°C, although a low amount was observed after 32 days
in the short-term study (Figure 4-4 a-b). GTX2 in Tissue 1 remained stable throughout the
yearlong study at +4°C while GTX3 showed signs of degradation after 6 months storage with
~20% of this toxin degraded by the end of the study, which suggests a more selective
degradation of the β-epimer occurs. At +20°C epimerization of GTX2,3 in Tissue 1 was
evident after 3 months storage.
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Tissue 2 while similarly stable at -20°C as in the case of Tissues 1 and 3 showed
epimerization of GTX2,3 after 12 months storage at +4°C and after 3 months at +20°C.
Epimerization was also observed to take place in Tissue 3 control materials but the process
occurred earlier than either Tissue 1 or 2 at +4°C. At this temperature epimerization was
evident in Tissue 3 material after 6 months storage compared to 12 months in the case of
Tissue 2 and no epimerization was observed in Tissue 1. At +20°C epimerization was
observed to take place after 3 months storage which was similar to both Tissues 1 and 2,
showing no clear advantage the preserving additives provided.
The long-term stability study samples as determined by PCOX LC-FLD show no significant
improvement in reducing epimerization rates through the inclusion of preserving additives.
The rates of epimerization of all three tissues were similar at +20°C; however the use of
antibiotics in Tissue 1 did lower epimerization rates in samples stored at +4°C (Figure 4-4 cd).
Epimerization of these toxins followed predicted patterns with the β-epimer GTX3 being
epimerized into the more stable α-form GTX2 [136], which was evident from both the short
and long-term stability data generated through the PCOX LC-FLD analysis.

CHROMATOGRAPHIC AND MATRIX STABILITY
Another important factor to consider when choosing an RM preparation technique is ensuring
good chromatographic stability is achieved. Figure 4-6 a-h displays chromatograms generated
by preCOX LC-FLD for Tissues 1-3 by both peroxide and periodate oxidation after 12
months storage at +20°C. Chromatograms of Tissue 3 stored at -80°C for 12 months are also
shown in this figure as a visual comparison.
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The chromatograms generated following peroxide oxidation (Figure 4-6 a-c) for Tissues 1-3
show some differences in chromatographic peaks inferring either differing levels of toxin
stability and/or the generation of naturally-flourescent matrix co-extractives over time.
Chromatograms of Tissues 1 and 2 materials showing no formation of additional
chromatographic peaks through the inclusion of either of the preserving additives compared
to the control material stored at -80°C. Tissue 3 in comparison did show the additional
formation of chromatographic peaks between 5.0 – 6.5 mins which could affect accurate
quantitation of the C-toxins as their retention times are similar, although these toxins were
not present in these tissues.
The periodate oxidised extracts used to quantify the N-hydroxylated toxins GTX1,4 are
contained in Figure 4-6 e-h. Good chromatographic stability was observed in all tissues up to
a retention time of ~9.0 mins which would not interfere with accurate quantitation of
GTX1,4. A large matrix peak, not present in the control material stored at -80°C was evident
in all three tissues at a retention time of ~9.2 mins however which indicates some matrix
instability. The presence of this additional peak would not affect accurate quantitation of
GTX1,4 however.
The retention time differences observed between the peroxide and periodate oxidised samples
is due to both sets of analysis been carried out on different days. Retention time checks were
carried out each day however, through comparison to standards.
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Figure 4-6: PreCOX LC-FLD chromatograms following peroxide (5a-d) and periodate (5e-h) oxidation of Tissues 1, 2, 3
and a control material stored for 12 months.
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The organoleptic properties of each of the materials prepared are another indicator of the
advantages using preserving additives have, particularly on matrix stability. Specifically the
odour of the untreated control materials stored at +4°C and +40°C was significantly worse
than either Tissue 1 or 2 materials stored at the same temperatures. The malodour indicated a
high degree of rancidity of the mussel matrix in Tissue 3 which was reduced in the other two
tissues.

4.2.3 CONCLUSIONS
All the materials used in this study were found to be homogeneous for the PSTs present as
evidenced through the coefficients of variation determined for toxin concentrations quantified
in selected tissue samples. This highlights the applicability of the in-house RM
homogenisation techniques in preparing suitable materials for the study, as proven in
previous studies at the MI [54].
The use of preserving additives improved the stability of the PSTs investigated in this section
of the study which was particularly evident in the short-term samples at the higher
temperature storage condition of +40°C. The use of the antibiotics (Tissue 1) improved the
stability of the toxins GTX2,3 and GTX1,4 and the antioxidant (Tissue 2) improved the
stability of dcSTX and STX when compared to the untreated control (Tissue 3) in the shortterm. Both Tissues 1 and 2 showed excellent stability at +4°C for all the toxins investigated,
whereas Tissue 3 showed some instability issues for GTX2,3 under this storage condition.
The results indicate that the use of either an antioxidant or antibiotics in stabilising PSTs
depends on the toxin profile present. Their combined use however may provide better overall
stability for a range of PSTs. These short-term stability observations have particular
importance in determining transportation conditions required for shipment of materials and in
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the case of either Tissue 1 or 2, this could be carried out at temperatures of up to +4°C for as
long as 32 days without adverse effects to toxin stability.
The long-term stability studies did not definitively prove the benefits of using preserving
additives in RM preparation. Some minor improvements were observed in the case of
GTX1,4 using either the antibiotics or the antioxidant but none were significant. Long-term
storage of biological RMs should be at temperatures of -20°C or below.
Tissues 1 and 2 showed good chromatographic stability in peroxide oxidised samples with no
formation of additional peaks evidenced in the chromatograms. Conversely Tissue 3 showed
the formation of extra chromatographic peaks although these would not necessarily affect
accurate quantitation of any of the PSTs investigated in this study but which could affect
quantitation of the toxins C1,2 if they were present. This highlights another advantage of
using preserving additives in RM preparation to not only improve toxin stability but to
improve matrix and therefore chromatographic stability.
The results of these experiments indicate the applicability of using preserving additives in
LRM and ILRM preparation but not for CRM production. The antibiotics and antioxidant
spikes improve short-term stability, important for example in delivery of PT materials but the
long-term stability of these materials was not significantly improved enough to warrant
feasibility studies being undertaken for CRM production.
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4.3

PRESERVING ADDITIVES AND THERMAL TREATMENT

This section of Chapter 4 investigates the combined use of an antioxidant, ethoxyquin and
three antibiotics, ampicillin, erythromycin and oxytetracycline which were separately
evaluated in section 4.2. This section also evaluates the effects thermal treatment through
autoclaving had on matrix stability and the PSTs present. The two stabilisation techniques
were, as in the case of the section 4.2 materials, investigated in parallel with an untreated
control material.
Short and long-term stability experiments as well as homogeneity determinations were
conducted on materials prepared by both techniques in comparison with an untreated control
using two LC-FLD methods.

This section of Chapter 4 details work described in Burrell et al. 2015 [113].
Stephen Burrell, Valentin Clion, Virginie Auroy, Barry Foley & Andrew D. Turner, 2015.
Heat treatment and the use of additives to improve the stability of paralytic shellfish
poisoning toxins in shellfish tissue reference materials for internal quality control and
proficiency testing, Toxicon. 99:80–88.
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4.3.1 MATERIALS AND METHODS

4.3.1.1 SOURCE TISSUES
The Icelandic, Spanish and blank toxin free Irish tissues from Table 2-1 were used to prepare
the RM used in this section of the study. The tissues were naturally contaminated with
GTX2,3, STX, GTX1,4, and dcSTX and were diluted with a blank toxin free mussel tissue
due to the high levels of PSTs present in the other tissues.
A bulk tissue (>4.0 kg) was prepared for use in this section of Chapter 4 and subdivided into
four separate lots, sealed in PP containers and stored at -20°C until further use. The bulk
tissue was prepared by combining the proportions of tissues detailed in Table 4-6 into a 5 L
Waring™ goblet. The bulk tissue was homogenised as described in section 4.2.1.1.
Table 4-6: Quantities of source tissues used to prepare bulk homogenate for additives, thermal treatment and freeze drying
studies.

Country
Species
Mytilus edulis
Iceland
Mytilus edulis
Norway
Mytilus galloprovancialis
Spain
Mytilus edulis
Ireland

Tissue
WF
WF
WF
WF

Quantity (kg)
1.26
1.00
1.00
0.74

Aliquots were taken for MC determination (n=3) using the rotary vacuum method and
analysis by preCOX LC-FLD (n=1) as described in the materials and methods section 2.4.1
and 2.3.1 respectively, to give approximate PST concentrations in the bulk tissue. The bulk
homogenate was immediately subdivided into 3 x ~0.8 kg (Tissues A-C) and 1 x ~0.8 kg
(freeze drying in Chapter 5, section 5.4) aliquots by pouring the required amount of tissue
into PP containers, sealing with lids and parafilm before storing at -20°C until required for
use. The PST levels and MC results from this bulk homogenate are presented in Table 4-7.
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Table 4-7: Toxin profile, concentrations and moisture content of bulk tissue used to prepare Tissues A-C and a freeze dried
material in chapter 5.

Concentration (µmol / kg)
dcSTX

GTX-2,3

GTX-5

STX

GTX-1,4

Total Toxicity
(µg STX diHCl-eq / kg)

0.65

0.94

0.06

0.62

0.22

685

Material
Bulk
homogenate

%
Moisture
Content
81.6

4.3.1.2 ADDITIVES AND THERMAL TREATMENT MATERIAL PREPARATION
Both the additives spiked (Tissue A) and thermally treated (Tissue B) materials were
prepared similarly as follows. The frozen bulk homogenate described in section 4.3.1.1 above
were removed from the freezer and allowed to defrost overnight in a fridge at +4°C. The
preserving additives were prepared at a concentration of 0.02% w/w by dissolving in ethanol
(1% w/w). For the additives spike, 0.18 ± 0.01 g each of ampicillin, oxytetracycline,
erythromycin and ethoxyquin were weighed into a 50 mL PP centrifuge tube using a
calibrated 3-place balance. 9.0 ± 0.1 g ethanol was added to the centrifuge tube, capped and
vortex mixed for 5.0 min.
For Tissue A the defrosted tissues were manually mixed using a spatula before transferring
734 ± 1 g into a Waring™ goblet. The additives/ethanol solution was then spiked into the
tissue, washing out the centrifuge tube with a small volume of DI water before manually
mixing with a spatula. The final weight of the tissue was made up to 900 ± 1 g with DI water
in order to obtain a final tissue with a MC of ~85%.
For Tissue B the defrosted tissues were manually mixed using a spatula before being
transferred to a 3L PP beaker and autoclaved (Systec VE-100, Focus Scientific Solutions,
Meath, Ireland) at 121°C for 15.0 ± 0.1 min. The tissues were allowed to cool to room
temperature before being transferred, including any liquid to a Waring™ goblet and
homogenised on medium power for 5.0 ± 0.1 min. Aliquots (n=3) were taken for MC
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determination which was determined to be ~82%. 670 ± 1 g of the tissue was gravimetrically
transferred into a Waring™ goblet. The final weight of the tissue was made up to 800 ± 1 g
with DI water in order to obtain a final tissue with a MC of ~85%.
The final homogenisation steps of Tissue A and B using both Waring™ and Polytron™
blenders, including the dispensing of both was carried out as described in section 4.2.1.2. A
total of 150 aliquots of Tissue A and 120 aliquots of Tissue B were dispensed providing a
sufficient quantity for short (n=45) and long-term (n=45) stability studies as well as
homogeneity (n=16) and MC (n=3) determinations. All materials were stored at -80°C until
further use.

4.3.1.3 UNTREATED CONTROL MATERIAL PREPARATION
The untreated control material (Tissue C) was prepared by defrosting the bulk homogenate
described in section 4.2.1.1 above overnight in a fridge at +4°C. The defrosted tissue was
manually mixed using a spatula before transferring 734 ± 1 g into a Waring™ goblet. The
final weight of the tissue was made up to 900 ± 1 g with DI water in order to obtain a final
tissue with a MC of ~85%.
Tissue C was homogenised and dispensed as described in section 4.2.1.3. A total of 150
aliquots of Tissue C were dispensed providing a sufficient quantity for short (n=45) and longterm (n=45) stability studies as well as homogeneity (n=16) and MC (n=3) determinations.
All materials were stored at -80°C until required.
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4.3.1.4 STUDIES AND ANALYSIS
The between-bottle homogeneity of the materials prepared in sections 4.3.1.2 and 4.3.1.3
above was assessed through the intra-batch analysis of 16 aliquots (3n1/3) selected through
stratified random sampling of the entire fill series.
All materials were stability tested over a short term (ca. 30 day) and long term (ca. 12 month)
period following a reverse isochronous experimental design [55]. The short term study was
conducted with triplicate samples consisting of five time points (0, 4, 6, 16 and 30 day for
Tissue A, 0, 4, 8, 15 and 28 days for Tissue B and 0, 4, 8, 15 and 32 days for Tissue C) and
three temperature conditions (-20°C, +4°C and +40°C). The time points used in the study of
each material were again slightly different as it was necessary to alter the time models
slightly to ensure analysis was completed within the required time frame. The long term
study was conducted with triplicate samples consisting of five time points (0, 3, 6, 9 and 12
month) and three temperature conditions (-20°C, +4°C and +20°C). The reference
temperature used in both studies was -80°C. The stability studies were set up and carried out
as described in section 4.2.1.4.
At the end time point all samples were removed from storage, allowed to equilibrate to room
temperature before being extracted and analysed by preCOX LC-FLD closely following
OMA AOAC 2005.06 [41] as detailed in section 2.3.1. PCOX LC-FLD [75] analysis was
additionally performed on all samples to specifically investigate the extent of epimerisation,
if any, of GTX2,3 in each material. For PCOX LC-FLD analysis, the crude acetic acid
extracts prepared according to section 2.3.1 were deproteinated and analysed following
AOAC 2011.02 [75].
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PST concentrations in sample extracts were quantified against a 4 - 5-point calibration for
each toxin and are expressed in µmol/kg with total saxitoxin equivalents calculated as an
estimation of total toxicity.
The MC of each of the Tissues A-C was determined using the rotary vacuum method as
described in the materials and methods section 2.4.1, selecting aliquots from the beginning,
middle and end of the fill series.

4.3.2 RESULTS AND DISCUSSION

4.3.2.1 HOMOGENEITY

Figure 4-7: Homogeneity results for the additives spiked (Tissue A), heat treated (Tissue B) and untreated control (Tissue C)
materials showing mean toxin concentrations (± 1 s.d) determined by preCOX LC-FLD (n=16).
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Figure 4-7 illustrates the homogeneity results for the three tissues, showing mean PST
concentrations and standard deviations (sd) associated with the triplicate analysis. This allows
for a visual representation of the effects each treatment had on the toxin content, specifically
if any toxin degradation occurred during the processing steps. The homogeneity results for
the individual analogues and total toxicity from the three materials showed a statistical
difference (P < 0.05; one-way analysis of variance [ANOVA]) between the three means,
showing there were some effects on toxin concentrations following treated sample
preparation. The quantity of toxin degraded during the preparation of materials and the
acceptability of these losses depends on the needs of the RM producer and whether the
improvements to toxin stability these techniques provide outweigh the toxin losses incurred
through each processing technique. This was particularly important in the case of the heat
treated materials, which showed the relative thermal stability of the toxins during exposure to
high temperatures, even though a 15% reduction in total toxicity was determined, compared
to the control. The toxin profiles in each tissue remained consistent, as evidenced from Figure
4-7, which showed no visual evidence for the degradation or biotransformation of toxins
through any of the stability techniques.
The homogeneity results for each material were acceptable with percentage relative standard
deviations (RSD%; n=16) of <8 % for total toxicity (mean = 5.0 %) and individual analogues
(mean = 4.9 %), which were within expected levels of variability associated with intra-batch
repeatability as determined through previous validation studies [120].
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4.3.2.2 SHORT-TERM STABILITY
PRECOX LC-FLD
Figure 4-8 a-e represents the short-term stability results for the three materials at three
different storage temperatures, -20°C, +4°C and +40°C, determined through preCOX LCFLD analysis. Data for dcSTX, GTX1,4, GTX2,3, GTX5 and STX were generated and
results were normalised to the average of replicate analysis (n=9) of samples stored at the
reference temperature of -80°C for the duration of the study. The limits of stability from
Figure 4-8 were generated from two times the standard deviation of the -80°C replicate
analyses.
Overall toxin stability was excellent in each of the materials, including the untreated tissues
when stored at -20°C or +4°C for the duration of the short-term study. The stability of the
toxins at +40°C differed between each stabilisation technique and the control materials with
the thermally treated tissues in particular showing significant stability improvements for all
toxins present when compared to the untreated materials. From these results, heat treatment
proved the most effective technique investigated with dcSTX, GTX1,4, GTX2,3 and STX
showing excellent stability, even at the highest temperature of +40°C in addition to the two
other temperature conditions investigated. Mean concentrations of the N-sulfocarbamoyl
toxin GTX5 were however found to fall well below the standard deviation limits which may
indicate some stability issues relating to this toxin. The level of degradation of GTX5
(ca.50%), in the +40°C materials was very similar for the two stabilisation techniques as well
as the untreated materials however which showed neither an improvement nor deterioration
in GTX5 stability through the use of either technique compared to the control.
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Figure 4-8: Short-term stability graphs for the PSTs present in Tissues A, B and C determined by preCOX LC-FLD. Results
are normalised to the time zero reference temperature of -80°C (error bars represent ± 2 s.d.).
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additives spiked and control materials at +40°C indicating that no clear advantage is provided
in the additive treated tissues in the case of short-term toxin stability. Spiking tissues with
these additives did however significantly improve the stability of GTX2,3 with no stability
issues evident from Figure 4-8 c under any of the temperature conditions studied. Conversely
stability issues could be observed for these toxins after 4 days in the control materials stored
105

Chapter 4
at +40°C where an apparent increase in concentration could be observed which culminated in
an approximate 40% increase by the end of the study.
The preCOX analysis of these samples therefore clearly indicated that thermally treating
materials provides a significant stability improvement to all the toxins investigated, except
GTX5, compared to both the additives spiked and control materials. The inclusion of
additives such as those used in this study only appear to improve the stability of the toxins
GTX2,3 in the short-term compared to the control with no significant improvement made in
stabilising the other toxins present, although no deterioration was evident either.
Previous studies carried out by Smith et al., proved the role of bacteria, present in the
digestive glands of shellfish species, in the biotransformation of PSTs [132]. They concluded
that, in the presence of bacterial isolates taken from mussel digestive glands, GTX1,4
reductively transformed with concomitant production of GTX2,3. A decrease in GTX1,4
concentration under the +40°C storage condition was observed in both the additives and
control materials, which culminated in a total decrease of approximately 40% (additives) and
80% (control) by the end of the study. The increase in GTX2,3 concentration observed in
Tissue C is therefore most probably due to the reductive transformation of GTX-1,4 present
in the tissue. This transformation is thought to take place by the reductive elimination of the
C-11 hydroxysulfate (OHSO3) and N-1 hydroxyl (OH) moiety (Figure 1-3) by bacteria as
previously described by Kotaki et al, 1985 [137]. This reaction was observed to take place
when these toxins were present with Vibrio and Pseudomonas spp. of bacteria present in blue
mussels.
Further evidence for this hypothesis can be found in the fact that the slight increase in GTX2,3 levels and the decrease in GTX-1,4 concentration observed in the additives material was
significantly less than that observed in the control. If the changes in toxin concentration are
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indeed due to bacterially induced biotransformations, then the inclusion of additives would
limit the role these bacteria have in toxin transformation, through lowering the cell counts in
the tissue, resulting in the smaller changes observed in the additives material.
Thermally treating the material also provided excellent stability with dcSTX, STX and GTX2,3 stable under all storage conditions for the duration of the study. GTX-5 showed some
degradation under the elevated storage condition however. This technique, while maintaining
the same level of stability for dcSTX and STX, improves the stability of the toxins GTX-2,3
when compared to the control material.

PCOX LC-FLD
Further analysis was conducted on the short-term stability study extracts for each of the
techniques by PCOX LC-FLD and results are presented in Figure 4-9 a-b. The PCOX LCFLD method was used specifically to determine the rate of epimerization of GTX2 and
GTX3, if any, in the materials prepared by each technique compared to those found in the
controls. Limits of stability and normalised results were calculated as per the preCOX
analysis above.
No epimerization or degradation was observed in any materials when stored at -20°C for the
duration of the study with results falling within the limits of stability set. The materials spiked
with additives also showed no evidence for epimerization of GTX2 and GTX3 at +4°C,
although some slight degradation of GTX3 was observed after day 30 of the study under this
temperature condition, with GTX2 remaining stable throughout. However epimerization of
these toxins was observed in the additives spiked samples stored at +40°C which was evident
after day 4 of the study.
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Figure 4-9: Stability graphs for the PST epimers GTX2,3 determined by PCOX LC-FLD for the short-term data (3a-b) and
the long-term data (3c-d) Results are normalised to the time zero reference temperature of -80°C (error bars represent ± 2
s.d.).

No epimerization was observed in materials stabilised through thermal treatment under any of
the temperature storage conditions, -20°C, +4°C or +40°C which showed stability
improvements over both the additives and untreated materials. GTX2 remained stable
throughout the study under all temperature conditions but there was some degradation of the
toxin GTX3 evidenced after 15 days at +4°C and after 4 days at +40°C.
The control material while stable at -20°C showed signs of epimerization under the other two
storage conditions investigated. This was evident after 32 days of the study in samples stored
at +4°C and after 4 days in samples stored at +40°C. The rates of epimerization were greater
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in the control materials compared to either the thermally treated or additives spiked materials
which was particularly apparent under the +40°C storage condition. This highlights the
significant improvements these techniques make to toxin stability and epimerization rates
compared to the control materials in the short-term.
The results from both the preCOX and PCOX analysis provide useful information on the
conditions required for transportation of materials stabilised using both techniques. Although
transportation of matrix RMs ideally should be made under frozen conditions, results indicate
materials would also be stable at +4°C for up to 15 days which would be indicative of any
adverse conditions potentially experienced during transit which is particularly important for
producers of RMs or PT providers.

4.3.2.3 LONG-TERM STABILITY

PRECOX LC-FLD
Figure 4-10 a-e represents the long-term stability results for the three materials at three
different storage temperatures, -20°C, +4°C and +20°C, determined through preCOX LCFLD analysis. Data for dcSTX, GTX1,4, GTX2,3, GTX5 and STX were generated and
results were normalised to the average of replicate analysis (n=9) of samples stored at the
reference temperature of -80°C for the duration of the study. The limits of stability from
Figure 4-10 were generated from two times the standard deviation of the -80°C replicate
analyses.
All three tissues exhibited excellent stability for all the toxins throughout the duration of the
yearlong study when stored at -20°C. Differing levels of stability were exhibited under the
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other storage conditions however with both the heat treated and additives spiked materials
showing significant improvements to toxin stability compared to the control materials.
Heat treating the tissues provided better stability for the non N-hydroxylated toxins; dcSTX,
GTX2,3 and STX including the N-sulfocarbamoyl toxin GTX5, compared to both the
additives spiked and control materials. In comparison, the N-hydroxylated toxins GTX1,4
exhibited better stability in the additives-spiked materials compared to the control and
thermally treated tissues.
Excellent stability was evident in the heat treated materials stored at +4°C in addition to the 20°C results. The toxins dcSTX and STX also showed excellent stability when stored at
+20°C throughout the study, although some slight degradation of GTX5 was evidenced after
9 months at this higher temperature. GTX1,4 showed signs of degradation after 3 months at
+20°C with these toxins totally degraded by month 9 in the heat treated materials, while an
increase in GTX2,3 concentration was observed in samples after 6 months storage at this
temperature.
The inclusion of combined additives to the tissues significantly improved the stability of the
toxins compared to the control materials. This was particularly evident for the toxins GTX1,4
which showed no signs of degradation or increases in toxin content throughout the study
under any of the storage conditions used even though these toxins were present at relatively
low concentrations in the tissues. Some slight degradation of dcSTX, GTX5 and STX was
evident after 12 months, 9 months and 9 months respectively when stored at +20°C, with
these toxins exhibiting no stability issues under the +4°C storage condition with results
falling between the limits of stability set. An increase in GTX2,3 concentration was observed
in the additives spiked samples after 3 months under both the +4°C and +20°C storage
temperatures.
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Figure 4-10: Long-term stability graphs for the PSTs present in Tissues A, B and C determined by preCOX LC-FLD. Results
are normalised to the time zero reference temperature of -80°C (error bars represent ± 2 s.d.).
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with GTX1,4 and GTX2,3 becoming completely degraded after 3 months storage at +20°C
and GTX5 showing significant degradation (>50%) after 9 months storage at the same
temperature. At +4°C GTX1,4 showed some signs of degradation after 6 months storage,
conversely an increase in GTX2,3 concentration was observed after 3 months storage at the
same temperature. GTX5 showed no stability issues at this temperature. An increase in STX
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concentration was observed after 3 months storage at +20°C which was not evidenced in
samples prepared by the two stabilisation techniques and this toxin was found to be stable at
+4°C in the untreated materials. dcSTX showed some signs of degradation after 9 months
storage at +20°C, although no dcSTX stability issues were observed in samples stored at the
other two temperatures. These results highlight the benefits of both stabilisation techniques
and specifically the level of stability provided to each toxin while emphasizing the significant
improvement each procedure makes in comparison to the untreated materials.

PCOX LC-FLD
Further analysis was conducted by PCOX LC-FLD on the long-term stability study extracts
of each of the materials and results are presented in Figure 4-9 c-d. Limits of stability and
normalised results were calculated as per the preCOX analysis. Data for the toxins GTX1 and
GTX4 were not generated as the concentration of these toxins in each material was <LOD of
the PCOX LC-FLD method.
No epimerization or degradation was observed in any materials when stored at -20°C for the
duration of the long-term study with results falling within the limits of stability set. As in the
case of the short-term study, no epimerization was observed in the heat treated materials
under any temperature condition, with the only stability issue evident in these materials being
a slight degradation of GTX3 observed after 3 months at +4°C.
Epimerization was observed in the additives spiked materials under both the +4°C and +20°C
storage temperatures after 3 months of the study, although this was a significant improvement
compared to the control materials where epimerization of the toxins was evident in the +4°C
samples but the GTX2,3 content was completely degraded by month 3 at +20°C.
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The thermal treatment of materials again proved to be the most effective in minimising or
eliminating the amount of epimerization of GTX2,3 with the additives spiked materials also
significantly reducing these rates compared to the control tissues.
Epimerization of these toxins followed predicted patterns with the β-epimer GTX3 being
epimerized into the more stable α-form GTX2 [136] which was evident from both the short
and long-term stability data generated through the PCOX LC-FLD analysis.

CHROMATOGRAPHIC STABILITY
The chromatographic stability of each of the preparation techniques were compared through
visual comparison. Figure 4-11 a-h displays chromatograms generated by preCOX LC-FLD
for the three materials by both peroxide and periodate oxidation after 12 months storage at
different temperatures. Chromatograms of the control material stored at -80°C for 12 months
are also shown in this figure as a visual comparison. The chromatograms generated through
peroxide oxidation (Figure 4-11 a-c) show differing levels of stability, with the control
material showing the total degradation of the toxins GTX2,3 and the formation of an
additional fluorescent peak close to that of GTX2,3 in the additives material (Tissue A).
Good chromatographic stability was observed in the heat treated materials (Tissue B) with no
visual evidence for the formation of additional chromatographic peaks by this processing
technique after peroxide oxidation when compared to the control material stored at -80°C.
The retention time differences observed in Figure 4-11 are due to the analysis of the tissues
being carried out on separate days using different HPLC columns. Retention time QC checks
through comparison to standards was however carried out each day.
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Figure 4-11: PreCOX LC-FLD chromatograms following peroxide (5a-d) and periodate (5e-h) oxidation of Tissues A, B, C
and a temperature control material stored for 12 months.
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The periodate oxidised extracts used to quantify the N-hydroxylated toxins GTX1,4 are
illustrated in Figure 4-11 e-h. In the case of the control and heat treated materials,
chromatograms from the +4°C storage condition are shown while a chromatogram for an
additives spiked material stored at +20°C for 12 months is shown. This is due to the fact that
the total GTX1,4 content in the heat treated and control materials was degraded under the
+20°C storage condition. Good chromatographic stability was observed in the samples shown
(Figure 4-11 e-h) with no visual evidence for the additional formation of chromatographic
peaks from any of the processing techniques after periodate oxidation.

4.3.3 CONCLUSIONS
The techniques investigated in this study were found to significantly improve the stability of
PSP toxins in M. edulis tissue matrices. The application of a heat treatment step or the
inclusion of additives during material processing provided a more stable matrix that was less
prone to degradation when compared to an untreated control material. As with previous
studies showing the role of bacteria in biotransformations of PSTs [132], techniques such as
those investigated in this study, aimed at reducing or eliminating the bacterial effects will
lower the rates of toxin degradation, epimerization or biotransformations. Although the
material processing and dispensing steps are not carried out aseptically, reducing or
eliminating bacteria present in the source tissues through these techniques significantly
improves the stability of matrix RMs [52].
As evidenced in both the short and long-term stability studies, frozen sample storage
improved toxin stability for all three tissues. Of particular interest however is stability under
elevated temperature conditions, which are used to mimic adverse transportation conditions.
This is particularly important for RM producers and PT providers to know, as well as
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ascertaining ideal long-term storage parameters. Under higher temperature storage
conditions, both stabilisation procedures significantly improved toxin stability compared to
the untreated control materials, although both techniques varied in the extent to which they
enhanced stability. Specifically, the thermal treatment provided better stability for the non-Nhydroxylated toxins GTX2,3, GTX5, STX and dcSTX while the additives spiked materials
provided better stability for the N-hydroxylated toxins GTX1,4.
This observation was particularly evident from the long-term study where the total GTX1,4
content in the thermally treated materials were completely degraded by month 9 with these
toxins remaining stable throughout the study in the additives spiked material (Figure 4-10 b).
The stability of STX and dcSTX in the thermally treated materials was significantly
improved compared to the additives spiked with both toxins remaining stable throughout the
12 months under all temperature conditions, whereas some degradation was observed at
+20°C in the additives spiked material. Thermally treating the material also eliminated the
epimerization of GTX2,3 in contrast to both the additives spiked and control materials,
although the inclusion of additives significantly improved the stability and lowered the
epimerization rates compared to the control materials.
Overall both material preparation techniques proved effective in stabilising both the tissue
matrix and the PSP toxins present as compared to the control material. Each technique
provided a greater degree of stability for certain toxins which indicate that combining the two
techniques for preparing RMs would result in a well stabilised material for both the non-Nhydroxylated and N-hydroxylated toxins. A combined technique of thermally treating the
source tissues prior to spiking with additives is described in the following section 4.4.
These techniques also provide a cost effective means of improving PSP toxin stability and
prove the applicability of these materials for a range of different uses including method
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development and validation as well as use in the general QC of routine monitoring methods
and PT schemes as detailed in the following section.
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4.4

COMBINED TECHNIQUES, QUALITY CONTROL AND QUASIMEME

This section of Chapter 4 presents data generated from a RM prepared by combining the
techniques described in section 4.3, specifically thermally treating the source tissues prior to
spiking with preserving additives. This optimised preparation technique is detailed and data is
presented from its use over a two year period in the Irish NMP (internal MI code LRM-0902) and in a development exercise as part of a proficiency testing scheme operated by
QUASIMEME since 2011 (PT code Tissue B in Chapter 6).
This material’s use in QUASIMEME PT schemes is detailed more thoroughly in Chapter 6
but is highlighted here because a separate issue became apparent during the planning stages
of the PT development exercise. This relates to methods used by some participants in
QUASIMEME exercises, specifically the use of the MBA and the potential effects which the
preserving additives/ethanol solution may have had on this assay. Although in this study each
additive is spiked into tissues at levels well below their individual LD50 values no data exists
in literature on their combined effects, if any. PST free M. edulis tissues as determined by
both LC-FLD and MBA were spiked with these additives at various levels, extracted
following the MBA protocol [40] and injected into mice to observe if there were any effects,
particularly PSP-like symptoms which could be misinterpreted. The extraction procedure as
described in the materials and methods section 2.3.3 for the MBA was scaled down to
incorporate the smaller aliquot size of 5 grams which was used for QUASIMEME samples.
This aliquot size was chosen due to the large amount of tissue which would have been
required to make samples for MBA at the prescribed quantity described in the official method
[40].
Short-term stability as well as homogeneity were determined experimentally on materials
prepared by the optimised preparation technique. Long-term stability was not assessed in this
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material due to its primary use in PT schemes and internal QC/QA where stability during
transportation is more of a requirement and which can be adequately determined through
short-term stability studies.

4.4.1 MATERIALS AND METHODS

4.4.1.1 SOURCE TISSUES
The Spanish and UK (Busta Voe) tissues from Table 2-1 were used to prepare the RM used
in this section of the study. The tissues were naturally contaminated with the carbamates
GTX2,3 and STX, the decarbamoyl toxin dcSTX as well as the N-sulfocarbamoyl toxins
C1,2 and GTX5.
The quantities detailed in Table 4-8 were combined in a 5 L Waring™ goblet. The bulk
tissues were homogenised as described in section 4.2.1.1.
Table 4-8: Quantities of source wet frozen tissues used to prepare RM with combined techniques of spiking preserving
additives with initial thermal pre-treatment..

Country
UK (Busta Voe)
Spain

Species
Mytilus edulis
Mytilus galloprovancialis

Quantity (kg)
1.4
1.4

Aliquots were taken for MC determination (n=3) using the rotary vacuum method and
analysis by preCOX LC-FLD (n=1) as described in the materials and methods section 2.4.1
and 2.3.1 respectively, to give approximate PST concentrations which are detailed in Table
4-9.
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Table 4-9: Concentrations for combined source tissues used to prepare RM.

Concentration (µmol / kg)

Total Toxicity
(µg STX diHCl-eq / kg)

Material

Bulk
homogenate

dcSTX

GTX2,3

GTX5

STX

C1,2

GTX1,4

1.45

2.12

0.13

2.36

-

2.9

2975

4.4.1.2 MATERIAL PREPARATION
The preserving additives solution was prepared at a concentration of 0.02% w/w by
dissolving in ethanol (1% w/w). For the additives spike, 0.6 ± 0.01 g each of ampicillin,
oxytetracycline, erythromycin and ethoxyquin were weighed into a 50 mL PP centrifuge tube
using a calibrated 3-place balance. 30 ± 0.1 g ethanol were added to the centrifuge tube,
capped and vortex mixed for 5.0 min.
The tissues were autoclaved in 2 x 3L PP beakers at 121°C for 15.0 min. Subsequently the
tissues were allowed to cool to room temperature before being transferred, including any
liquid, into a Waring™ goblet and homogenised on medium power for 5.0 min. Aliquots
(n=3) were taken for MC determination which was determined to be 76.9% with a %RSD of
0.31%. 2215 ± 1 g of the tissue were gravimetrically transferred into a Waring™ goblet. The
additives /ethanol solution was spiked into the tissue washing out the centrifuge tube with a
small volume of DI water before manually mixing with a spatula. The final weight of the
tissue was made up to 3000 ± 1 g with DI water in order to obtain a final tissue with a MC of
~83%.
The final homogenisation and dispensing steps followed were as described in section 4.2.1.2.
A total of 582 aliquots were dispensed which provided sufficient quantities for short-term
stability studies, homogeneity determinations as well as its intended use as a QC material for
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the Irish NMP and as a material in the first PSP development exercise organised by
QUASIMEME. All materials were stored at -80°C until further use.

4.4.1.3 MBA MATERIALS
An M. edulis tissue was sourced from an Irish NMP sample originating from Carlingford
Lough, Co. Louth, Ireland and shown to be free from all EU regulated marine biotoxins by
fully accredited MI methods preCOX LC-FLD and MBA for PSP toxins, LC-MS/MS for the
lipophilic toxins and LC-UV for domoic and epi-domoic acid (MI Irish National
Accreditation Board No. 130T). The tissue was homogenised in a 3 L Waring™ goblet
before being subdivided into four separate lots. Three tissues were prepared with additive
spikes at 0.01, 0.02 and 0.05% w/w by dissolving antibiotic and antioxidant chemicals in
ethanol at a volume of 1% of the total tissue weight.
The 0.01% (100 mg/kg) solution was prepared by weighing 0.012 ± 0.001 g each of
ethoxyquin, ampicillin, erythromycin and oxytetracycline into a 50 mL PP centrifuge tube
with 1.20 ± 0.01 g ethanol. This solution was vortex mixed (Vortex Genie-2, Scientific
Industries, NY, USA) for 5.0 min before being spiked into 120 ± 1 g of the M.edulis tissue
described above in a 1 L Waring™ goblet, stirred with a spatula and homogenised on
medium power for 5.0 min.
The 0.02% and 0.05% additives solutions were prepared identically as above spiking 0.024 ±
0.001g and 0.060 ± 0.001 g of each additive respectively into 1.2 ± 0.1 g ethanol in a PP
centrifuge tube. Each additive solution was spiked separately into 120 ± 1 g M.edulis tissue
described above in a 1 L Waring™ goblet, stirred with a spatula and homogenised on
medium power for 5.0 min. The fourth tissue remained untreated and contained no additives
or ethanol spike.
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4.4.1.4 STUDIES AND ANALYSIS
The between-bottle homogeneity of the material was assessed through the intra-batch
analysis of 10 aliquots selected through stratified random sampling of the entire fill series.
The number of aliquots chosen for homogeneity determination was based on the
recommendations of ISO for PT materials [71].
The material was stability tested over the short term following a reverse isochronous
experimental design [55] as conducted previously for other tissues. The short term study was
conducted with triplicate samples consisting of five time points (0, 2, 8, 16 and 30 day) and
three temperature conditions (-20°C, +4°C and +40°C). The reference temperature used was 80°C. The stability studies were carried out as described in section 4.2.1.4.
At the end time point all samples were removed from storage, allowed to equilibrate to room
temperature before being extracted and analysed by preCOX LC-FLD closely following
OMA AOAC 2005.06 [41] as detailed in section 2.3.1. PCOX LC-FLD analysis was not
performed on this RM due to its primary use as an internal QC/QA material for the preCOX
LC-FLD method routinely used at the MI for PST analysis.
PST concentrations in sample extracts were quantified against a 5-point calibration for each
toxin and are expressed in µmol/kg with total saxitoxin equivalents calculated as an
estimation of total toxicity as described in section 2.3.1.
The MC was determined using the rotary vacuum method as described in the materials and
methods section 2.4.1, selecting aliquots from the beginning, middle and end of the fill series.
For the additives spiking MBA experiments, each material was extracted according to the
AOAC official method 959.08 [40] using a scaled down procedure to incorporate the 5.0 g
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aliquot size. Aliquots (1mL) were injected intraperitoneally into male albino CD1 strain mice
in triplicate.

4.4.2 RESULTS AND DISCUSSION

4.4.2.1 ADDITIVES SPIKING MBA EXPERIMENTS
Mice were observed for 60 min after intraperitoneal injection with the extracted additives
materials. No PSP-like or other symptoms were observed during this time which could be
misinterpreted as a PSP positive sample. The additives should therefore have no adverse
effect on PSP determination using the MBA.

4.4.2.2 HOMOGENEITY AND MOISTURE CONTENT
As evidenced from Table 4-10 the homogeneity of the PST-positive material was sufficient
and was suitable for its intended purposes as a QC/QA and PT material. The target %CV of
8% was achieved for each analyte so again below expected levels of intra-batch repeatability.
The homogeneity of the toxins C1,2 were not determined due to the lack of a CRM
calibration standard available at the time, although homogeneity of the other toxins should be
indicative of overall homogeneity in this tissue.
Table 4-10: Homogeneity results for LRM-09-02 (n=25)

dcSTX

GTX2,3

GTX5

STX

C1,2

GTX1,4

Average

0.77

1.44

0.12

0.40

-

0.34

Total Toxicity
(µg STX diHCl-eq /
kg)
888

Stdev

0.03

0.08

0.01

0.02

-

6.6

47

0.2

%CV

3.8

5.6

6.3

4.7

-

5.2

4.7

0.7

Concentration (µmol / kg)
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4.4.2.3 SHORT-TERM STABILITY
Figure 4-12 a-e represents the short-term stability results for the material prepared using the
combined techniques at three different storage temperatures, -20°C, +4°C and +40°C,
determined following preCOX LC-FLD analysis. Data for dcSTX, GTX1,4, GTX2,3, GTX5
and STX were generated and results were normalised to the average of replicate analysis
(n=9) of samples stored at the reference temperature of -80°C for the duration of the study.
As with previous experiments the limits of stability illustrated in Figure 4-12 were generated
from two times the standard deviation of the -80°C replicate analyses.
Overall toxin stability was excellent in the materials stored at -20°C and +4°C for the
duration of the short-term study. The stability of the toxins at +40°C differed however with
GTX2,3 being the only toxins stable at this elevated storage temperature. Degradation was
evident after 8 days in the case of dcSTX and after 16 days in the case of the toxins GTX1,4,
GTX5 and STX. GTX5 showed the most signs of degradation with ~80% of this toxins total
content in the tissue destroyed by the end of the study compared to ~60% of dcSTX and 40%
of GTX1,4 and STX.
The results from the short-term stability studies provide useful information on the conditions
required for transportation which was particularly important for this materials use in a PT
scheme. Although transportation of matrix RMs ideally should be made under frozen
conditions, results indicate materials would also be stable at +4°C for up to 30 days and at
+40°C for as long as 8 days. This would mimic any adverse conditions potentially
experienced during transit to participants, particularly to countries where delivery is
logistically difficult.
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Figure 4-12: Short-term stability graphs for LRM-09-02.
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4.4.2.4 INTERNAL QC AND PT SCHEMES
Total toxicity data generated through the use of this RM is presented in the Shewhart chart in
Figure 4-13. This RM was used over a two year period from January 2011 to December 2012
as part of the Irish NMP for marine biotoxins and the data was generated using the preCOX
LC-FLD method AOAC2005.06 [41]. This data was used to estimate the long-term method
reproducibility as an RSD of 8.7%, which was used to calculate an expanded uncertainty of
measurement (U) of ~17% at a concentration level just above the EU regulatory limit of
800µg STX diHCl eq./kg based on a coverage factor of 2. The data generated through this
materials use and in validation and optimisation experiments was instrumental in the MI
ceasing its use of the MBA and moving to PSP analysis by preCOX LC-FLD which was
accredited by the Irish National Accreditation Board (INAB) in 2010 (130T).
The within lab reproducibility, expressed as an RSD of 8.7% (Total Toxicity) correlates well
with data generated through previous validation studies [120,138,139]. In a single laboratory
validation carried out on mussel tissues and reported by Turner et al., [120] long-term method
reproducibility (> 2 months) was estimated through repeat analysis of an internal LRM. The
RSD (%) was determined to be between 11-69% for the individual analogues with total
toxicity giving a result of 17%. The low RSD (%) value determined at the MI is indicative of
both long-term method reproducibility as well as the long-term stability of the LRM being
used.
The use of such materials for internal QC can give valuable information on trends or drifts
associated with the method. Figure 4-13 also demonstrates the within-laboratory
reproducibility of this method which has been fully in-house validated. Changes to the system
made over the two year period this material was in use had no noticeable effects on the
overall performance of the method and therefore this RM use. Such changes included new
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personnel being trained on and incorporated into running the method, analytical column and
guard cartridge replacements, changes in suppliers of chemicals and consumables such as
solid phase extraction cartridges, preparation of new standards on a monthly basis and the
general and annual maintenance carried out on the instrument. The use of this RM in the Irish
NMP also demonstrates the long-term stability of the material using a classical stability
model.

Figure 4-13: Shewhart chart representing total toxicity data collected over a two year period at the Marine Institute in the
analysis of PSP toxins by preCOX LC-FLD (AOAC2005.06) as part of the Irish NMP.

The same RM has been used in three PSP development exercises of the QUASIMEME PT
scheme over a four year period. These exercises gave further evidence for long-term stability
and reproducibility, evidenced through consistent assigned values of 977, 950 and 986 µg
STX diHCl eq./kg determined by participants and the associated between laboratory RSD
values of 15, 16 and 13% respectively determined from participants receiving satisfactory z-
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scores. The assigned values were determined from participants using a range of different
methods based on preCOX and PCOX LC-FLD and MBA which demonstrates the
applicability of these materials for a range of different methods. This PT data is further
discussed in chapter 6.
A material prepared using one of these techniques was used in another PT scheme operated
by VEREFIN in 2013. This PT scheme was organised to assess the performance of
designated EU laboratories in analysing STX due to its inclusion on the schedule I list of UN
chemical weapons. The details of these PT schemes are not discussed in this thesis but are
described in Harju et al. 2015a and 2015b [140,141].

4.4.3 CONCLUSIONS
From the results contained in this section the combined techniques of thermally treating the
source tissues prior to spiking with additives produced a stable RM for the toxins studied.
The results were indicative of both short-term stability under transportation conditions and
the long-term stability of the material as evidenced through consistent assigned values in the
case of the proficiency testing scheme and a low relative standard deviation of 10.5% for total
toxicity data generated over 24 months as part of the Irish NMP.
Materials prepared by these techniques were used successfully for a number of different
purposes including method development, optimisation and validation studies, as a QC tool in
the Irish NMP for PSP toxins and as PT materials used by QUASIMEME and VEREFIN.
The relatively simple techniques described in this chapter so far produce materials
sufficiently stable and homogenous for the toxins studied.
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4.5

HIGH PRESSURE PROCESSING

The research described in this section of Chapter 4 details work described in Turner et al.
2014 [135].
Andrew D. Turner, Andy L. Powell and Stephen Burrell. 2014. Novel application of High
Pressure Processing for the production of shellfish toxin matrix reference materials. Toxicon.
90:1-14
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This work was carried out in collaboration with Dr. Andrew Turner and his team in CEFAS,
Weymouth, UK. From the work described in this section the initial trial materials, batch 1 &
2 (HPP 1-6) were prepared by Dr. Turner. This included the extraction and analysis of these
initial optimisation materials. Microbiological determination was conducted by Andrew
Powell at CEFAS. The materials were HPP treated at AFBI facilities in Belfast. The
optimised HPP tissue was transferred on ice to MI facilities where it was processed and
dispensed by the author. The homogeneity and stability experiments were designed and
conducted by the author at the MI including all toxin analysis by preCOX and PCOX LCFLD. The control material was prepared by Dr. Turner at CEFAS, including all toxin
analysis, and results were provided to the author for comparison purposes.
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High Hydrostatic Pressure Processing (HHP) or High Pressure Processing (HPP) is a
pasteurisation technique which has been employed for over a hundred years as a non-thermal
method of preserving and sterilising food [69]. The process has been applied to high water
content foodstuffs including seafood [142] and, owing to the minimal impact the process has
on the physical and nutritional characteristics of the product coupled to its sterilising
properties, is of interest to RM producers. The pressure is evenly distributed throughout the
foodstuff by using water as the transmission medium. Pressures typically in the range of
150MPa to 600 MPa are applied to the product for 1 – 15 min. [70]. Application of HPP in
the area of shellfish safety has garnered significant interest, particularly for bivalve molluscs
such as oysters. This species, typically eaten raw may have significant microbial activity
owing to the filter feeding activities of the animal, with HPP removing total viable counts as
well as specific microbiological contaminants including Escherichia coli, Vibrio and
norovirus [70,143–146].
The novel application of HPP was therefore investigated for the removal of biological
activity from homogenised oyster tissues, specifically in producing stable and homogeneous
matrix reference materials. The effects of various HPP parameters on biological activity and
PSP toxin concentrations was assessed.
Short and long-term stability experiments as well as homogeneity determinations were
conducted on materials prepared by both techniques in comparison with an untreated control
using two LC-FLD methods which enabled the quantitation of individual PSP toxins and
toxin epimeric pairs. The within-batch repeatability of the process was assessed through the
treatment of replicate samples under different processing conditions and the between-batch
repeatability examined through the treatment of a second larger volume of tissue also
subsequently subjected to analysis to assess material homogeneity and stability.
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4.5.1 MATERIALS AND METHODS

4.5.1.1 INITIAL STUDIES (CARRIED OUT BY THE COLLABORATOR AT CEFAS AND AFBI)
CONTAMINATED OYSTER PREPARATION
Pacific oysters (Crassostrea gigas) fed mass cultured toxic Alexandrium algae as described
previously [147], were used to produce two batches of PSP positive material. 350L of an
Alexandrium fundyense culture (strain CCMP 1719) was produced using a 12 tubular bag
photobioreactor set to a 14:10 hour light:dark cycle at 17°C. The culture was subsequently
fed to the Pacific oysters over a 5 day period using aerated re-circulating tanks set to 17°C.
The oysters were removed from the tank after this period, shucked, homogenised and placed
in polythene bags and stored at -20°C until further use. The first batch was diluted with PSPfree Pacific oyster tissue to reduce the total PSP levels to close to the regulatory action limit.
The second batch remained undiluted.

HIGH PRESSURE PROCESSING
Following homogenisation, 700 g of the oyster tissue was divided into six sub-samples, with
each further sub-divided into three sub-samples. These triplicate sub-samples were labelled
and bagged together. In order to successfully transmit pressure through the material, it was
necessary to suitably package the tissues to ensure the integrity of the seal was maintained.
This involved further sealing the tissues in separate vacuum-pack bags which were placed
into additional polythene bags, grouping replicates together. Samples were then sent to the
Food Microbiology Branch of Agri-Food and Bioscience Institute (AFBI) of Northern Ireland
together with travel control materials which were to remain unprocessed during the
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procedure. The packaged samples were allowed to equilibrate to room temperature before the
processing conditions detailed in Table 4-11 were applied.
Table 4-11: Experimental conditions used for HPP treatment of oyster tissues (batch 1 and 2).

Sample
HPP1
HPP2
HPP3
HPP4
HPP5
HPP6

Pressure (bar)
2000
3500
7000
2000
3500
7000

Temperature (°C)
5
5
5
35
35
35

Time (min)
5
5
5
5
5
5

A processing error resulted in samples being treated for 1.0 min only, with the remaining 4.0
min treatment applied the next day. Six months after this initial treatment, a second batch of
materials, in singe 300 g samples was subjected to HPP using the same processing conditions
but administered in single 5 min treatments. After both treatments, samples were shipped
back to CEFAS under temperature controlled conditions alongside the untreated travel
controls. On receipt at CEFAS, samples were opened and processed immediately.

BACTERIAL LEVEL TESTING
Pouches containing the HPP-treated as well as the untreated control samples were opened and
tested for microbial activity using a total viable count (TVC) method. Each tissue sample was
tested by taking duplicate 100µL aliquots of serial log10 dilutions spread onto the surface of
plate count agar (Oxoid CM0325) plates, with dilutions performed using 0.1% peptone water
depending on the microbial activity of the sample. Plates were incubated at 25 ± 1°C for a
total of 7 days before being visually assessed, with plates yielding up to 300 colony forming
units (CFU)/plate recorded for each dilution test. The mean of each duplicate pair was used
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and results were expressed as CFU/g LRM. The nominal limit of detection of the TVC
method was 5CFU/g.

TOXIN ANALYSIS
Aliquots of the HPP treated tissues as well as the untreated travel controls were removed
from their packaging and allowed to equilibrate to room temperature. After thorough mixing
aliquots were taken for toxin analysis with the remaining material stored at -20°C for future
stability testing.
Sample extraction, SPE cleanup and oxidation was carried out at CEFAS flowing OMA
AOAC 2005.06 [41]. LC-FLD analysis was performed using an Agilent (Stockport, UK)
1200 LC-FLD system with a Gemini C18 reversed-phase column (150 mm x 4.6 mm, 5 μm;
Phenomenex, Manchester, UK) (set to 35 °C). Mobile phases and LC gradient conditions
used were those described previously [147].
Samples were extracted and analysed at the MI by preCOX LC-FLD closely following OMA
AOAC 2005.06 [41] as detailed in section 2.3.1. PCOX LC-FLD [75] analysis conducted at
the MI was additionally performed on all samples to specifically investigate the extent of
epimerisation. For PCOX LC-FLD analysis, the crude acetic acid extracts prepared according
to section 2.3.1 were deproteinated and analysed following AOAC 2011.02 [75].
Toxin concentrations were quantified against 5-6-point calibration standards with both
individual PST concentrations and total saxitoxin equivalents determined. For the
homogeneity and stability experiments, the extraction was scaled down to enable the testing
of a suitable number of aliquots, specifically performing extractions on 2.0 g tissue and
diluting to a total of 5.0 mL prior to C18 clean-up.
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STUDY DESIGN
The first batch of HPP-treated tissues, including untreated travel controls were analysed for
PSP toxin concentration as well as being assessed for biological activity. Triplicate samples
from each of the processing conditions HPP1-6 were analysed to determine the within batch
variability of each condition as well as determining optimum HPP parameters. The second
batch of HPP treated materials was assessed as these materials were subjected to a single 5
min HPP treatment while also generating a sufficient volume of tissue for stability testing.
Extracted tissues were analysed by LC-FLD in triplicate with samples spread evenly
throughout the instrumental sequence. Selected HPP-treated tissues were re-homogenised and
assessed for homogeneity and stability as described below.

4.5.1.2 ANALYSIS AND STUDY DESIGN (CARRIED OUT BY THE AUTHOR AT THE MI)
HOMOGENEITY
The selected HPP-treated bulk tissues were combined, mixed thoroughly before weighing 2.0
g aliquots into pre-labelled plastic vials and hermetically sealed with foil caps under a stream
of nitrogen. Aliquots were stored at -20°C until required for analysis. The homogeneity of the
HPP-treated oyster tissue was assessed through the intra-batch analysis of samples selected
through stratified random sampling. Ten aliquots were selected, extracted and analysed
according to section 2.3.1.

STABILITY STUDIES
All materials were stability tested over a short term (ca. 14 day) and long term (ca. 6 month)
period following a reverse isochronous experimental design [55]. The short term study was
conducted with triplicate samples consisting of five time points (0, 2, 5, 10 and 14 day) and
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four temperature conditions (-20°C, +4°C, +20°C and +40°C). The long term study was
conducted with triplicate samples consisting of five time points (0, 1, 2, 4 and 6 month) and
three temperature conditions (-20°C, +4°C and +20°C). The reference temperature used in
both studies was -80°C. In the case of all the stability studies; aliquots (n=3) were removed
from -80°C storage on the prescribed day and transferred to the storage conditions being
investigated.
At the end time point in both studies samples were removed from the various storage
conditions, allowed to equilibrate to room temperature before being extracted and analysed
by preCOX LC-FLD closely following OMA AOAC 2005.06 [41] as detailed in section
2.3.1. PCOX LC-FLD [75] analysis was additionally performed on all samples to investigate
the extent of epimerisation, if any. For PCOX LC-FLD analysis, the crude acetic acid extracts
prepared according to section 2.3.1 were deproteinated and analysed following AOAC
2011.02 [75].
PST concentrations in sample extracts were quantified against a 4 - 5-point calibration for
each toxin and are expressed in µmol/kg with total saxitoxin equivalents calculated as an
estimation of total toxicity.
The stability studies for the untreated oyster tissue were carried out at a different time and
using a different model to the HPP described above so the time points graphically represented
in both the short and long-term studies differ slightly (Figure 4-16 & Figure 4-18).
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4.5.2 RESULTS

PROCESSING CONDITIONS
The processing conditions recorded during the HPP treatment of the batch 1 and 2 materials
are detailed in Table 4-12. The pressures recorded during the HPP treatment were all within
1% of the set values. Adiabatic heating during the process could not be avoided so the
processing temperatures recorded during the treatment are different to the set values.
Table 4-12: Actual HPP conditions recorded during the two processing batches.

Batch 1

Batch 2

Sample

Maximum
temperature

Minimum
pressure (bar)

Maximum
pressure
(bar)

Maximum
temperature

Minimum
pressure (bar)

Maximum
pressure
(bar)

HPP1

15°C

1998

2020

15°C

1998

2017

HPP2

18°C

3999

4030

17°C

3996

4019

HPP3

21°C

5989

6023

22°C

5961

6023

HPP4

42°C

1997

2019

39°C

1988

2011

HPP5

45°C

3977

4027

45°C

3977

4019

HPP6

50°C

5959

6021

49°C

5961

6029

BIOLOGICAL ACTIVITY
The TVC testing results of both HPP treated batches of oyster tissue and the untreated travel
controls are contained in Table 4-13. The data clearly demonstrates the advantages HPP has
on removing biological activity with each treatment HPP 1-6 significantly reducing microbial
activity compared to the travel controls, although the lower values in replicate C, batch 1
were noted. The most intensive treatment HPP 6 provided the greatest success in terms of
microbial removal.
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Table 4-13: Results from duplicate microbial testing of HPP-treated Pacific oyster tissues plus travel controls from two
batches of processing, after incubation for 7 days at 25°C (units CFU/g; LOD = 5 CFU/g).

Batch 1
Sample

Replicate A

Batch 2

Replicate B

Replicate C

HPP 1

<LOD

20

20

<LOD

40

40

<LOD

<LOD

HPP 2

<LOD

20

10

<LOD

20

50

300

<LOD

HPP 3

<LOD

30

50

20

30

<LOD

200

<LOD

HPP 4

10

40

20

<LOD

70

<LOD

800

<LOD

HPP 5

20

<LOD

<LOD

30

40

<LOD

1100

300

HPP 6

<LOD

20

<LOD

<LOD

<LOD

<LOD

<LOD

<LOD

Travel

160000

120000

340000

160000

10000

10000

6000000

6000000

4.5.2.1 PRECOX LC-FLD

BATCH 1
Mean toxin concentrations including total toxicity for each of the HPP treatments and
untreated control materials are detailed in Table 4-14. Toxin concentrations were found to be
similar in each of the HPP treatments including the travel controls, apart from HPP 1 where a
lower concentration of GTX1,4 was determined which resulted in a lower STX-eq/kg value
(Figure 4-14).
Table 4-14: Results from PreCOX LC-FLD analysis of HPP-treated tissues (batch 1) and travel controls, showing toxin
concentrations and total saxitoxin in STX di-HCl eq/kg (± 1 s.d; n=3).

GTX1,4
NEO
C1,2
GTX2,3
STX
Total

HPP1
83 ± 7
46 ± 4
3.7 ± 0.4
5.8 ± 0.7
4.4 ± 0.5
143 ± 12

HPP2
102 ± 7
55 ± 4
4.6 ± 0.3
6.8 ± 0.6
5.2 ± 0.3
174 ± 11

HPP3
102 ± 6
55 ± 3
4.4 ± 0.3
6.6 ± 1
5.0 ± 0.4
173 ± 10

HPP4
109 ± 7
58 ± 3
3.9 ± 0.2
6.1 ± 0.6
5.2 ± 0.3
182 ± 10

HPP5
103 ± 5
54 ± 2
4.2 ± 0.4
7.2 ± 0.8
5.4 ± 0.2
174 ± 7

HPP6
103 ± 5
56 ± 3
4.5 ± 0.7
6.9 ± 0.8
5.1 ± 0.2
175 ± 7

Controls
100 ± 7
58 ± 7
4.2 ± 0.4
7.3 ± 0.8
5.2 ± 0.3
175 ± 15

The percentage relative standard deviations (%RSD) as seen in Table 4-14 were below those
expected for within-batch repeatability determined for this method during validation studies
[120,148]. There was a statistical difference found in the HPP 1 (GTX1,4, NEO, GTX2,3 and
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total STX-eq.) and HPP 4 materials (GTX2,3 only) using two-tailed t-tests using pooled
standard deviations (two samples assuming equal variance). Two-tailed t-tests showed no
statistical difference between the means of the other materials however.
Chromatograms of selected HPP treated and travel controls after periodate and peroxide
oxidation are illustrated in Figure 4-15. They show no visual evidence for the generation of
additional chromatographic peaks in comparison to the control materials which may relate to
the formation of degradation or other naturally fluorescent products.
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Figure 4-14: Results from PreCOX LC-FLD analysis of HPP-treated oyster tissues and travel controls showing mean toxin concentrations ± 1 s.d. (n=3).
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Figure 4-15: Chromatograms obtained from the PreCox LC-FLD analysis following periodate and peroxide oxidation of
travel controls and HPP-treated oyster tissues.
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BATCH 2
Mean toxin concentrations including total toxicity for each of the HPP treatments (batch 2)
and untreated control materials are detailed in Table 4-15 where tissues were HPP treated for
a single 5 min step. Although STX-eq values between HPP 1-6 and the travel controls were
similar, some differences between individual toxin concentrations were noted across the
various treatments. The HPP 1-3 samples processed at the lower temperature of 5°C showed
no visual differences in toxin concentrations compared to the travel controls. Conversely the
HPP 4-6 samples processed at the higher temperature of 35°C showed some evidence for a
reduction of GTX2,3 and STX concentrations and an increase in GTX1,4 and NEO
concentrations, compared to the travel controls. A statistical difference was found for the
lower GTX2,3 and STX concentrations but not the GTX1,4 or NEO increases after a twotailed t-test.
Table 4-15: Results from PreCOX LC-FLD analysis of HPP-treated tissues (batch 2) and travel controls, showing toxin
concentrations and total saxitoxin in STX di-HCl eq/kg (± 1 s.d; n=3).

GTX1,4
NEO
C1,2
GTX2,3
STX
Total

HPP1
284 ± 61
197 ± 35
20 ± 1.4
45 ± 6
62 ± 8
609 ± 110

HPP2
282 ± 86
187 ± 50
21 ± 0.7
45 ± 3
63 ± 7
600 ± 125

HPP3
269 ± 3
206 ± 31
20 ± 1.7
40 ± 3
51 ± 3
587 ± 41

HPP4
357 ± 37
231 ± 23
20 ± 0.6
36 ± 1
46 ± 1
692 ± 61

HPP5
329 ± 70
227 ± 57
18 ± 0.3
33 ± 0.7
43 ± 1
651 ± 128

HPP6
317 ± 8
217 ± 26
19 ± 1.0
35 ± 2
43 ± 1
632 ± 37

Controls
296 ± 34
194 ± 27
21 ± 0.3
51 ± 4
65 ± 4
628 ± 70

BULK SAMPLE TESTING
Bulk materials were prepared for homogeneity and stability testing from HPP 5 and HPP 6,
batch 2 materials only, which were treated at 6000 bar and 50°C for 5 min.

4.5.2.2 HOMOGENEITY
From the coefficients of variances contained in Table 4-16, all materials were suitably
homogeneous for all the PSP toxins present. A target %CV of below 8% for each analyte,
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including total toxicity was set which is below expected levels of variability associated with
intra-batch repeatability, determined through in-house validation of the LC-FLD method at
the MI. The homogeneity techniques employed were sufficient and the materials were
suitable for the analytical study.
Table 4-16: Mean concentrations (STX di-HCl eq/kg), standard deviations (sd) and percentage relative standard deviations
(%RSD) of toxins in HPP-treated tissues as determined by PreCOX LC-FLD (n=10).

Mean
sd
%RSD

GTX-2,3
77
5
6.2

STX
55
1
2.5

C-1,2
34
2
4.5

GTX-1,4
307
9
2.9

NEO
486
26
5.3

Total
960
35
3.6

4.5.2.3 SHORT-TERM STABILITY

PRECOX LC-FLD
Figure 4-16 displays the stability results generated by preCOX LC-FLD analysis over 14
days for the HPP oyster tissue, and 16 days for the untreated controls, at four different
temperature conditions. Data were generated for all toxins present in the materials as well as
total toxicity (Figure 4-16a-f)

and results were normalised to the average of replicate

analyses of samples stored at -80°C for the duration of the study (time zero). Limits of
stability were generated from two times the standard deviation of the -80°C time zero
average.
Similar stability between the HPP treated and control materials was observed at storage
temperatures of -20°C and +4°C for the duration of the 14 and 16 day studies respectively.
Significant improvements could be observed between both materials at the higher
temperatures studies however, particularly for the toxins C1,2, GTX2,3 and NEO.
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Figure 4-16: Stability charts of PSTs and total saxitoxin equivalents in HPP and untreated tissues over 14 days (HPP) and
16 days (untreated) storage respectively, following preCOX LC-FLD analysis. Concentrations are normalised to time zero
(error bars represent ± 2 sd).
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Excellent stability was exhibited for all toxins stored at +20°C in the HPP materials with
GTX2,3 also found to be stable at +40°C for the duration of the study. Some signs of
degradation of the other toxins were observed under the +40°C storage temperature but not to
the extent as that observed in the untreated controls. In the case of NEO ~70% of this toxin
was degraded by the end of the study in the untreated control compared to ~25% in the HPP
materials. An apparent increase in GTX2,3 concentration was observed in the untreated
controls at +20°C and +40°C after 8 and 4 days respectively. No stability issues were noted
for these toxins in the HPP treated materials however.

PCOX LC-FLD
PCOX LC-FLD analysis was conducted on the HPP tissues stored under all four storage
conditions (-20°C, +4°C, +20°C and +40°C) and results are presented in Figure 4-17. The
same analysis was conducted on the untreated tissues, with only three storage conditions (20°C, +4°C and +22°C) studied however. The stability results of the PSP epimers C1,2,
GTX1,4 and GTX2,3 in both tissues are presented in Figure 4-17a-f with limits of stability
and normalised results calculated as per the preCOX analysis above.
Excellent stability was observed in both the HPP and untreated tissues at -20°C for all the
epimers over the course of the short-term study. In addition GTX1,4 were found to be stable
at +4°C in both tissues with no signs of epimerisation evident from Figure 4-17 c+d.
Epimerisation was observed to take place in the untreated material at +22°C for these toxins,
while some degradation of GTX4 was evident in the HPP tissue at +20°C and +40°C with
GTX1 showing good stability under the same temperature conditions.
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Figure 4-17: Stability charts of the PST epimers C1,2, GTX1,4 and GTX2,3 in HPP and untreated tissues over 14 days
(HPP) and 19 days (untreated) storage respectively, following PCOX LC-FLD analysis. Concentrations are normalised to
time zero (error bars represent ± 2 sd).
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GTX2,3 showed good stability in both tissues when stored frozen at -20°C but epimerisation
was observed to take place in tissues stored above this temperature. No epimerisation of C1,2
was observed to take place at +4°C in either tissue but was evident in samples stored at the
higher temperatures. The rate of epimerisation was far greater in the untreated tissues stored
at +22°C in comparison to HPP samples stored at either +20°C or +40°C however, which
demonstrates the significant improvements that this stability technique has over untreated
samples.

4.5.2.4 LONG-TERM STABILITY

PRECOX LC-FLD
Figure 4-18 shows the long-term stability results over 6 months duration for all toxins,
including total toxicity in both the HPP and untreated oyster tissues generated by preCOX
LC-FLD. Three temperature conditions were studied in both tissues with -20°C and +4°C
common to both and the higher temperature conditions of +20°C and +40°C studied in the
HPP and untreated tissues respectively. This was due to the stability studies of both tissues
being carried out at different times and using a different model. Normalised concentrations
and limits of stability were calculated as above.
Excellent stability was exhibited throughout the 6 month study for all toxins stored at -20°C,
however differing levels of stability were observed at the other temperature conditions. In
addition to the -20°C results, HPP treated materials also exhibited excellent stability at +4°C
with the exception of GTX1,4 where some degradation was observed after 2 months at this
temperature. As in the case of the HPP materials, GTX1,4 stability issues were evident at
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+4°C in the untreated controls but additionally stability problems were observed after 6
months for GTX2,3.

Figure 4-18: Stability charts of PSTs and total saxitoxin equivalents in HPP and untreated tissues over 6 months storage,
following preCOX LC-FLD analysis. Concentrations are normalised to time zero (error bars represent ± 2 sd).

147

Chapter 4
In the case of GTX1,4, some degradation was observed in the HPP material at both the +4°C
and +20°C storage conditions after 2 months and 1 month respectively. The same level of
degradation was observed in the untreated material at +4°C, but an increase in GTX1,4
concentration was observed at +40°C, both evident after 3months.
In materials stored at higher temperatures, C1,2 and STX stability issues were evident in the
untreated controls with ~80% and 90% of the toxins degraded by the end of the study. These
toxins were found to be stable in the HPP materials, although the different temperature
conditions in both studies are noted.
The total toxicity, expressed in STX equivalency, was found to be stable in the HPP material
at -20°C and +4°C but some slight degradation was observed at +20°C, while the untreated
material gave stable results under all temperature conditions over the 6 months.

PCOX LC-FLD
Long-term stability results of both HPP treated and control materials generated by PCOX
LC-FLD analysis are presented in Figure 4-19. Temperature conditions of -20°C and +4°C
were assessed in both tissues with an additional +20°C storage temperature studied in the
HPP tissue only. The limits of stability and normalised results contained in Figure 4-19a-f
were calculated as above.
Excellent stability in both the HPP and untreated controls were exhibited over the 6 month
study when stored frozen at -20°C, with no signs of epimerisation or toxin degradation
observed. In addition the untreated material also showed excellent stability at +4°C for all
three pairs of epimers studied.
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Epimerisation of C1,2 and GTX2,3 was observed to take place in the HPP treated material,
particularly at +20°C. GTX1 was found to be stable in both the HPP and untreated tissues
under all storage conditions over the 6 month study. GTX4 showed signs of degradation after
1 month at +20°C and after 6 months at +4°C in the HPP tissue while no degradation was
observed in the untreated tissues for this toxin.

Figure 4-19: Stability charts of the PST epimers C1,2, GTX1,4 and GTX2,3 in HPP and untreated tissues over 6 months
storage, following PCOX LC-FLD analysis. Concentrations are normalised to time zero (error bars represent ± 2 sd).
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4.5.3 DISCUSSION
The treatment of Pacific oyster tissues by High Pressure Processing under different
conditions was shown to successfully remove biological activity from the materials. Analysis
by preCOX LC-FLD showed that HPP under these conditions showed no significant changes
to toxin content compared to untreated controls. In addition there was no visual
chromatographic differences between the HPP treated and control materials either.
A reduction in GTX1,4 concentrations was noted in one set of samples (HPP 1, batch 1), the
causes of which are unknown. The second batch of HPP treated materials, processed in a
single 5 min step showed statistically different GTX2,3 and STX results in samples treated at
higher temperatures compared to the untreated controls. This may have been caused by the
single 5 min processing step, although it is not clear if these differences are repeatable or not.
The stability of the PSP toxins was significantly improved in HPP treated materials both in
the short and long-term compared to control samples where no pre-treatment was carried out.
Figure 4-16 - Figure 4-19 which were generated by different analytical methods employed to
investigate potential degradation, conversion or epimerisation issues associated with this
stabilisation technique graphically present these findings.
Under frozen storage conditions both the HPP and untreated materials showed excellent
stability. At storage temperatures above freezing, toxins in HPP treated materials showed
significant stability improvements over untreated particularly in the short-term. Figure 4-16af clearly illustrates this with all toxins, in particular GTX2,3 and NEO stability considerably
improved when compared to the controls. Transportation of HPP treated materials should be
carried out under frozen conditions but stability results prove that even at temperatures as
high as +4°C the toxins would be stable for up to 5 days. This has particular relevance for
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RM producers or PT providers where the stability of the toxins during transportation is of
critical importance.
No toxin degradation was observed in the HPP tissue for any toxins in the short-term 14 day
study up to temperatures of +20°C, while some toxins, namely GTX2,3 and STX were also
stable at temperatures as high as +40°C. Conversely untreated materials showed stability
issues at temperatures above +4°C, particularly GTX2,3 and NEO. Epimerisation of the
toxins GTX2,3 observed in HPP tissue in the short-term stability study would require
materials to be transported at temperatures below +4°C.
The results generated through these studies clearly show the improvements HPP treatment
gives to PSP toxin stability and highlight the advantages this processing technique gives.

151

Chapter 4

4.6

OVERALL CONCLUSIONS

The main aims of the research undertaken as part of these studies were to improve the
understanding of the mechanisms of PST degradation, biotransformation, and epimerization
taking place in various shellfish tissue matrices. The chapter has detailed various techniques
investigated for their potential effects on reducing or eliminating these toxin instability
issues, and through the findings, shortlist applicable methods for the production of RMs for
various uses. As discussed in the introduction, RMs have multiple uses and the techniques
investigated were evaluated for their potential feasibility in CRM, ILRM or simple LRM
production. Each technique was evaluated not only for its influence on PST stability, which is
of critical importance, but also for its accessibility and ease of use by laboratories. Investment
in the equipment used in producing these RMs to both stabilise and ensure homogeneity can
be substantial and therefore accessibility may be an issue for monitoring and research
laboratories particularly those under fiscal constraints. This chapter presents techniques
which are polar opposite in terms of equipment costs with HPP providing arguably the best
stabilisation method investigated but also representing the costliest in terms of equipment
required. Conversely simpler techniques such as the use of preserving additives or thermal
treatment represent a cost effective means of producing high quality RMs. These techniques
may not be feasible in CRM production owing to the superior stability offered by alternatives
such as HPP or freeze drying (Chapter 5), but their use as internal LRMs and for use as PT
materials has been adequately demonstrated.
Table 4-17 lists the RMs prepared in this chapter and summarises the stability observations
determined through the short and long-term studies. As expected no issues were observed in
any of the tissues when stored at -20°C including the untreated control materials which shows
degradation, epimerization and biotransformations of toxins are minimised under this storage
condition.
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Table 4-17: Summary of RMs prepared in Chapter 4 with short and long-term stability details.
Material

Matrix

Stabilisation
Technique

Tissue 1

Mussel

Antibiotic
Spike

Tissue 2

Mussel

Antioxidant
Spike

Tissue 3

Mussel

Untreated
Control

Tissue A

Mussel

Additives Spike

Tissue B

Mussel

Thermal
Treatment

Tissue C

Mussel

Untreated
Control

LRM-09-02

HPP Tissue

Mussel

Oyster

Additives Spike
& Thermal
Treatment

HPP

Stability
Analyte

-20°C

+4°C

dcSTX
GTX2,3
GTX5
STX
GTX1,4
dcSTX
GTX2,3
GTX5
STX
GTX1,4
dcSTX

Degradation
348 days
348 days
348 days
348 days
348 days
351 days
351 days
351 days
351 days
351 days
354 days

Epimerization
n/a
32 days
n/a
n/a
n/a
n/a
32 days
n/a
n/a
n/a
n/a

GTX2,3

354 days

GTX5

354 days

STX

+20°C

Degradation
348 days
32 days
348 days
348 days
69 days
351 days
32 days
221 days
351 days
73 days
354 days

Epimerization
n/a
16 days
n/a
n/a
n/a
n/a
8 days
n/a
n/a
n/a
n/a

32 days

17 days

n/a

224 days

354 days

n/a

GTX1,4

354 days

dcSTX
GTX2,3
GTX5
STX
GTX1,4
dcSTX
GTX2,3
GTX5
STX
GTX1,4
dcSTX

+40°C
Epimerization
n/a
0 days
n/a
n/a
n/a
n/a
0 days
n/a
n/a
n/a
n/a

Degradation
69 days
0 days
154 days
154 days
154 days
224 days
0 days
73 days
351 days
158 days
221 days

Epimerization
n/a
0 days
n/a
n/a
n/a
n/a
0 days
n/a
n/a
n/a
n/a

Degradation
8 days
32 days
3 days
3 days
8 days
8 days
17 days
4 days
17 days
4 days
17 days

6 days

0 days

0 days

6 days

0 days

n/a

73 days

n/a

6 days

n/a

354 days

n/a

354 days

n/a

17 days

n/a

n/a

76 days

n/a

76 days

n/a

0 days

n/a

364 days
364 days
364 days
364 days
364 days
364 days
364 days
364 days
364 days
364 days
364 days

n/a
364 days
n/a
n/a
n/a
n/a
364 days
n/a
n/a
n/a
n/a

364 days
30 days
364 days
364 days
364 days
364 days
364 days
364 days
364 days
364 days
364 days

n/a
16 days
n/a
n/a
n/a
n/a
364 days
n/a
n/a
n/a
n/a

168 days
0 days
91 days
168 days
364 days
175 days
91 days
175 days
364 days
0 days
183 days

n/a
0 days
n/a
n/a
n/a
n/a
364 days
n/a
n/a
n/a
n/a

6 days
30 days
6 days
6 days
4 days
28 days
28 days
8 days
28 days
8 days
15 days

n/a
0 days
n/a
n/a
n/a
n/a
0 days
n/a
n/a
n/a
n/a

GTX2,3

364 days

364 days

32 days

0 days

0 days

0 days

0 days

0 days

GTX5

364 days

n/a

364 days

n/a

77 days

n/a

8 days

n/a

STX

364 days

n/a

364 days

n/a

0 days

n/a

15 days

n/a

GTX1,4

364 days

n/a

77 days

n/a

0 days

n/a

4 days

n/a

dcSTX

30 days

n/a

30 days

n/a

n/a

n/a

2 days

n/a

GTX2,3

30 days

n/a

30 days

n/a

n/a

n/a

30 days

n/a

GTX5

30 days

n/a

30 days

n/a

n/a

n/a

8 days

n/a

STX

30 days

n/a

30 days

n/a

n/a

n/a

8 days

n/a

GTX1,4

30 days

n/a

30 days

n/a

n/a

n/a

8 days

n/a

GTX2,3

180 days

180 days

180 days

180 days

120 days

14 days

2 days

2 days

STX

180 days

n/a

180 days

n/a

120 days

n/a

14 days

n/a

GTX1,4

180 days

180 days

30 days

180 days

14 days

180 days

8 days

14 days

C1,2

180 days

180 days

180 days

180 days

180 days

10 days

0 days

0 days

NEO

180 days

n/a

180 days

n/a

30 days

n/a

5 days

n/a

N.B. All time points listed in columns titled degradation indicate stability was observed up to and including that stated; after which degradation or instability issues were observed.
Time points listed in columns titled epimerization indicate this was not observed to occur in materials up to and including this point; after which epimerization was observed.
A time point of 0 indicates degradation or epimerization was observed to occur before the first time point in the study.
n/a analysis not carried out.
*degradation or epimerization observed before the first time point of 3 months.
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Thermally treating materials significantly improved toxin stability with tissues stabilised in
this way showing no instability issues when stored at +4°C over a one year period in addition
to the -20°C observations. This treatment was the only one observed to have no stability
issues at +4°C. This treatment also eliminated or minimised epimerization of the toxins
GTX2,3 over the same time period at -20°C, +4°C and +20°C. This relatively simple
technique of autoclaving source tissues prior to being dispensed provides considerable
benefits in RM preparation and could be used as a stabilisation pre-step to any of the other
techniques investigated in combining these procedures.
The use of antibiotics in RM preparation gave more stability to the PSTs when compared to
the use of an antioxidant alone. This was particularly evident in the +20°C and +40°C
samples where instability issues were observed earlier in Tissue B, apart from STX which
was found to be more stable in this material. The stability enhancements observed in the
antibiotics spiked material (Tissue 1) were also observed in the combined additives spiked
material (Tissue A) which indicated these improvements have come mostly from the effects
of antibiotics. The use of the antioxidant would still be recommended however because of the
stability improvements this additive provides for STX compared to antibiotics.
HPP also proved an excellent stabilisation technique significantly decreasing instability
issues compared to untreated controls. Arguably this technique provided no significant
stability improvements compared to the thermal treatment of tissues with the latter technique
being substantially more cost effective. However, both studies were carried out in different
matrices so a study of HPP treatment of M. edulis tissues would be required to definitively
prove this conclusion.
An interesting observation concerns the toxins GTX2,3 in the untreated control materials,
Tissue 1 and Tissue C which can be seen in the long-term stability graphs in Figure 4-5 and
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Figure 4-10. Figure 4-5 shows GTX2,3 increases at +40°C by the first time point after 3
months storage and this increase remains relatively consistent over the yearlong study with
no obvious degradation of these toxins. Conversely Figure 4-10 shows the complete
degradation of GTX2,3 at the same temperature after 3 months storage. The source of
GTX2,3 in both tissues is slightly different but the preparation techniques in both cases were
identical so the source of the instability issues could come from the alternative tissues used in
both or potential contamination during the process as steps are not carried out aseptically.
Bacteria may have been introduced into the tissue during its preparation which has led to the
instability issues observed or this issue could relate to different bacterial colonies being
present in the source tissues.
Another interesting observation relates to dcSTX and the instability issues observed in the
antibiotics material (Tissue 1) compared to the untreated control (Tissue 3) where stability up
to 221 days storage at +20°C was evident for this toxin. This deterioration in stability of
dcSTX could be due to bacteria being introduced during the processing steps as these are not
carried out aseptically; although spiking with antibiotics should minimise these effects.
Microorganisms, such as bacteria present in the shellfish can spoil the tissue leading to the
degradation of the material. Toxin biotransformations are also known to take place in tissues
when certain bacteria are present [132], so any process aimed at reducing the numbers of
these microorganisms, destroying them completely or stopping them from multiplying will
aid in the stabilisation of the tissue.
All the techniques investigated in these studies improved the stability of the PSP toxins
overall. The applicability of each technique in preparing RMs depends on their final use
however.
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The relatively simple techniques of thermal pre-treatment or the inclusion of additives
improves the stability of the material without adding significant costs. These techniques
could be employed by most laboratories and would lead to a significant improvement in the
standard of RMs being produced. Bacteria play a major role in the stability of both the matrix
and the toxins themselves, as evidenced through the stability studies, and biotransformations
have been observed to take place in these tissues.
The techniques detailed in this chapter were used to prepare materials which have been used
in PT schemes globally. Multiple materials were prepared by additives spiking with an initial
heat treatment step and used in QUASIMEME PT schemes as detailed in Chapter 6. Another
material, stabilised in the same way was prepared and used in a PT scheme organised by
VERIFIN, one of eighteen laboratories globally which has been assigned “designated status”
by the OPCW (Organisation for Prohibition of Chemical Weapons). This scheme was
organised to assess EU MSs proficiency in determining PSTs, in particular STX which is a
Schedule 1 substance under the CWC (Chemical Weapons Convention).
Based on the information generated in this chapter, recommendations for the preparation of
stable and homogeneous reference materials would be:


The homogenisation techniques employed in these studies, such as the use of
Waring™ and Polytron™ blenders, were sufficient to prepare materials fit for
purpose.



HPP was the most effective in stabilising PSTs in a Pacific oyster tissue matrix
although access to the relevant equipment may be a limiting factor in using this
technique for other purposes than CRM preparation.
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The thermal treatment of tissues significantly improves matrix and PST stability and
presents a cheap and simple technique in preparing RMs. Furthermore thermal
treatment could be carried out in combination with other stabilisation techniques.



Materials prepared through the combined use of preserving additives coupled with a
thermal pre-treatment step significantly improve PST stability. Materials prepared in
this way were shown to have a wide range of applications including PT, internal
QC/QA or for validation studies.
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FREEZE DRYING
5.1 BACKGROUND AND AIMS
The presence of water in biological matrices is an essential ingredient for microbial growth.
The previous chapter dealt with stabilisation techniques in the preparation of wet tissue RMs
where water was not removed but increased in most cases to alter the final MC of the
material to reflect natural shellfish matrices. The biological matrix, unless stabilised through,
for example one of the techniques investigated in the previous chapter is prone to bacterially
induced degradation, biotransformations or epimerization as evidenced from the instability
issues of untreated control materials. Removal of water from the matrix should therefore
improve stability through alteration of the environment necessary for bacterial colonies to
flourish.
The techniques investigated in the previous chapter proved effective in stabilising PSTs in
mussel and oyster tissue matrices but their feasibility in the production of CRMs was
questionable mainly due to epimerization issues observed at storage conditions above
freezing. An alternative technique of freeze drying was investigated in order to ascertain if
stability, particularly epimerization rates, could be minimised or eliminated. Freeze drying
was previously investigated in the preparation of RMs for PSTs [67,68,149] where
homogeneity and stability were adequately demonstrated in mussel tissues. The stability
experiments carried out in the study by van Egmond et al., in 1998 [149] was not assessed in
comparison with wet tissue homogenates however, nor were the details provided on the
freeze drying processes involved, parameters which are critically important in assuring
homogeneity with consistent recoveries [150]. More recently this technique was used to
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successfully prepare a candidate CRM for multiple phycotoxins [63–65], although this
material did not contain PSTs.
The aim of this chapter was to investigate this stabilisation technique by developing a freeze
drying method using instrumentation at the MI, incorporating specialised processing and
dispensing techniques, to ensure homogeneity and minimise water uptake by the hygroscopic
material. Feasibility of producing an oyster CRM was assessed and a large scale RM was
produced using the optimised freeze drying, processing and dispensing conditions. The
ultimate aim was to prepare a candidate RM for certification.
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5.2

FEASIBILITY STUDY

The research described in this section of Chapter 5 appears as described in Turner et al. 2013
[133].
Turner A, Lewis A, Hatfield R, Higman W, Burrell S (2013) A feasibility study into the
production of a freeze-dried oyster reference material for paralytic shellfish poisoning toxins.
Anal Bioanal Chem 405:8621–8632.

ACKNOWLEDGEMENT OF COLLABORATION
The work in this section was carried out in collaboration with Dr. Andrew Turner and his
team at CEFAS. The RM was freeze dried, processed and dispensed by the author and
collaborator at MI facilities. The finished product was shipped back to CEFAS facilities on
ice and stability studies were set up and conducted by the collaborator at his facilities. Toxin
analysis was carried out by the author and collaborator during a site visit by the author to
CEFAS facilities.

Figure 5-1: Site visit made by the author to CEFAS facilities during the freeze drying feasibility studies.
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Here, the objective was to develop procedures using modern freeze-drying processes for the
generation of a freeze dried shellfish tissue and to conduct experiments to assess the
characteristics of the material in relation to its suitability as a candidate RM. Oyster tissue
was selected as the matrix of preference for two main reasons. Firstly, there is a known issue
in this species with the comparability of method performance between the MBA and nonanimal testing methods [77]. Availability of a suitable CRM in this matrix would provide a
useful tool for ongoing method assessment purposes. Secondly, it was the authors
understanding that a mussel reference material was to be made available by the NRCC in the
near future, so concentrating on a different shellfish species was likely to be of greater
interest. This section of work was a collaborative study involving CEFAS and the MI.
Paralytic Shellfish Toxin (PST) contaminated oyster tissues generated following shellfish
feeding experiments at CEFAS were shipped to the MI where a suitable freeze-drying
process had been developed, optimised and applied. Preliminary materials were assessed at
both laboratories before tailored tissue materials were shipped back to CEFAS for subsequent
investigations to assess the RM characteristics, including the comparison of toxin profiles
with the wet tissues and assessing the stability and homogeneity between tissue sub-samples.
In particular the stability of the tissues was examined over both short term and long term
storage and over a range of temperature conditions. The data generated was subsequently
used to determine the feasibility in producing a freeze dried oyster tissue for PSP toxins with
the future aim of producing a large volume of certified RM. The flow chart contained in
Figure 5-2 details the steps involved in preparing the feasibility study materials.
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Figure 5-2: Flow chart of process used to prepare freeze dried feasibility study tissues.
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5.2.1 SOURCE TISSUE
Pacific oyster (Crassostrea gigas) tissue contaminated with PSTs was prepared at CEFAS
through mass culturing of toxic Alexandrium fundyense [147] and feeding experiments as
described in section 4.5.1.1. Once complete, the oysters were shucked and homogenised as
one batch of ~4 kg of whole flesh tissue. The bulk tissue was further sub-divided in two, half
of which was used to prepare a wet tissue RM and the other half used to prepare the freeze
dried RM. The wet tissue RM was prepared at CEFAS through the addition of DI water, to
adjust the MC to ~85%, and adjustment to pH 4.0 to stabilise the toxins present in the tissue.
The tissue was dispensed as 6.0 g aliquots into PP vials and hermetically sealed under a
stream of nitrogen. Aliquots were stored at -20°C until further use.
The MC of the sub-sample for freeze drying was determined gravimetrically following
replicate baking steps at CEFAS before being adjusted to ~85% MC through the addition of
DI water. The tissue was then frozen at -20°C before dispatch to the MI using temperature
controlled transport containers. Upon receipt, the material was stored at -20°C until further
use.

5.2.2 FREEZE DRYING
All equipment used to prepare the freeze dried materials were acid washed, rinsed thoroughly
with DI water before being placed in a desiccator containing activated silica beads. The
oyster tissue was removed from the freezer and allowed to defrost to room temperature
overnight before being homogenised further through the use of Waring™ and Polytron™
blenders. The tissue was transferred into two stainless steel freeze drying trays, covered in
tinfoil and frozen overnight at -20°C.
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The trays were removed from the freezer and immediately transferred to the freeze dryer
(VirTis, Virtual 50XL) which were then subjected to a 116 hour freeze drying programme.
The freeze drying programme was similar to that described in Table 5-5, FD-1 but 20 hours
longer in duration. The process involved increasing the temperature in the chamber over a
116 hour period from -35°C to +20°C through a series of ramping steps. Simultaneously the
pressure inside the chamber was reduced from atmospheric pressure to ~1 Pa.
Upon completion of the programme the trays were removed from the chamber and the freeze
dried cakes of oyster tissue were manually ground using a pestle to break up large
conglomerates. The tissue was transferred to stainless steel bowls containing 25 x 20 mm
steel balls, in ~100 g lots. The tissue was milled using a planetary ball mill (Retsch PM100)
for 5.0 min at 400 rpm. The milled material was sieved through a 2mm sieve to remove large
pieces of material, followed by a 125 µm sieve to remove any material with particle sizes
>125 µm for 30 min. This was due to issues with the homogeneity of powder materials with
particle sizes above 125µm. To minimise water uptake by the hygroscopic freeze dried
material, the sieving unit was covered with a polyethylene sheet and a steam of low moisture
content argon was constantly flushed over the unit [62]. The sieved material was manually
mixed using a large spatula before dispensing 2 x 2.2 g aliquots into 5 mL amber glass
ampoules, sealed under a vacuum of low moisture content argon. The remaining material was
transferred to PP bags, vacuum heat sealed and stored at -20°C until further use.

5.2.3 DISPENSING
The optimum aliquot size to dispense these materials was determined through weighing
variable masses (0.1, 0.2, 0.3, 0.5 and 1.0 g) of the 2.2 g aliquot, dispensed in the previous
section, into 50 mL PP centrifuge tubes. The tissues were reconstituted to 5.0 g through the
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addition of DI water and vortex mixing for 5.0 min. The five samples were then extracted and
analysed according to OMA AOAC 2005.06 as described in section 2.3.1.
The remaining freeze dried material was removed from the freezer and allowed to equilibrate
to room temperature overnight. The vacuum sealed bag was opened and the freeze dried
material transferred to a PP beaker. The material was mixed using a large spatula before
being dispensed as ~0.53 g aliquots into pre-labelled 5 mL amber glass ampoules. The
dispensing steps were carried out in a modified glove box purged with low moisture content
argon which was kept at a low constant flow throughout the process. After dispensing, the
aliquots were removed from the glove box and transferred to the freeze dryer where they
were vacuum sealed under an atmosphere of low moisture content argon. 300 aliquots were
dispensed and crimp capped before being stored at -20°C until further use.

5.2.4 RECONSTITUTION, EXTRACTION AND TOXIN ANALYSIS
The freeze dried material was re-constituted by weighing 0.50 ± 0.01g into 50 mL PP
centrifuge tubes. 4.50 g of DI water was added, making a total sample mass of 5.0 ± 0.01g.
Re-constituted freeze dried tissues were then extracted and analysed closely following OMA
AOAC 2005.06 [41] as detailed in section 2.3.1. PCOX LC-FLD [75] analysis was
additionally performed on all samples. Crude acetic acid extracts prepared according to
section 2.3.1 were deproteinated and analysed following AOAC 2011.02 [75]. The
instrumentation used in this study was the same as that described in section 4.5.1.1 (Toxin
Analysis), with additional PCOX analysis performed at CEFAS using a standard Agilent
1200 LC-FLD instrument including a quaternary LC pump module, two Agilent isocratic
pumps and an external column oven containing the post-column reaction coil.
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PST concentrations in sample extracts were quantified against a 6-point calibration for each
toxin with PST concentrations and total saxitoxin equivalents determined.

5.2.5 TOXIN PROFILE AND HOMOGENEITY STUDIES
The toxin profiles of the untreated wet tissue RM and the freeze dried RM were compared by
extracting aliquots (n=3) of each material. The freeze dried RM was initially re-constituted,
as described above before both untreated and freeze dried aliquots were extracted and
analysed following OMA AOAC 2005.06 as described in section 2.3.1. Analysis of both
materials was performed in the same chromatographic sequence.
The homogeneity of both the untreated and freeze dried materials was assessed through the
intra-batch analysis of 14 aliquots. Tissues were re-constituted, extracted and analysed as
described above.

5.2.6 STABILITY STUDIES
Short and long-term stability studies were conducted on both the untreated and freeze dried
materials following a reverse-isochronous experimental design [55]. The short term study
was conducted with triplicate samples consisting of five time points (0, 4, 10, 19 and 33 days)
and four temperature conditions (-20°C, +4°C, +22°C and +40°C). The long term study was
conducted with triplicate samples consisting of five time points (0, 3, 6, 9 and 12 month) and
three temperature conditions (-20°C, +4°C and +40°C). The reference temperature used in
both studies was -80°C.
At the end time point all samples were removed from storage, allowed to equilibrate to room
temperature before being re-constituted as described above, and extracted and analysed by
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preCOX LC-FLD closely following OMA AOAC 2005.06 [41] as detailed in section 2.3.1.
PCOX LC-FLD [75] analysis was additionally performed on all samples to specifically
investigate the extent of epimerisation of GTX1,4, GTX2,3 and C1,2. For PCOX LC-FLD
analysis, the crude acetic acid extracts prepared according to section 2.3.1 were deproteinated
and analysed following AOAC 2011.02 [75].

5.2.7 RESULTS AND DISCUSSION

5.2.7.1 CHARACTERISATION
PreCOX LC-FLD analysis results from variable masses of re-constituted freeze dried
material are contained in Table 5-1. Total saxitoxin equivalents values ranged from 140 –
2060 µgSTXdiHCl-eq/kg for the powder masses of 0.1 – 1.0 g, although the N-hydroxylated
PSTs were quantified directly from SPE C18 cleaned extracts so these values may be
overestimated [151]. The signal to noise ratios of the main quantitation peaks are also
summarised in Table 5-1.
Table 5-1: PST concentrations (µg STX di-HCl eq/kg) determined by preCOX LC-FLD in freeze-dried oyster tissues
following reconstitution to a total of 5.0g with variable masses (0.1 to 1.0g) of powder (signal to noise ratios of quantitation
peaks shown in brackets).

GTX1,4
NEO
C1,2
GTX2,3
STX
Total

0.1g
71 (2.7)
34 (2.6)
4.8 (1.8)
18 (1.3)
12 (2.7)
140

Weight of freeze-dried powder
0.2g
0.3g
0.5g
117 (7.0)
333 (10)
493 (15)
112 (6.8)
180 (8.1)
254 (15)
13 (2.9)
18 (5.1)
26 (6.8)
30 (2.9)
48 (5.1)
70 (6.8)
31 (8.4)
35 (12)
55 (14)
302
613
898

1.0g
1143 (21)
614 (20)
56 (8.5)
139 (8.5)
107 (20)
2060

The aliquot size of 0.50 g in Table 5-1 was chosen and the materials were dispensed at this
mass. This aliquot size ensured that after re-constitution, extraction and analysis that the
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material had a concentration close to the EU regulatory limit. This size was also chosen as at
this level the least concentrated toxins in the material still produced a signal to noise of >5.0
after preCOX LC-FLD.

Figure 5-3: PreCOX and PCOX LC-FLD chromatograms of freeze-dried and unprocessed wet oyster tissue.
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Figure 5-3 a-d contains chromatograms of both freeze dried and untreated wet oyster tissues
after periodate and peroxide oxidation and analysis by preCOX LC-FLD. Chromatograms of
both tissues were visually similar and showed the presence of the non-N-hydroxylated toxins
C1,2, GTX2,3 and STX and the N-hydroxylated toxins GTX1,4 and NEO. There was
evidence for the formation of additional chromatographic peaks which may have been caused
by the freeze drying process. The PCOX LC-FLD chromatogram of the freeze dried tissue is
contained Figure 5-3 e, which also shows no additional fluorescent peaks from the freeze
drying process.

Figure 5-4: Comparison of PST profiles in a) wet untreated and b) freeze-dried oyster tissues (error bars represent ± 1 s.d.
of triplicate samples).

Toxin profiles of both the untreated wet tissue RM and the freeze dried RM are contained in
Figure 5-4 and are expressed as a percentage of total saxitoxin equivalents. The PST profiles
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in both tissues had similar relative proportions, although a potential loss in concentration of
NEO was noted but were still within repeatability limits. There was no visual evidence for
any degradation or conversion of the PSTs through the freeze drying process.

5.2.7.2 HOMOGENEITY
Both the freeze dried and untreated wet tissue RMs were suitably homogenous for all the
PSTs detected, as evidenced through the coefficient of variances contained in Table 5-2.
A target %CV of below 8% for each analyte including total toxicity was set. This value is
below expected levels of variability associated with intra-batch repeatability, determined
through in-house validation of the preCOX LC-FLD method [148]. The homogeneity
techniques employed were therefore sufficient and the materials suitable for the study.
Table 5-2: Mean concentrations (µg STX di-HCl eq/kg), standard deviations (sd) and percentage relative standard
deviations (%RSD) of toxins in reconstituted freeze-dried and untreated wet frozen oyster tissues as determined by preCOX
LC-FLD (n=14).

Sample
Freeze-dried

Mean
sd
%RSD

GTX1,4
519
32
6.1%

NEO
320
17
5.3%

C1,2
26
2
6.9%

GTX2,3
70
5
7.8%

STX
59
3
4.3%

Total
993
48
4.9%

Wet tissue

Mean
sd
%RSD

718
30
4.1%

770
51
6.7%

17
1
6.1%

34
3
7.7%

48
2
3.4%

1586
65
4.1%

The data from both materials was similar and showed there were no major effects on the
distribution of toxins in the freeze dried powder from sample processing, re-constitution or
analysis.
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5.2.7.3 SHORT-TERM STABILITY

PRECOX LC-FLD
Figure 5-5 a-j represents the short-term stability results for the untreated wet tissue RM and
the freeze dried RM at four different storage temperatures, -20°C, +4°C, +22°C and +40°C,
determined through preCOX LC-FLD analysis. Data for GTX1,4, GTX2,3, NEO, C1,2 and
STX were generated and results were normalised to the average of replicate analysis (n=9) of
samples stored at the reference temperature of -80°C for the duration of the study. The limits
of stability from Figure 5-5 were generated from two times the standard deviation of the 80°C replicate analyses.
Overall toxin stability was excellent in both materials when stored at -20°C for the duration
of the study with the freeze dried materials additionally showing excellent toxin stability at
+4°C. The stability of the toxins at the higher temperatures studied showed variability
however. Some degradation of GTX1,4 and NEO in the untreated RM was observed after 14
days storage at +4°C, while the other toxins present in the material remained stable at this
temperature. At the higher temperatures of +20°C and +40°C degradation of NEO, C1,2 and
STX was evident after as little as 4 days of the study with ~80% of the total toxin content in
the case of NEO degraded by day 33. Apparent increases in GTX1,4 and GTX2,3
concentrations were evident in materials stored at these higher temperatures with ~30% and
~60% increases respectively noted at +40°C (Figure 5-5 a-e).
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Figure 5-5: PreCOX LC-FLD results showing short term stability of PST concentrations normalised to the -80°C reference
samples in untreated wet frozen (3a-3e) and freeze-dried (3f-3j) oyster tissues over 1 month (error bars represent ±1 sd of
triplicate samples).

Conversely the freeze dried materials showed no evidence for the degradation or
enhancement of any toxins when stored at -20°C or +4°C. At +20°C STX and NEO also
showed excellent stability but there was evidence for the degradation of GTX1,4 after 9 days
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and increases in C1,2 and GTX2,3 concentrations after 19 and 33 days respectively at this
temperature. At +40°C STX also showed excellent stability during the study but degradation
of GTX1,4 and NEO was evident after 9 and 4 days respectively. Under this temperature
condition apparent increases in C1,2 and GTX2,3 concentrations after 4 days were noted.
These results prove conclusively the significant stability enhancement freeze drying gives
PSTs compared to untreated wet tissue RMs in the short-term. This has particular importance
for transporting materials where temperatures could potentially rise above freezing.

PCOX LC-FLD
Further analysis was conducted on the short-term stability study extracts for both the
untreated wet tissue RM and the freeze dried RM by PCOX LC-FLD and results are
presented in Figure 5-6 a-l. Limits of stability and normalised results were calculated as per
the preCOX LC-FLD analysis above. No PCOX LC-FLD stability data for the tissues stored
at +40°C is presented due to instability issues in both wet and freeze-dried tissues stored at
this temperature.
Excellent stability was exhibited in both the untreated and freeze dried materials stored at 20°C throughout the study with no evidence for epimerisation taking place under frozen
conditions. In addition the freeze dried materials also showed no evidence for epimerisation
of any of the three epimeric pairs at +4°C over the 33 day study. At the higher temperature
storage condition of +20°C epimerisation was observed to take place in the freeze dried
materials with increases in relative concentrations of GTX1, GTX2 and C1, coupled with
decreases in GTX4, GTX3 and C2 respectively.
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Conversely epimerisation was observed to take place at +4°C and +20°C in the untreated wet
tissue RM. At +4°C GTX1,4 and GTX2,3 showed signs of epimerisation after 33 days but
C1,2 remained stable at this storage condition. At +20°C epimerisation was clearly evident
after 4 days of the study for all three epimeric pairs with an approximate 80% toxin
conversion observed by the end of the study.
These results again highlight the advantages freeze drying materials have on the stability of
PSTs, particularly epimerisation which was significantly reduced. These results confirm the
transport of freeze dried materials containing these toxins could be carried out at
temperatures of up to +4°C.
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Figure 5-6: PCOX LC-FLD results showing short term stability of PST concentrations normalised to the -80oC reference
samples in untreated wet frozen (4a-4f) and freeze-dried (4g-4l) oyster tissues over a 1 month assessment period (error bars
represent ±1 sd of triplicate samples).
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5.2.7.4 LONG-TERM STABILITY

PRECOX LC-FLD
Figure 5-7 a-e represents the long-term stability results for both materials at two different
storage temperatures, -20°C and +4°C, determined through preCOX LC-FLD analysis.
Results were normalised and limits of stability set as described above. Data was not
generated for materials stored at +40°C due to the instability of the toxins at this temperature.
Overall excellent stability was observed in both materials when stored at -20°C throughout
the 12 month study with freeze dried materials also showing excellent stability at +4°C with
no signs of toxin degradation or enhancement during this period. The wet tissue RM did show
stability issues however, with degradation of GTX1,4 noted by month 3 and increases in C1,2
and GTX2,3 concentrations after 6 and 3 months respectively.
This study highlights the long-term stability of PSTs in freeze dried materials with excellent
stability observed under frozen or refrigerated storage conditions. The data confirms freeze
drying materials to be advantageous in stabilising these toxins compared to untreated wet
tissues.
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Figure 5-7: PreCOX LC-FLD results showing normalised long term stability data of a) GTX1,4 b) NEO c) C1,2 d) GTX2,3
e) STX in untreated wet frozen and freeze-dried oyster tissues held at -20oC and +4oC over 1 year (error bars represent sd
of triplicate samples).

PCOX LC-FLD
Further analysis was conducted by PCOX LC-FLD on the long-term stability study extracts
of both materials and results are presented in Figure 5-8 a-f. Limits of stability and
normalised results were calculated as above. PCOX LC-FLD analysis was only conducted on
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samples stored at -20°C and +4°C due to stability issues in materials stored above these
temperatures.
No epimerization or degradation was observed in the freeze dried materials stored at both 20°C and +4°C, with any variability throughout the 12 months being within the limits
specified by within-batch repeatability.

Figure 5-8: PCOX LC-FLD results showing long term stability of PST concentrations normalised to the -80oC reference
samples in untreated wet frozen and freeze-dried oyster tissues held at -20oC (6a-c) and +4oC (6d-f) over a 12 month
assessment period (error bars represent ±1 sd of triplicate samples).

The untreated wet tissue RMs showed signs of epimerisation and degradation at both these
storage conditions however. Epimerisation of GTX4 to GTX1 was observed in these
materials at both temperature conditions studied with signs of additional degradation of
GTX4 in samples stored at +4°C (Figure 5-8 a+d). Epimerisation of GTX2,3 was also
observed in the untreated tissues stored at +4°C which was evident after 9 months storage.
An increase in GTX2 concentration was noted in frozen samples, although epimerisation is
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not assumed as this increase did not coincide with any decreases in GTX3 concentration. No
epimerisation of C1,2 was observed to take place in the wet tissue RM at either of the
temperatures studied.
Overall the long-term stability study gave further evidence for the improvements freeze
drying provides in the production of RMs, with no epimerisation observed in frozen or
refrigerated tissues over a 12 month period.

5.2.7.5 USE AS CANDIDATE REFERENCE MATERIAL
The work detailed in this section of the study has shown the feasibility in producing a freeze
dried oyster tissue as a candidate RM for PSP toxins. The technique, including all associated
processing steps, were sufficient to produce homogeneous materials with significant PST
stability enhancements made when compared with untreated wet tissue RMs. The freeze
dried tissues showed excellent short and long-term stability, the data of which can be used to
determine optimum transportation and long-term storage conditions.
The results confirm freeze drying as an excellent technique to prepare PST RMs with scope
to produce a larger, production scale batch of materials that could be released as a
commercial product.

5.2.8 CONCLUSIONS
Through feeding experiments of Pacific oysters, a naturally contaminated tissue was used to
prepare a wet tissue and a freeze dried RM. Initial characterisation of the materials showed no
visual evidence for changes to the toxin profile of the material from the freeze drying process.
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Analysis of replicate aliquots of both the untreated and freeze dried materials showed the
materials to be homogeneous, which proved the freeze drying processing techniques
developed during these studies were sufficient. Short and long-term stability, determined
using both the preCOX and PCOX methods proved conclusively the advantages this
technique gives compared to untreated wet tissue RMs. The study provides good evidence for
the applicability of the freeze drying process for the preparation of homogenous and stable
PST reference materials, with excellent scope for producing CRMs.
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5.3

OPTIMISATION STUDIES

5.3.1 AIMS AND OBJECTIVES
The feasibility study carried out in the previous section demonstrated the improved stability
this technique provides for PSTs and also indicated that the facilities at the MI are suitable for
producing high quality freeze dried RMs. This section focused on optimising the freeze
drying programme including the processing and dispensing steps.
Freeze drying programmes of 2, 3 and 4 days duration were compared and contrasted to
observe the effects on PST content and MC. The hygroscopic nature of freeze dried materials
coupled to the fact that these materials were not always kept under low moisture conditions
for example during transfer to different apparatus led to a re-freeze drying study being
examined. This process was investigated with tissues freeze dried, processed and dispensed
before being re-freeze dried in their containers using a short time programme before sealing.
The capacity of the freeze drier and processing techniques were also determined as this would
be a factor in producing any large scale RMs using this method. The dispensing of the freeze
dried materials was also optimised using a semi-automated powder dispenser (ZinsserAnalytic, Berkshire, UK) purchased and used instead of manually dispensing each aliquot
using a spatula and bench top balance, as was carried out in the feasibility study in the
previous section.
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5.3.2 SOURCE TISSUES
The Spanish tissue from Table 2-1 was used to prepare the optimisation study material which
contained, dcSTX, GTX5 and STX. An initial bulk tissue was prepared by transferring ~3.0
kg of the Spanish tissue into a 5 L Waring™ goblet with 0.300 ± 0.001 L DI water to aid
mixing. The tissue was homogenised on medium power for 5.0 min before aliquots were
taken for MC determination (n=3) using the rotary vacuum method and analysis by preCOX
LC-FLD (n=1) as described in the materials and methods section 2.4.1 and 2.3.1 respectively,
to give approximate PST concentrations in the bulk tissue. The bulk homogenate was
immediately subdivided into 5 aliquots by pouring ~ 0.6 kg of tissue into PP containers,
sealing with lids and parafilm before storing at -20°C until required for use. The PST levels
and MC results from this bulk homogenate are presented in Table 5-3.
Table 5-3: Toxin profiles, concentrations and moisture content of bulk tissue used in freeze drying optimisation studies.

Concentration (µmol / kg)
dcSTX

GTX5

STX

Total Toxicity
(µg STX diHCl-eq / kg)

1.31

0.13

0.04

507

Material
Bulk
homogenate

% Moisture
Content
82.9

5.3.3 FREEZE DRYING
Table 5-4 gives details of the various freeze drying programs evaluated in the optimisation
studies. As discussed previously five freeze drying optimisation experiments were conducted
using various lengths of time, depth of tissue in each tray and one process where the material
was re-freeze dried after being dispensed.
Each experiment, FD-I - FD-V was conducted on separate days but each study followed
similar processes. A container was removed from the freezer and allowed to defrost overnight
at +4°C. 526.0 ± 0.1 g of each tissue was transferred to a 1 L Waring™ goblet, made up to
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600.0 ± 0.1g with DI water to adjust the MC to ~85% and homogenised on medium power
for 5.0 min.
Table 5-4: Details of the five freeze drying conditions used in optimisation studies.

Material

FD Times
(hours)

Tissue depth
on tray (mm)

Secondary
Freeze Drying

FD-I

96

~5

No

FD-II

72

~5

No

FD-III

72

~10

No

FD-IV

72

~10

Yes

FD-V

48

~10

No

The tissue was then transferred to two freeze drying trays in the case of FD-I and FD-II
experiments and transferred into one tray in the case of the FD-III, FD-IV and FD-V
experiments. This was to ensure the depth of tissue in each tray was roughly as stated in
Table 5-4.
Table 5-5: Details of freeze drying programmes used to prepare materials contained in chapter 5.

Process
Thermal
Treatment

Primary Drying

Secondary Drying
Secondary Set
Point
Condenser

FDI
0
2
2.1
5.7
7.7
8.7
28.7
29.7
48.7
49.7
56.7
57.7
71.7
72.7
74.7
78.7
94
96

FDFDII/III/IV
V
Time (h)
0
0
1.5
1
1.6
1.1
4.3
2.8
5.8
3.8
6.5
4.3
21.5
14.3
22.3
14.8
36.5
24.3
37.3
24.8
42.5
28.3
43.3
28.8
53.8
35.8
54.5
36.3
56
37.3
59
39.3
70.5
47
72

48

Secondary
2nd Step

Temperature
(°C)

Pressure
(mbar)

Hold/Ramp

0
1
0.6
1.4
1.9
2.2
7.2
7.4
12.2
12.4
14.2
14.4
17.9
18.2
18.7
19.7
23.5

20
-35
-35
-35
-35
-25
-25
-20
-20
-10
-10
0
0
20
20
20
20

1013
1013
1013
1.03
1.03
0.21
0.21
0.13
0.13
0.13
0.13
0.13
0.13
0.01
0.01
0.01
0.01

R
H
R
H
R
H
R
H
R
H
R
H
R
H
R
H

24

20

0.01

H

-70°C

Condition

The trays were then placed into the freeze drier, the door was sealed and the pre-programmed
freeze dry sequence as described in Table 5-5 was started.
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5.3.4 MATERIAL PROCESSING AND DISPENSING

MATERIAL PLANNING AND
SOURCE TISSUE SELECTION

FREEZE DRYING

MANUAL CRUSHING WITH
PESTLE

BALL MILLING

SIEVING UNDER A STREAM

>125µm

OF LOW MOISTURE ARGON

DISCARD

<125µm
TISSUE MANUALLY MIXED
USING LARGE SPATULA.

ALIQUOTS DISPENSED IN
PRE-LABELLED VIALS USING
SEMI-AUTOMATED UNIT

ALIQUOTS VACUUM SEALED
UNDER ARGON AND CRIMP
CAPPED

STORAGE AT -20°C
Figure 5-9: Flow chart depicting steps in the preparation of the freeze dried materials contained in section 5.3.

All equipment used to process and dispense the freeze dried material was first washed in a
2% Decon-90™ solution followed by thorough rinsing in DI water. The equipment was then
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placed in an oven at +40°C for ~5.0 hours before being transferred to a large desiccator
containing activated silica beads. These steps were carried out in order to reduce the potential
for bacterial contamination as much as possible through the use of Decon-90™ and to keep
the equipment sufficiently dry to process the hygroscopic freeze dried materials.
The flowchart contained in Figure 5-9 illustrates the freeze drying process followed. Upon
completion of the freeze drying programme, the vacuum was released and the door was
opened. The tray was removed and the cake formed by the freeze dried material was
manually ground to break up large conglomerates using a large mortar. Approximately 90.0 g
freeze dried material remained after the process and in each case this was transferred equally
to three grinding bowls containing 25 x 15 mm stainless steel balls. The lid was attached and
the material was ground for 5.0 ± 0.1 min at 400 rpm using a planetary ball mill (Retsch PM
100, Verder Group, The Netherlands).
The material was transferred to a 125 µm sieve fitted with a base plate and attached to a
motorised sieve shaker (Impact Test Equipment Ltd., U.K.). The sieve shaker was covered
with a large plastic sheet and sealed with brown tape. A hose was inserted through an
opening made at the top of the sheet and low moisture content argon was flushed over the
sieve plates during the shaking sequence of 30.0 ± 0.1 min. A small hole was made at the
bottom of the sheet to allow pressure release during this process.
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Figure 5-10: Photo of modified glove box constructed to dispense the freeze dried materials described in this chapter
showing the setup for dispensing the RMs.

The base plate containing the material (~80.0 g) passed through the 125 µm sieve was
transferred to a 100 mL PP beaker and placed immediately into the modified glove box
constructed for dispensing the materials in this section. The glove box also contained all the
dispensing equipment and the setup is illustrated in Figure 5-10.
The glove box chamber was purged with low moisture content argon for ~5.0 min with the
exhaust valve fully open. The argon flow rate was lowered before dispensing the freeze dried
material as 0.76 g aliquots using a calibrated powder dispenser (Zinnsser Analytical,
Germany) into 5 mL amber serum vials (Wheaton, USA). The freeze dried material was
continually mixed with a spatula throughout the dispensing process.
An antistatic fan was switched on throughout the dispensing process and an antistatic gun
discharged periodically to prevent issues with dispensing powders and static. After being
fully dispensed the FD-I – FD-IV vials were removed from the glove box, placed on a freeze
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dry tray, and lyophilisation stoppers inserted half way. In the case of the FD-V materials
lyophilisation stoppers were not initially inserted and the vials were placed back into the
freeze drier and subjected to the 2nd step freeze drying program as detailed in Table 5-5. Once
this 2nd freeze drying step was complete, lyophilisation stoppers were inserted halfway in the
vials.
All materials, FD-I – FD-V, were placed back into the freeze drier, the door was sealed and
the vacuum applied, removing air from the chamber. A cylinder of low moisture content
argon was attached to the exhaust vent of the freeze drier before releasing half the vacuum in
the chamber to argon. The shelves were contracted, pushing the lyophilisation stoppers fully
in and sealing the vials, before releasing the chamber to atmospheric pressure. This created a
small vacuum inside each of the vials which held the lyophilisation stoppers in place. The
vials were removed from the freeze drier, crimp capped before being stored at -80°C until
further use. Only 50 aliquots of each material FD-I – FD-V were dispensed and any
remaining freeze dried material discarded as this number was sufficient to carry out the
studies contained in this section.
Figure 5-11 illustrates the processes involved in dispensing the freeze dried materials.
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Figure 5-11: Pictures showing the various steps in the freeze drying process, I) Virtis 50XL instrument, II) dispensing freeze
dried materials inside modified glove box, III) dispensed materials in freeze drier with shelves contracted to push
lyophilisation stoppers into place IV) sealed aliquots of freeze dried materials and V) various stages of materials being
dispensed with empty containers (A) to sealed and crimp capped aliquots (F).
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5.3.5 RECONSTITUTION, EXTRACTION AND TOXIN ANALYSIS
A total of 10 aliquots was randomly selected from the entire fill series and all extracted on the
same day. All materials FD – I -V were first reconstituted with DI water by weighing 0.75 ±
0.01 g into a PP centrifuge tube and making the final weight up to 5.0 ± 0.1 g with DI water.
The centrifuge tubes containing the tissue were then vortex mixed for 1.0 ± 0.1 min,
sonicated for 1.0 ± 0.1 min followed by vortex mixing for 1.0 ± 0.1 min. The reconstituted
tissue was then extracted according to OMA AOAC 2005.06 as detailed in Section 2.3.1.
Toxin analysis was only carried out using preCOX LC-FLD as stability and specifically
epimerization was not being assessed in this study. The moisture content of the freeze dried
tissues was determined using a volumetric Karl Fischer method as described in Section 2.4.2.

5.3.6 RESULTS AND DISCUSSION
The homogeneity results are detailed in Table 5-6 and graphically represented in Figure 5-12
to give a visual comparison. The FD-I and FD-II materials showed the least amount of toxin
degradation from 3 and 4 day freeze drying when compared to the source tissue
concentrations contained in Table 5-3.
Table 5-6: Homogeneity results for freeze dried tissues prepared in optimisation studies (n=10).
Concentration (µgSTX diHCleq/kg)
Material

dcSTX

GTX-5

STX

Total Toxicity

Average

Stdev

%CV

Average

Stdev

%CV

Average

Stdev

%CV

Average

Stdev

%CV

FD-I

441

14

3.2

4.8

0.4

7.8

17

1

6.5

463

15

3.3

FD-II

452

19

4.3

5.2

0.2

3.9

18

1

4.6

475

20

4.2

FD-III

401

17

4.5

4.5

0.2

5.2

15

1

5.2

422

19

4.4

FD-IV

372

13

3.6

4.3

0.2

3.7

15

1

4.7

392

14

3.6

FD-V

391

16

4.3

4.9

0.3

5.2

16

1

3.5

412

17

4.2
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The results suggest the use of longer, less aggressive freeze drying programmes of 96 or 72
hours in duration coupled with tissue depths of ~50 mm are ideal for these materials. Under
these conditions PST degradation from the freeze drying process is minimised, leaving total
toxin content very similar to that found in the original source tissues.

Figure 5-12: Graphical representation of homogeneity data generated for freeze drying optimisation studies using a
logarithmic scale.

There was a statistical difference (P < 0.05; one-way analysis of variance [ANOVA]) found
between the means of the five materials which showed some effects on toxin concentration
following each of the freeze drying treatments. FD-IV materials showed the greatest level of
toxin degradation which was most likely caused by the re-freeze drying of these aliquots. The
more aggressive freeze drying programme of 2 days (FD-V) demonstrated the benefits of
using a longer programme as toxin instability was caused by the more rapid increases in
temperature and pressure required for this programme.
The moisture content of these tissues was assessed using a volumetric Karl Fischer method
and the results are contained in Table 5-7. Moisture content of these freeze dried tissues is
important to minimise the risk of bacterial growth and ideally this level should be below ~5%
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[56]. The conditions investigated in this section gave varying results with 4 and 3 day freeze
drying programmes producing MC levels acceptable for materials and close to the targeted
value of 5%. Materials freeze dried only once and with a tissue depth of 100 mm (FD-III &
FD-V) gave the highest MC determined which indicates that tissue depth in each tray should
be below 10 mm and ideally ~5 mm in order to obtain a sufficiently low MC.
Table 5-7: Moisture content of freeze dried tissues.

Material

Average

Stdev

%CV

FD-I

5.5

0.3

6.1%

FD-II

5.8

0.4

6.9%

FD-III

7.2

0.4

5.7%

FD-IV

2.7

0.1

4.2%

FD-V

8.9

0.5

7.9%

The FD-IV materials gave the lowest MC of any determined which although in theory this
provides the most inhospitable conditions for microbial growth it also produces the most
hygroscopic material which when opened would absorb water relatively quickly affecting
toxin concentration and compromising efforts to accurately certify the material [62,63].
From these results the ideal conditions were determined to be either 3 or 4 day freeze drying
programmes with ~ 5 mm tissue depth in each tray. The results indicate the freeze drying of
tissues can be adequately carried out at the MI using in-house apparatus and the various
processing steps are sufficient in dealing with hygroscopic materials.
The optimised FD process used in this study is represented on the phase diagram of water
graphically represented in Figure 5-13. The red trace corresponds to the freeze drying
programme applied and shows the process of water sublimation from the tissue, passing
straight from the solid to the gas phase.
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Figure 5-13: Phase diagram of water showing optimised freeze drying program.

Figure 5-14 below shows the variation of temperature and pressure applied during the FD
process as a function of time and illustrates the conditions used in the 96 hour freeze drying
programmes.
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Figure 5-14: Graphical representation of temperature and pressure changes applied to the tissues during the 4-day
optimised freeze drying process.
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5.4

FREEZE DRYING USING OPTIMISED PROGRAM

The previous section sought to optimise the conditions for freeze drying materials at the MI
and also the processing conditions necessary to produce small and relatively large scale
freeze dried materials. The optimised techniques show that the processing of hygroscopic
materials using the equipment either constructed or purchased as part of these studies, to be
suitable for producing freeze dried materials with the required MCs and sufficient
homogeneity.
Once the optimised conditions had been determined further studies were conducted to assess
the stability of a range of PSTs in both short and long-term studies.

5.4.1 SOURCE TISSUES
The material used in this section was prepared as part of the additives study in chapter 4 as
described in Section 4.3.1.1. The bulk homogenate was removed from the freezer and
allowed to defrost overnight in a fridge at +4°C. The tissue was manually mixed with a
spatula before transferring 734 ± 1 g into a Waring™ goblet. The final weight was made up
to 900 ± 1 g with DI water to alter the final MC to ~85% as the freeze drying programme was
optimised with tissues at this level. The slurry was poured into the freeze drying trays with a
tissue depth of ~50 mm, and placed into a freezer overnight at -20°C.

5.4.2 FREEZE DRYING AND MATERIAL PROCESSING
The trays were removed from the freezer and placed into the freeze drier for the duration of
the 96 hour programme as detailed in Table 5-5. Upon completion of the freeze drying
programme the material was removed from the instrument and was processed and dispensed
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as described in Section 5.3.4. Dispensed aliquots were placed into -80°C storage until further
use. 130 aliquots of this material were dispensed which gave sufficient numbers for short and
long-term stability studies as well as homogeneity determination. The remaining freeze dried
material not dispensed was transferred to a vacuum bag, sealed and stored at -80°C.

5.4.3 STABILITY AND HOMOGENEITY STUDIES
The between-bottle homogeneity of the materials was assessed through the intra-batch
analysis of 16 aliquots (3n1/3) selected through stratified random sampling of the entire fill
series.
The material was stability tested over a short term and long term period following a reverse
isochronous experimental design [55] as in previous experiments. The short term study was
conducted with triplicate samples consisting of five time points (0, 4, 7, 17 and 31 day) and
three temperature conditions (-20°C, +4°C and +40°C). The long term study was conducted
with triplicate samples consisting of five time points (0, 3, 6, 9 and 12 month) and three
temperature conditions (-20°C, +4°C and +20°C). The reference temperature used in both
studies was -80°C. In the case of all the stability studies; aliquots (n=3) were removed from 80°C storage on the prescribed day and transferred to the storage conditions being
investigated.
At the end time point all samples were removed from storage, allowed to equilibrate to room
temperature before removing the crimp seal and lyophilisation stopper. Immediately 0.75 ±
0.01 g of each tissue was weighed out to minimise moisture uptake of the hygroscopic
material. The tissues were reconstituted and extracted as described in Section 5.3.5.
Analysis was carried out by preCOX LC-FLD closely following OMA AOAC 2005.06 [41]
as detailed in Section 2.3.1. PCOX LC-FLD [75] analysis was additionally performed on all
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samples to specifically investigate the extent of epimerisation, if any, of GTX2,3 in each
material. For PCOX LC-FLD analysis, the crude acetic acid extracts prepared according to
Section 2.3.1 were deproteinated and analysed following AOAC 2011.02 [75].
PST concentrations in sample extracts were quantified against a 4 - 5-point calibration for
each toxin and are expressed in µmol/kg with total saxitoxin equivalents calculated as an
estimation of total toxicity.
The MC of these freeze dried tissues was not determined due to technical issues with the Karl
Fischer apparatus which could not be rectified during the course of these studies. The 96 hour
freeze drying programme, including material processing and dispensing techniques as
detailed in Section 5.3 has previously demonstrated that materials can be produced with a MC
of ~5% however.

5.4.4 RESULTS AND DISCUSSION
All the materials prepared in this section of the study were suitably homogenous for all the
PSP toxins quantified, as evidenced through the coefficient of variances contained in Table
5-8. The homogeneity techniques employed were therefore sufficient and the materials were
suitable for the analytical study.
Table 5-8: Homogeneity results for freeze dried material prepared using optimised 96 hour program (n=16).
dcSTX

GTX-2,3

GTX-5

STX

Total
Toxicity

µg STX diHCl-eq. / kg
Average

237.9

237.4

2.7

263.2

738.5

Stdev

8.4

15.8

0.1

8.3

32

%CV

3.5

6.7

4.4

3.2

4.3
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5.4.4.1 SHORT-TERM STABILITY

PRECOX LC-FLD
Short-term stability graphs for dcSTX, STX, GTX-2,3, GTX1,4 and GTX-5 are presented in
Figure 5-15. Results are normalised to the -80°C freezer mean on day zero and are presented
with error bars of the standard deviation from the triplicate analyses.
Excellent stability was demonstrated at -20°C and +4°C for all the toxins studied in this
section with all data points falling within the limits of stability set. The PSTs dcSTX, STX,
GTX1,4 and GTX5 also showed excellent stability when stored at +40°C in addition to the
other conditions. Some slight instability issues were evident for GTX2,3 at this temperature
condition with a slight increase in concentration observed after 17 days storage. This GTX2,3
increase was not as pronounced as that observed in the control materials (Figure 4-8) which
highlights the stability improvements this technique provides.
The results provide evidence that the toxins would be stable during transportation, even at
elevated temperatures of up to +40°C for 17 days. This has particular relevance for PT
providers or suppliers of RMs where stability during transportation to participants or
customers is critical.
As discussed in the previous chapter, the role of bacteria could explain the slight increases in
GTX2,3 concentration observed in freeze dried samples stored at +40°C through
biotransformations [132]. GTX2,3 increases were also observed in the untreated control
(Tissue C) materials as evidenced in Section 4.3.2.2.
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Figure 5-15: Short-term stability graphs by preCOX LC-FLD for freeze dried material using optimised method.

As evidenced from the short-term stability results above, freeze drying provides the best
stability for both PSTs and the matrix itself compared to the other two techniques
investigated or the untreated control (Figure 4-8) where stability issues at +40°C were
evident.
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PCOX LC-FLD
Further analysis was conducted by PCOX LC-FLD on the short-term stability study extracts
of each of the materials and results are presented in Figure 5-16 a-b. Limits of stability and
normalised results were calculated as per the preCOX analysis above. Data for the toxins
GTX1 and GTX4 were not generated as the concentration of these toxins in each material
was <LOD of the PCOX LC-FLD method.
No epimerization or degradation was observed in any materials when stored at -20°C or +4°C
for the duration of the study with results falling within the limits of stability set. However
epimerization was observed in materials stored at +40°C which became evident after 4 days
of the study. As such, it would seem that tissue samples stabilised by freeze-drying only,
would still need to be sent under temperature control conditions, if the end user required
quantitation of individual epimers. These results were similar to those observed for Tissue A
in Section 4.3.2.2 (where additives were used to stabilise the matrix) which shows no
significant improvement freeze drying makes to epimerization rates in the short-term
compared to additives spiking. Freeze drying does, however, improve stability compared to
the untreated control (Tissue C, Section 4.3.2.2) where epimerization was also observed at
+4°C in addition to the +40°C samples.
Interestingly the thermally treated material (Tissue B) in Section 4.3.2.2 did not show any
epimerization of GTX2 and GTX3 under any of the temperature conditions studied. GTX2
remained stable throughout the study and GTX3 showed some slight degradation but
epimerization of these toxins was not evidenced. This demonstrated the improvement that
thermally treating materials has on epimerization rates and suggests this step could be
performed in tandem with any other stabilisation technique being undertaken to combine the
advantages of these various techniques.
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Epimerization of these toxins followed predicted patterns with the β-epimer GTX3 being
epimerized into the more stable α-form GTX2 [136] which was evident from both the short
and long-term stability data generated through the PCOX LC-FLD analysis.

Figure 5-16: Short and long-term stability data by PCOX LC-FLD for freeze dried material using the optimised method.
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5.4.4.2 LONG-TERM STABILITY

PRECOX LC-FLD
Figure 5-17 a-e represents the long-term stability results for the freeze dried material at three
different storage temperatures, -20°C, +4°C and +20°C, determined through preCOX LCFLD analysis. Data for dcSTX, GTX1,4, GTX2,3, GTX5 and STX were generated and
results were normalised to the average of replicate analysis (n=9) of samples stored at the
reference temperature of -80°C for the duration of the study. The limits of stability from
Figure 5-17 were generated from two times the standard deviation of the -80°C replicate
analyses.
The stability of all the toxins studied in this section was maintained for 9 months under all the
temperature conditions,

-20°C, +4°C

and

+20°C

with

no evidence

for toxin

biotransformations or degradation during this time. Interestingly by the last time point of the
study (month 12) instability of dcSTX, STX and GTX5 was evident in samples under all
storage conditions with data points falling outside the limits of stability set. GTX2,3 also
showed the same drop in concentration in the month 12 samples under all temperature
conditions although no data points fell outside the limits of stability. Conversely GTX1,4
exhibited excellent stability throughout the yearlong study under all temperature conditions.
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Figure 5-17: Long-term stability graphs by preCOX LC-FLD for freeze dried material using optimised method.

The cause or causes of these instability issues for the non N-hydroxylated toxins in the month
12 samples are unknown but may have been caused by an error in re-constituting the tissues
prior to extraction. The concentrations of the N-hydroxylated toxins GTX1,4 after periodate
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oxidation did not show the same decrease in concentration. The fact that all three temperature
conditions degraded to approximately the same level in the case of each toxin is peculiar and
could be indicative of a systematic error. Previous materials described in this thesis stabilised
in multiple ways and indeed untreated control materials were all stable when stored at -20°C.
The excellent stability exhibited by the freeze dried materials in the early part of the longterm study also makes this sudden instability drop difficult to explain. The analysis of all the
long-term stability samples was repeated using fresh reagents but results confirmed the
instability issues in the month 12 samples.
Freeze drying greatly improved toxin and matrix stability compared to the control material as
can be seen from Figure 4-10. In particular the gonyautoxins 1-4 were completely degraded
by month 3 of the study at +20°C in the control but remained stable in the freeze dried
materials up to 9 months. Freeze drying also improved the stability of the other toxins present
in these tissues compared to the untreated controls.
In addition this technique showed improvements over additives spiking and heat treatment
(Figure 4-10), particularly GTX1,4 in the heat treated and GTX2,3 in the additives spiked
materials. This has proven freeze drying to be the most effective in stabilising the PSTs
compared to additives spiked, heat treated or untreated controls as described in Section 4.3.

PCOX LC-FLD
Further analysis was conducted by PCOX LC-FLD on the long-term stability study extracts
and results are presented in Figure 5-16 c-d. Limits of stability and normalised results were
calculated as described for the preCOX analysis above.
As in the case of the short-term study no epimerization or degradation was observed in the
freeze dried materials stored at -20°C or +4°C for the duration of the study with results
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falling within the limits of stability set. A small amount of epimerization was however
observed in materials stored at +20°C which was evident after 12 months of the study. The
only other instability issue observed at this temperature was a slight degradation of GTX3,
evident after 3 months.
Freeze drying significantly improved the stability of the PSTs compared to the untreated
control (Tissue C) evident in Section 4.3.2.3 where these toxins were completely degraded by
month 3 of the study at storage temperatures of +20°C. Improvements were also evident in
samples stored at +4°C where epimerization of GTX2,3 was observed in Tissue C (Figure
4-9) but these toxins remained stable in the freeze dried tissues for 12 months. Freeze drying
also showed improvements in PST stability compared to materials spiked with additives
(Tissue A) where epimerization of GTX2,3 could be observed after 3 months storage at +4°C
and +20°C.
Similar levels of stability were evident in the -20°C and +4°C freeze dried and heat treated
(Tissue B) samples as described in Section 4.3.2.3. Although slight, the epimerization of
GTX2,3 observed in the freeze dried materials after 12 months storage represented a minor
deterioration in stability of toxin epimers compared to those heat treated where this
phenomenon was not observed (Figure 4-9). Both stabilisation techniques did however show
instability of GTX3 evident by the slight degradation of this toxin at +20°C (freeze dried) and
+4°C (Heat treated) after 3 months.

CHROMATOGRAPHIC STABILITY
As in the case of the other techniques investigated, chromatographic stability of freeze dried
materials, specifically those stored at +20°C was assessed in comparison to untreated control
materials. Figure 5-18 a-f displays chromatograms generated by preCOX LC-FLD for the
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freeze dried and untreated control (Tissue C) materials by both peroxide and periodate
oxidation after 12 months storage at different temperatures. Chromatograms of the untreated
control material stored at -80°C for 12 months are also shown in this figure as a visual
comparison.
The chromatograms generated following peroxide oxidation (Figure 5-18 a-c) show differing
levels of stability, with the control material showing the total degradation of the toxins
GTX2,3 by month 12 of the study. Conversely excellent GTX2,3 stability was evident in the
freeze dried tissues stored at +20°C for 12 months with the chromatogram visually identical
to that from the untreated control material stored at -80°C for 12 months (Figure 5-18 a+c).
Additionally there was no visual evidence for the formation of additional chromatographic
peaks from the freeze drying process itself.
The chromatograms obtained following the analysis of periodate oxidised extracts used to
quantify the N-hydroxylated toxins GTX1,4 are illustrated in Figure 5-18 d-f. Again freeze
dried materials showed excellent chromatographic stability with the chromatogram identical
to that observed in the untreated control stored at -80°C. The untreated control stored at
+20°C for 12 months did not show good stability however with the chromatogram showing
the total degradation of GTX1,4 (Figure 5-18 e). There was no visual evidence for the
additional formation of any chromatographic peaks in the freeze dried chromatograms giving
further evidence for the improvements this technique offers in stabilising the matrix.
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Figure 5-18: Chromatograms of freeze dried and control materials under different storage conditions after peroxide or
periodate oxidation and preCOX LC-FLD analysis.

206

Chapter 5
5.4.5 CONCLUSIONS
Similarly to the optimisation studies in section 5.3 freeze drying and the associated
processing techniques developed at the MI produced homogeneous RMs with significant
stability improvements in comparison to an untreated control as well as heat treatment and
the use of preserving additives. Freeze drying also provided a more stable matrix as
demonstrated by the chromatographic stability of samples stored at high temperatures.
Whilst this study has shown compelling evidence for advantages with freeze drying, the
technique does however require specialised equipment not readily accessible by most
biotoxin laboratories. There is also the requirement for personnel with expertise in both the
freeze drying process itself as well as the labour intensive processing techniques. The freeze
drying process does also significantly alter the biological matrix compared with wet
materials, so some researchers may debate whether such materials are ideally applicable for
internal QC RM preparation. Materials treated by heat and chemical additives which were
prepared from the same bulk homogenate, provide much more cost effective techniques albeit
without providing materials with the same levels of toxin stability. Use of heat treatment or
the preserving additives may be acceptable for the preparation of an internal QC material but
freeze drying clearly provides a more appropriate tool for CRM production.
Excellent short-term stability was demonstrated in these materials even at higher storage
temperatures which indicates transport of these materials could be carried out at temperatures
above freezing. This would provide a very significant advantage to the RM producer if
transporting these materials globally. Long-term stability was also demonstrated by preCOX
LC-FLD, although a potential anomaly was seen in the month 12 samples under all storage
conditions which could not be definitively explained.
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PCOX LC-FLD analysis of short and long-term stability study samples showed evidence for
instability issues of GTX2,3 in the +40°C and +20°C stored samples respectively.
Epimerization of these toxins was observed particularly in the +40°C samples in the shortterm studies with the rates of epimerization significantly reduced at +20°C in the long-term,
thus demonstrating the significance of temperature on epimerization rates. The extent of
epimerization of these toxins was less than that observed in the additives spiked material and
untreated controls but interestingly heat treatment reduced these rates more than the freeze
dried materials (Figure 4-9 a-d). This suggests that heat treating the materials prior to freeze
drying may provide a more stable matrix less prone to epimerization issues. This
experimental technique is described in the next section.
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5.5

COMBINED FREEZE DRYING WITH THERMAL PRE-TREATMENT

An additional experiment described in this section coupled this freeze drying technique with
a thermal pre-treatment step in an effort to combine the superior stability of the PSTs
observed in the freeze dried materials with the reduced epimerization rates of heat treated
materials, as seen in Chapter 4.
The material was prepared in combination with a study on the individual use of preserving
additives together with an untreated control material as described in Chapter 4 (Section 4.2).

209

Chapter 5
5.5.1 SOURCE TISSUES AND INITIAL TREATMENT
The source tissues and quantities used to prepare this material can be seen in Table 4-1 and
the preparation of this initial material is described in Section 4.2.1.1.
The tissue was removed from the freezer, allowed to defrost in a fridge at +4°C overnight
before being transferred to a 5L PP beaker. The beaker was covered with tin foil and sealed
with autoclave tape, making small holes in the tinfoil lid to allow pressure release during the
process. The tissue was autoclaved (K200E Touchclave, LTE, UK) at 121°C for 15 min,
cooled in a fridge at +4°C before transferring 590 ± 1 g of the material to a 2L Waring™
goblet. The final weight was made up to 763 ± 1 g with DI water to adjust the final MC to
~85% as the four day freeze drying programme was optimised with materials containing this
level of moisture. The tissue was homogenised on medium power for 5.0 ± 0.1 min before
dividing the slurry equally into two freeze drying trays at a tissue depth of ~1.0 ± 0.1 cm. The
trays were covered with tinfoil and placed in a freezer at -20°C overnight.

5.5.2 FREEZE DRYING AND MATERIAL PROCESSING
The trays were removed from the freezer and placed into the freeze drier where the 96 hour
programme as detailed in Table 5-5 was started. Upon completion of the freeze drying
programme the material was removed from the instrument, processed and dispensed as
described in Section 5.3.4. A total of 120 aliquots of this material were dispensed as 0.78 ±
0.01 g portions (to ensure minimum retrieval of 0.75 g for extraction) and stored at -80°C
until further use.
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5.5.3 STABILITY AND HOMOGENEITY STUDIES
The between-bottle homogeneity of the materials was assessed through the intra-batch
analysis of 15 (3n1/3) aliquots selected through stratified random sampling of the entire fill
series.
All materials were stability tested over a short term (31 day) and long term (12 month) period
following a reverse isochronous experimental design [55] as described previously. The short
term study was conducted with triplicate samples consisting of five time points (0, 4, 8, 16
and 31 day) and three temperature conditions (-20°C, +4°C and +40°C). The long term study
was conducted with triplicate samples consisting of five time points (0, 3, 6, 9 and 12 month)
and three temperature conditions (-20°C, +4°C and +20°C). The reference temperature used
in both studies was -80°C. The stability studies were carried out as described in section
4.2.1.4.
At the end time point all samples were removed from storage, allowed to equilibrate to room
temperature before removing the crimp seal and lyophilisation stopper. 0.75 ± 0.01 g of each
tissue was weighed out immediately after the stopper was removed to minimise moisture
uptake. The tissues were reconstituted and extracted as described in Section 5.3.5.
Analysis was carried out by preCOX LC-FLD as per OMA AOAC 2005.06 [41] (Section
2.3.1). PCOX LC-FLD [75] analysis was additionally performed on all samples to assess the
presence of any epimerisation, if any, of GTX2,3 in each material. For PCOX LC-FLD
analysis, the crude acetic acid extracts prepared according to Section 2.3.1 were deproteinated
and analysed following AOAC 2011.02 [75].
PST concentrations in sample extracts were quantified against a 4 - 5-point calibration for
each toxin and are expressed in µmol/kg with total saxitoxin equivalents calculated as an
estimation of total toxicity.
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The MC of these freeze dried tissues was not determined due to technical issues with the Karl
Fischer apparatus which could not be rectified during the course of these studies. As
determined in the optimisation studies in Section 5.3 however, the 96 hour freeze drying
programme and associated processing and dispensing techniques produced materials with the
required MC of ~5%.

5.5.4 RESULTS AND DISCUSSION
All the materials prepared in this section of the study were suitably homogenous for all the
PSP toxins quantified, as evidenced through the coefficient of variances contained in Table
5-9, which were all below 8%. The homogeneity techniques employed were therefore
sufficient and the materials deemed suitable for the consequent study.
Table 5-9: Homogeneity results from freeze dried material with thermal pre-treatment (n=15).
dcSTX

GTX2,3

GTX5

STX

GTX1,4

Total
Toxicity

µg STX diHCl-eq. / kg
Average

198.4

622.5

1.8

598.1

297.9

1718.7

Stdev

5.6

43.6

0.1

15.2

22.2

57.1

%CV

2.8

7.0

5.2

2.5

7.4

3.3

Homogeneity results of Tissues 1-3 summarised in Table 4-4 compare similarly to those
above which shows the stability of the PSTs subjected to freeze drying and thermal treatment.
The total toxicity figures above and those of the untreated control (Tissue 3) show no
significant toxin degradation occurred during the stabilisation processes.
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5.5.4.1 SHORT-TERM STABILITY

PRECOX LC-FLD
Short-term stability graphs for dcSTX, STX, GTX2,3, GTX5 and GTX1,4 are presented in
Figure 5-19 for the material prepared. Results are normalised to the -80°C freezer mean on
day zero and are presented with error bars of the standard deviation from the triplicate
analyses.
Excellent stability was demonstrated at -20°C and +4°C for all the toxins studied in this
section with all data points falling within the limits of stability set. There were some
instability issues evidenced in samples stored at +40°C however, with dcSTX, STX, GTX2,3
and GTX5 degrading slightly by the end of the study, as evidenced by data points falling
outside the limits of stability. However, the calculated limits of stability, particularly for the
toxins dcSTX, STX, and GTX5, were very tight. This was due to the low %CVs determined
for materials stored at -80°C for the duration of the study from which these figures are
calculated (n=9). GTX5 is also present at a very low concentration (~ 400 times less than the
EU reg. limit) in these materials which is just above the LOQ of the preCOX LC-FLD
method as determined through in-house validation (data not shown). GTX1,4 remained stable
throughout the short-term study even at the elevated storage temperature of +40°C. The
results therefore indicate again that transportation of these heat treated and freeze dried
materials could be carried out under freezing or cooled storage conditions, but could not be
conducted at room temperature safely.
This combined technique also significantly improved the stability of the PSTs relative to an
untreated control as well as antibiotic and anti-oxidant spiked materials as seen in Figure 4-3.
These four materials were all prepared from the same bulk homogenate prepared in Section
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4.2 so these materials can be compared for the levels of stability they provide. In terms of
percentage difference of toxin degradation observed, this freeze drying technique with
thermal pre-treatment provided better stability for dcSTX (9%), STX (8%) and GTX5 (48%)
compared to the untreated control (Tissue 3) in samples stored at +40°C.
Under the same temperature conditions the material also showed significant improvements
over the use of antibiotics (Tissue 1) for all the PSTs except GTX2,3 where degradation of
these toxins was observed in the freeze dried material but remained stable in the antibiotics
spiked tissues. Similar levels of stability were observed in the antioxidant spiked material
(Tissue 2) for the toxins dcSTX and STX but stability improvements were observed in the
freeze dried materials for the gonyautoxins 1-5.
The short-term stability results further emphasise the applicability of this technique in
preparing RMs and the inclusion of a thermal pre-treatment step before freeze drying
provides the same level of stability as freeze drying alone for most toxins, although GTX5
showed slightly more instability issues.
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Figure 5-19: Short-term stability graphs for PSTs present in the freeze dried material with thermal pre-treatment.

PCOX LC-FLD
Further analysis was conducted by PCOX LC-FLD on the short-term stability study extracts
of each of the materials and results are presented in Figure 5-20 a-b. Limits of stability and
normalised results were calculated as per the preCOX analysis. Data for the toxins GTX1 and
GTX4 were not generated as the concentration of these toxins in each material was <LOD of
the PCOX LC-FLD method.
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No epimerization or degradation was observed in any materials when stored at -20°C or +4°C
for the duration of the study with results falling within the limits of stability set.
Epimerization was observed however in materials stored at +40°C, evident after 4 days of the
study, which was similar to the observations made in the Section 5.4 for freeze drying alone.
The epimerization rates were significantly reduced however in the thermally pre-treated
materials which gives evidence for the benefits of combining the two techniques.
Significant improvements were made over the untreated control (Tissue 3) as observed in
Figure 4-4, with rates of epimerization reduced by ~40% in samples stored at +40°C and
eliminated in samples stored at +4°C. Similarly this technique reduced epimerization rates in
the antibiotic (Tissue 1) and the antioxidant (Tissue 2) spiked materials in the +40°C samples
by ~15% in both cases. Epimerization was evident in the Tissue 1 and 2 materials stored at
+4°C but this had been eliminated in the freeze dried material which again shows the
advantages this technique provides.
PCOX LC-FLD analysis of both the short and long-term stability study samples showed
epimerisation of the β-epimer GTX3 into the more stable α-form GTX2 as expected [136].
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Figure 5-20: Short and long-term stability data by PCOX LC-FLD for freeze dried material with thermal pre-treatment step.

5.5.4.2 LONG-TERM STABILITY

PRECOX LC-FLD
Long-term stability graphs for dcSTX, STX, GTX2,3, GTX5 and GTX1,4 are presented in
Figure 5-21 for the material prepared in this section. Results were normalised to the -80°C
freezer mean on day zero and are presented with error bars of the standard deviation from the
triplicate analyses.
Excellent toxin stability was exhibited in the freeze dried materials following the long-term
study with none of the toxins investigated showing any signs of degradation even at the
elevated storage temperature of +20°C. The data therefore provides evidence for the excellent
long-term stability of these toxins in freeze dried materials which are thermally pre-treated.
These materials could be stored at temperatures of up to +20°C without adversely affecting
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PST content although long-term storage would always be recommended at temperatures
below freezing.

Figure 5-21: Long-term stability graphs for freeze dried material with thermal pre-treatment.

The degradation of the toxins observed in the month 12 freeze dried samples from the
previous section (Figure 5-17) was not evident in these materials. This shows either the
improved stability of this combined technique or, as is more likely, the same anomaly
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observed in that dataset was not repeated in the preparation and analysis of these dual-treated
materials.
The stability of the PSTs was greatly enhanced in these materials compared to the untreated
control (Tissue 3, Section 4-2) apart from STX which displayed comparable stability to this
material. This combined technique also showed better stability compared to the use of the
antibiotics (Tissue 1) and antioxidant (Tissue 2) spiked materials from the same figure,
particularly for the toxins GTX2,3 where significant increases (~30%) were observed in
samples stored at +40°C.

PCOX LC-FLD
Further analysis was conducted by PCOX LC-FLD on the long-term stability study extracts
of each of the materials and results are presented in Figure 5-20 c-d. Limits of stability and
normalised results were calculated as per the preCOX analysis.
No epimerization or degradation was observed in any materials when stored at -20°C, +4°C
or +20°C for the duration of the long-term study with results falling within the limits of
stability set. These results show the significant improvements the thermal pre-treatment step
makes in reducing epimerization rates over an extended time period compared to freeze
drying alone (Figure 5-16). This was particularly evident in the case of GTX3 which showed
signs of degradation after month 3 of the study in materials prepared by freeze drying alone
(Figure 5-16) with this toxin remaining stable for 12 months in the materials prepared by the
combined techniques.
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Significant improvements were made over the untreated control (Tissue 3) as observed in
Figure 4-4, with rates of epimerization reduced by ~20% in samples stored at both +4°C and
+20°C. This combined technique also significantly reduced epimerization rates compared to
the antibiotics (Tissue 1) and antioxidant (Tissue 2) spiked materials by as much as 40% in
the +20°C samples.

CHROMATOGRAPHIC STABILITY
The chromatographic stability of the combined freeze dried and thermally pre-treated
material was assessed against an untreated control. Figure 5-22 a-f displays chromatograms
generated by preCOX LC-FLD for the material described in this section and an untreated
control (Tissue C, Section 4-2) by both peroxide and periodate oxidation after 12 months
storage at different temperatures. Chromatograms of the untreated control material stored at 80°C for 12 months are also shown in this figure as a visual comparison.
The chromatograms generated through peroxide oxidation (Figure 5-22 a-c) show the
excellent chromatographic stability of the freeze dried and thermally treated material stored at
+20°C (a) compared to the control (c) stored at -80°C. There was no visual evidence for the
formation of extra fluorescent components from the freeze drying process itself or from
storage at this elevated temperature for 12 months. The control material stored at +20°C for
12 months (b), while still maintaining the same toxin profile, did show evidence for the
formation of extra chromatographic peaks between 2 – 7 min. Although this did not affect
quantitation of any of the PSTs present in these materials, some of these peaks may be
problematic in quantifying the C-toxins if they were present.
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Figure 5-22: Chromatograms of freeze dried/thermally treated and control materials stored at different temperatures after
peroxide and periodate oxidation and analysis by preCOX LC-FLD.
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The periodate oxidised extract analysis used to quantify the N-hydroxylated toxins GTX1,4
are illustrated in Figure 5-22 d-f. Again the freeze dried and thermally treated material stored
at +20°C (d) showed excellent chromatographic stability with the chromatogram identical to
that observed in the untreated control (f) stored at -80°C. There was no visual evidence for
the additional formation of any chromatographic peaks in the freeze dried chromatograms
giving further evidence for the improvements this technique gives in stabilising the matrix.
The untreated control stored at +20°C for 12 months (e) showed the formation of two extra
peaks in the chromatogram at ~6 min, although the toxin profile remained intact.

5.5.5 CONCLUSIONS
As demonstrated within this chapter, freeze drying is an excellent technique for preparing
homogeneous PST RMs. Excellent stability has been observed over both short and long-term
timeframes over a range of different temperatures. The application of a thermal treatment step
to the source tissues prior to being freeze dried was successful in further lowering the rates of
epimerization observed in materials prepared by freeze drying alone (Section 5-4). Both
techniques stabilise PSTs and the matrix in different ways that combined, result in a
procedure suitable for RM preparation. The thermal treatment of the materials sterilizes and
therefore destroys most if not all bacteria in the source tissues which alone would produce a
very stable material. The processing and dispensing steps are not carried out aseptically
however so bacterial contamination of the aliquots during these steps is inevitable. The freeze
drying of tissues lowers the water content of the final product creating an environment
unsuitable for microbial growth. These combined techniques therefore result in the same
desired outcome, lowering rates of degradation, epimerization or biotransformations, through
different routes, sterilization and water removal.
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This procedure could have specific application in the production of CRMs and is arguably the
most appropriate technique investigated in this thesis for these purposes owing to the superior
stability exhibited in those materials.
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5.6

PREPARATION OF CANDIDATE PSP CRM

The preparation of RMs, particularly those intended for internal QC, method development
and validation use or for distribution to participants in PT exercises, can be performed
adequately using one of the relatively simpler techniques described in Chapter 4. These
techniques such as heat treatment or the use of preserving additives including all associated
processing techniques have been shown successfully to produce homogenous materials,
stable for their intended purposes. The preparation of these relatively small scale RMs does
not therefore necessitate the use of freeze drying even with the advantages this technique
affords the user.
This labour intensive and significantly more costly technique does have applicability in the
production of CRMs however where long-term stability of the toxins and matrix is of primary
importance. CRM production is also generally carried out through dispensing large quantities
of materials thus lowering the overall unit cost.
The experiments conducted in this chapter so far have resulted in the development of an
optimised freeze drying programme and processing technique that produces high quality
homogeneous and stable materials. Using these optimised techniques a large scale freeze
dried material was prepared in collaboration with CEFAS, UK as a candidate CRM.

5.6.1 SOURCE TISSUES AND INITIAL TREATMENT
The material was prepared from a naturally contaminated oyster tissue matrix which was
produced through feeding experiments carried out in CEFAS facilities. The feeding
experiments are detailed in Section 5.2.1.
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Approximately 12 kg of homogenised oyster tissue in PP containers was sent to the MI in
temperature controlled transport boxes. After receipt the PP containers were immediately
transferred to a freezer at -20°C until further use.
The tissues were initially removed from the freezer and allowed to defrost at +4°C before
being transferred equally to 4 x 5 L PP beakers. The beakers were covered with tin foil and
sealed with autoclave tape, making small holes in the tinfoil lid to allow pressure release
during the process. The tissues were autoclaved (K200E Touchclave, LTE, UK) at 121°C for
15 min, cooled in a fridge at +4°C before transferring to a 25 L PP bucket previously washed
with Decon-90 (which contains a bactericide), followed by rinsing with DI water.
The material was then homogenised using a Silverson BX batch mixer (Silverson, MA, USA)
set on medium power for 30.0 ± 0.1 min (Figure 5-23). The bucket was placed in an ice-bath
during mixing to prevent localised heating of the tissues through friction.

Figure 5-23: Silverson BX batch mixer used to homogenise the oyster material prior to freeze drying.
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Aliquots were taken for MC determination (n=3) using the rotary vacuum method and
analysis by preCOX LC-FLD (n=1) as described in the materials and methods Section 2.4.1
and 2.3.1 respectively, to give approximate PST concentrations in the bulk tissue. The bucket
was sealed and stored in the fridge at +4°C until further use.
The concentrations and MC of this tissue are summarised in Table 5-10. The levels
determined for this tissue were at concentrations that would ensure the final freeze dried
material would have total toxicity slightly higher than the current EU regulatory limit. This
analysis also confirmed the profile of the material as containing most of the relevant PSTs.
The MC determined was higher than the 85% normally used but the capacity of the freeze
drier was sufficient for this quantity of water removal.
Table 5-10: Concentrations of PSTs and MC of bulk tissue used to prepare candidate CRM.
Concentration (µmol / kg)
Material
Oyster Tissue
Homogenate

dcGTX2,3

GTX-2,3

STX

C1,2

GTX-1,4

NEO

0.74

0.48

0.31

0.23

1.94

0.72

Total Toxicity
(µg STX diHCl-eq / kg)

%
Moisture
Content

1331

92.6

5.6.2 FREEZE DRYING AND MATERIAL PROCESSING
The container of tissue was removed from the fridge and re-homogenised using the Silverson
BX batch mixer (Silverson, MA, USA) set on medium power for 5.0 ± 0.1 min. The
homogenised slurry was then poured into seven freeze drying trays at a tissue depth of ~5
mm, wrapped in tin foil and placed in a walk-in freezer at -20°C overnight.
The trays were subsequently removed from the freezer and placed into the freeze drier where
the 96 hour programme detailed in Table 5-5 was started. Upon completion of the freeze
drying programme the material was removed from the instrument and the freeze dried tissue
in each tray was manually cut up and transferred into a bag, vacuum sealed and stored at
+4°C. The quantities of tissues pre and post freeze drying are contained in Table 5-11.
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Table 5-11: Weights of wet and freeze dried tissues in preparation of candidate CRM.

Freeze Drying
Tray
1
2
3
4
5
6
7
Total

Weight of wet tissue slurry
before freeze drying (kg)
1.451
1.388
1.469
1.396
1.544
1.472
1.458

Weight of freeze
dried material (kg)
0.127
0.123
0.129
0.126
0.138
0.132
0.132

10.178

0.907

As described in previous sections all equipment used to process and dispense the freeze dried
materials was first washed in Decon-90 followed by rinsing in DI water. The equipment was
placed in an oven at +40°C for ~4 hours to dry before being placed in a desiccator until
further use.
The freeze-dried material was processed in batches as follows:
1. Two vacuum sealed bags of freeze dried tissue were taken and placed in the modified
glove box, along with three large steel bowls containing 25 x 20 mm stainless steel balls
and the 125 µm sieve, base plate and lid.
2. The glove box lid was fitted and clamped and the exhaust valve opened. A cylinder of
low moisture content argon was attached to the entry valve and the chamber was purged
for ~5.0 ± 0.1 min before lowering the flow rate of argon.
3. The vacuum bags of freeze dried material were opened and poured equally into the three
milling bowls before placing the lids on top.
4. The argon flow was stopped and the glove box lid removed. The milling bowls were
taken and secured on the planetary ball mill (Retsch PM 100-Verder Group, The
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Netherlands). The tissues were ground for 5.0 ± 0.1 min each before being placed back
into the glove box.
5. The glove box lid was fitted and clamped and the exhaust valve opened. The entry valve
was opened and the chamber was purged for ~5.0 ± 0.1 min before lowering the flow rate
of argon. The lids of the milling bowls were then removed and the contents of each bowl
transferred to the 125µm sieve plate. The sieve lid was attached before opening the glove
box.
6. The material was placed on the motorised sieve shaker (Impact Test Equipment Ltd.,
UK) and covered with a plastic sheet, sealed with tape. A hose from a cylinder of low
moisture argon was inserted into the sheet cover at the top of the sieve shaker, flushing
the gas over the sieve plates. The freeze dried material was sieved for 30.0 ± 0.1 min
before removing and placing back into the glove box.
7. The chamber was purged with low moisture argon as described above before removing
the sieve lid and 125µm sieve plate. The contents of the base plate were transferred to a
vacuum bag before removing the glove box lid and vacuum sealing the bag.
Steps 1 – 7 were repeated until all seven bags of freeze dried material had been processed
which gave ~800 g of milled and sieved freeze dried tissue.
The material was dispensed by transferring the amber glass vials from the dessicator into the
glove box along with the freeze dried material, semi-automated powder dispenser and all
other associated equipment required. The setup of the glove box is as appears in Figure 5-10.
The glove box lid was fitted and clamped before purging the chamber with low moisture
argon. The antistatic fan was turned on and the antistatic gun discharged to aid in dispensing
the powders. The antistatic gun was discharged periodically throughout the dispensing
process.
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The vacuum bags containing the freeze dried materials were opened and transferred into a
large PP container and continually mixed with a large spatula for 5.0 ± 0.1 min. The powder
dispenser was calibrated to ~0.77 g aliquot sizes before the material was dispensed into prelabelled amber vials. After 588 aliquots had been dispensed, parafilm was placed over the
beaker containing the remaining freeze dried material. The glove box lid was taken off and
the amber vials were removed and placed on freeze drying trays. Lyophilisation stoppers
were inserted halfway before placing the trays into the freeze drier. The door was sealed and
the vacuum applied removing air from the chamber. A cylinder of low moisture argon was
attached to the exhaust valve and a partial vacuum was released allowing argon to flow into
the freeze drying chamber. The shelves were contracted which pushed the lyophilisation
stoppers fully into the vials before releasing the remaining vacuum to atmosphere. The vials
were removed and placed in boxes.
Simultaneously to the aliquots being sealed above, empty amber vials were transferred from a
desiccator to the glove box. The lid was put on and clamped, purging the chamber of air with
low moisture argon and removing static build-up through use of the gun. The remaining
material was dispensed before sealing the vials with lyophilisation stoppers as described
above. All vials were further crimp sealed manually.
A total of 1003 aliquots of this freeze dried material were dispensed and stored at -20°C. The
vials were placed into boxes and transferred back to CEFAS facilities under cooled
conditions.
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5.6.3 ASSOCIATED STUDIES
The stability and homogeneity studies have not been carried out on this material to date due
to time constraints at the collaborators laboratory and the completion of another candidate
PSP CRM stabilised through gamma irradiation [151,152]. The material is stored at -80°C
until required for homogeneity, stability and/or certification studies.

5.6.4 CONCLUSIONS
Although no stability or homogeneity studies have been carried out on this material to date,
the process does highlight the fact that facilities and techniques developed at the MI during
the course of these studies are applicable in the preparation of medium scale freeze dried
materials.
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5.7

SUMMARY OF FINDINGS AND CONCLUSIONS

This chapter has focused on the processing technique of freeze drying and its effects on PST
and matrix stability for the preparation of RMs. Although this technique has previously been
used to prepare a PST CRM it was never made commercially available. The previous study
only covered one matrix, mussel, which contained two toxins, STX and dcSTX, and the
freeze drying, processing and dispensing processes used were not detailed. Finally, the
material was not prepared in parallel with an untreated control material to measure the
effectiveness of the technique.
For these reasons the technique of freeze drying was evaluated here specifically to ascertain
the following:


The feasibility of preparing RMs by this method using MI facilities and evaluating
multiple PSTs in a matrix other than mussel which had been previously studied.



Once the feasibility of carrying out this technique at the MI had been established, to
optimise the process, including the freeze drying programme, processing and
dispensing techniques and to determine the capabilities of the MI in terms of capacity.



Investigate issues arising from the initial feasibility study, specifically increased
GTX2,3 concentrations observed in materials stored at higher temperatures.



Using the techniques developed, to prepare a relatively large scale freeze dried
material as a candidate CRM.

The initial feasibility study contained in Section 5.2 details the first biotoxin RM to be
prepared in MI facilities and was successful in demonstrating the capabilities of equipment,
which had been recently purchased by the MI, in preparing materials by this technique. This
initial study confirmed freeze drying as a very effective technique in PST RM preparation
which was carried out in a new matrix, and which contained multiple toxins, some of which
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had not been previously evaluated. These initial studies did however highlight some stability
issues, specifically increasing toxin concentrations, which were evident in both the short and
long-term stability studies affecting the gonyautoxins1-4 and the C-toxins. Significant rates
of epimerization were also observed in this initial material which affected all three pairs of
epimers.
The processing and dispensing techniques used to prepare these materials were then
optimised in an effort to solve the issues highlighted above. Although the MC of this initial
material was not determined as a KF apparatus was not available at the time of preparation, it
seemed that moisture uptake by the highly hygroscopic material during the processing steps
led to a final MC that was too high and therefore lead to the instability observed. This was
due to various processing and dispensing steps being followed outside of moisture controlled
conditions, i.e. outside of the glovebox purged with low moisture argon.
The optimisation experiments therefore sought to develop the freeze drying process in order
to minimise moisture uptake during the various stages of production. A KF apparatus was
acquired for these optimisation studies and the resulting data demonstrated the suitability of
the processing and dispensing techniques, as well as the specific freeze drying time
programmes, to produce materials with the desired MC of ~5%.
Two other freeze dried materials were prepared in tandem with studies on preserving
additives and thermal treatment as detailed in Chapter 4. Full stability and homogeneity
studies were carried out on these materials, specifically to determine if improvements were
made from the feasibility studies, namely reduced rates of epimerization and a reduction or
elimination of toxin biotransformations. The first material prepared by freeze drying alone
improved the stability of the toxins, specifically increasing GTX2,3 and GTX1,4
concentrations observed in the feasibility study materials was significantly reduced. These
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stability improvements could be due to a lower MC in these materials compared to the
feasibility materials although this could not be substantiated as technical difficulties with the
KF apparatus prevented their MC being determined. The stability improvements could also
be due to both studies being carried out in mussel and oyster tissue matrices respectively and
the different bacterial loads each naturally contains. Although overall toxin stability was
improved, epimerization rates were observed to take place at similar levels and to the same
extent.
For this reason a further technique was investigated which involved heat treating the
materials prior to freeze drying. These techniques would combine the benefits of both,
sterilization through heat treatment to destroy bacteria and freeze drying to lower the MC
sufficiently to ensure conditions, for any remaining microbial activity, were as inhospitable as
possible. The material prepared in this way showed improvements over materials previously
prepared, specifically reducing epimerization rates over the long-term while providing the
same level of overall toxin stability observed in materials prepared by freeze drying alone.
Finally this chapter described the preparation of a material on a relatively large scale as a
candidate CRM using the optimised freeze drying, processing and dispensing techniques
developed, including initially thermally treating the materials. This material has not been
characterised, assessed for homogeneity or stability or been certified to date. This is due to a
gamma irradiated PST CRM being made commercially available during this time coupled to
the fact that the biotoxin CRM market is relatively small. It is likely that the material will be
assessed as a full CRM within the next 12 months (CEFAS, personal communication).
From the studies contained in this chapter, freeze drying has proven to be the most effective
technique for preparing PST RMs, providing superior stability to any of the other techniques
investigated in the previous chapter. The applicability of the technique is, however, limited
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solely to the preparation of CRMs and no other RM forms such as LRMs or ILRMs. This is
due to the highly labour intensive process of freeze drying, processing and dispensing
materials, as well as the large capital investment needed for all equipment which cost in
excess of €250,000 in the case of the MI facilities. In terms of everyday usage in the case of
general LRMs for internal QC/QA purposes, freeze drying would not represent a cost
effective means of preparation and techniques such as the use of preserving additives or
simple thermal treatment provide a better option for monitoring or research laboratories.
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MATERIAL USE IN PROFICIENCY TESTING SCHEMES –
QUASIMEME
Chapter 6 details work described in Burrell et al. 2015, including extra data analysis not
contained in the TrAC article.
Stephen Burrell, Steven Crum, Barry Foley & Andrew D. Turner, 2015. Proficiency Testing
of Laboratories for Paralytic Shellfish Poisoning Toxins in Shellfish by QUASIMEME: A
Review. Trends in Analytical Chemistry. (Accepted Manuscript TRAC-D-15-00087)
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6.1 INTRODUCTION AND BACKGROUND
As discussed in Chapter 1, an essential component in any effective monitoring program is the
proper application of a quality management system, incorporating both quality assurance and
quality control [153]. Proficiency testing (PT) plays a vital role in the implementation of
these programs, and participation in these schemes is a requirement both legislatively in the
EU [72,73] as well as by most national accreditation bodies.
The stabilisation techniques described in Chapter 4, specifically the application of a thermal
pre-treatment step prior to spiking with preserving additives was selected to prepare materials
for use in these PT exercises. The techniques were chosen not only for the enhanced stability
they provide the PSTs, especially during transport to participants laboratories, but also for the
cost effectiveness of the preparation technique. This latter point was particularly important in
the early rounds of this scheme in demonstrating the commercial viability of running this
development exercise. For instance freeze drying would arguably provide superior PST
stability but the unit cost to produce these materials in the quantities needed in these exercises
would be too high to justify, which could jeopardise the sustainability of future exercises.
Six rounds of PSP exercises have been delivered by QUASIMEME since 2009 with a wide
array of different methodologies used by participants.

6.1.1 METHODS OF ANALYSIS
There are few internationally recognised methods available for determining PSP toxins and
these have been discussed in Chapter 1. Participants of QUASIMEME exercises over the last
six years have used a range of these plus other developed methods and the breakdown,
including total numbers of subscribers in each round are detailed in Table 6-1.
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Table 6-1: Total number of participants in each round including breakdown of methods used.

Methods Used
Year

Round

2009
2010
2011
2012
2013
2014

57
61
65
69
72
2014-1

preCOX

PCOX

MBA

ELISA

LC-MS/MS

Total Number of
Participants

8
9
8
9
13
13

2
5
5
5
6
5

4
2
4
2
2
2

2*
-

1
3

14
16
19
16
22
23

*Ridascreen ELISA used by participants

The methods used by QUASIMEME participants are described in section 1.8, including some
of the major drawbacks and advantages of each method. The majority of QUASIMEME
participants have used preCOX LC-FLD methods since these exercises began. Participation
in these exercises is predominated by EU laboratories with approximately 60% of total
subscriptions coming from this region. Two preCOX methods have been used to date with
most participants using OMA AOAC 2005.06 [41]. The second closely-related method, used
by one participant in 2014 is that described by the European Committee for Standardisation
(CEN) and was recently published as European standard DIN EN 14526 [154]. Both methods
involve the oxidation of toxins into iminopurine derivatives before separation and
determination by LC-FLD. Participants using PCOX methods of analysis have increased
since the start of this development exercise and numbers have remained steady in the
intervening years. Most PCOX participants have used OMA AOAC 2011.02 [75] to
determine the toxicity of QUASIMEME samples. One participant (Lab 5) used the original
PCOX method developed by Oshima [17] for the first three years, 2009-2011. This lab did
not submit results during the subsequent two years but submitted results again in 2014 using
OMA AOAC 2011.02 (Table 6-4). The complexities in accurate identification of these toxins
using either preCOX or PCOX methods are discussed in Chapter 1. To illustrate these
complexities example chromatograms of a sample used in these exercises are contained in
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Figure 6-1 a-d. Participants using mass spectrometry for determining PSP toxins have only
recently submitted results using this technique in 2013 and 2014.

Figure 6-1: Chromatograms of Tissue B (QST076BT, 095BT & 133BT) obtained by a) preCOX LC-FLD analysis of
fraction 2 obtained after carboxylic acid solid phase extraction (SPE), periodate oxidised, b) preCOX LC-FLD analysis of
C18 SPE cleaned, peroxide oxidised, c) PCOX LC-FLD analysis of GTX/STX toxins and d) PCOX LC-FLD analysis of Ctoxins.
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6.1.2 TOXICITY EQUIVALENCY FACTORS (TEFS)
The PSP analogues differ substantially in their toxicity and their TEFs have been derived
from MBA data. Table 1-1 lists the TEFs reported by Oshima et al. in 1995 [17] alongside
values compiled by the Scientific Panel on Contaminants in the Food Chain (CONTAM) of
the European Food Safety Authority (EFSA) in 2009 [6]. The two sets of data are similar
with the exception of dcSTX where the TEF was increased to 1.0 from 0.5131 by the
CONTAM panel. This change would significantly affect reported total toxicities of samples
with dcSTX as the predominant toxin present which is the case in some of the samples
supplied by QUASIMEME. The implications of these differences are discussed in detail
below.

6.1.3 STATISTICAL METHODS

FOR

THE

ASSESSMENT

OF

PROFICIENCY TESTING

PERFORMANCE
The assessment of laboratory performance or PT data has historically been carried out using
ISO guide 5725: Accuracy (trueness and precision) of measurement methods and results, to
obtain an estimate of the mean and the uncertainty of the measurement [155]. The standard
makes the assumption that values are normally distributed and there is an equal withinlaboratory variance, and it was developed for PT studies where participants were required to
use the same protocol. Due to the nature of PT schemes where different analytical methods
are used, data is very often non-normally distributed and may be either positively or
negatively skewed or bi- or multi-modal.
Laboratories in PT studies should, in principle only participate when their methods are fully
validated and statistically controlled and under these circumstances datasets are then
normally distributed. QUASIMEME exercises generally have world-wide participation and
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therefore methodologies and standards may differ between countries which may give rise to
systematic differences in the datasets.
In an effort to overcome issues associated with non-normally distributed data, robust statistics
have been applied to data from PT schemes. Robust statistics are statistical methods which
perform well for data from a wide range of probability distributions, particularly nonnormally distributed datasets containing a small number of outliers. Extreme values are not
discarded as outliers with this approach and are down weighted to minimise the effect on the
entire dataset. This approach works well with datasets that have 7-10% of extreme values or
even highly skewed datasets but the robust means may be affected in datasets containing a
small number of values (< 10) or a larger proportion of extreme values [156]. This
breakdown in the robust model is caused by the group of down weighted values forming their
own cluster which influences the magnitude of both the robust mean and standard deviation.
Extreme values can generally be traced back to gross reporting errors by participants or the
use of incorrect units and these errors can generally be identified from the dataset or through
contact with the laboratory. Removing these extreme values adds a subjective element into
the evaluation which the robust model sought to avoid.

6.1.4 QUASIMEME’S COFINO MODEL FOR DATA ASSESSMENT
The data assessment carried out by QUASIMEME is based on ISO guide 13528 concerning
the proficiency testing of analytical chemistry laboratories [157] with some slight
modifications. The assigned value and z-scores are calculated using a model developed by
Cofino et al. [158] which was specifically designed for use in the determination of population
characteristics [159]. Robust statistics form the basis to the ISO13528 guide to data
assessment but this model can be limited where a high percentage of extreme values are
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submitted. The Cofino model is unique as it can be used directly with a whole range of
datasets including tailing or skewed data, datasets containing extreme outliers and bimodal or
multimodal distributions.
The model works by identifying clusters of data within a dataset exhibiting a high level of
agreement. From this the mean, standard deviation (s.d.) and percentage of data associated
with each cluster is calculated. A distinct advantage this model has over the standard robust
model is that no preparation of the dataset is necessary, either by using subjective boundaries
or outlier testing before entering it into the database for assessment.
The Cofino model uses the concept of wavefunctions from quantum mechanics and applies
them utilising the power of matrix algebra. The model uses probability density functions for
each observation weighting values centred around the mean more heavily than those further
away from the mean. The mean and variance estimators derived from this model are less
sensitive to asymmetric, tailing datasets. The detailed, graphical information provided by the
model can be seen in Figure 6-2 and the derivation of each is described in the QUASIMEME
handbook [159]. The graphical information includes:
-A plot of the population density functions (Figure 6-2a).
-Matrix overlap (Kilt) plot which is a colour density plot very sensitive to identifying the
structure of data, especially modality (Figure 6-2 b).
-A ranked overview of the means and standard deviations of each data set (Figure 6-2 c).
-Z-score plot for reviewing performance against targets (Figure 6-2 d).
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Figure 6-2: Data plots for the toxin dcSTX found in sample QST132BT in 2012. a) Summed probability density functions
(PDFs) for all data (black line) and for the first mode, PMF1, (blue line) with histogram of individual measurements in grey.
Each observation from a participant is described by a PDF and is not regarded as a value using the Cofino model. b) The
Kilt plot (Overlap matrix) showing degree of overlap of each pair of data. Areas of the map coloured white indicate
complete overlap (agreement) for the observations concerned while black indicates no overlap. c) Ranked overview of all
data with error bars of ± 2 s.d. d) Ranked z-score plot for all data.

6.2

MATERIALS AND METHODS

All materials were prepared by the author and designed to test the performance of
QUASIMEME participant methods with the analysis of a wide variety of analytes, whilst
minimising the number of samples to be tested. Materials incorporated a range of toxin
concentration levels and different complexities in toxin profile composition. The shellfish
tissues used were naturally contaminated with a range of different PSP toxins and prepared
following in-house procedures to ensure homogeneity. Stabilisation of the toxins and
matrices was achieved using a combination of heat treatment and the addition of antibiotics
and an antioxidant [60,113] with short-term stability and homogeneity studies performed on
all materials before distribution to participants [51].
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A total of eight materials have been used over the six exercises 2009-2014, with Tissues A &
C being incorporated into four rounds each, Tissues B & D used in three rounds, Tissue E
used in two rounds and Tissues F, G & H used in one round only. Table 6-2 lists each of the
materials and the rounds in which they were used, the assigned codes, predominant toxins
present, matrices studied and the homogeneity results determined. The coefficients of
variation were calculated from the homogeneity data in Table 6-2 and compared to expected
levels of method variability determined through validation of the test method, below which
the RM was deemed sufficiently homogenous.
The exercises are true proficiency tests, meaning no standardised method protocol was
provided by QUASIMEME and participants were requested to use the analytical method
routinely employed at their laboratories. The only stipulation in the protocol was the use of
the TEFs supplied and these were requested to be used in total toxicity calculations. In 2009
(R57) and 2010 (R61), the TEFs supplied in the protocol were those reported by Oshima
[17], while in 2011 (R65), 2012 (R69), 2013 (R72) and 2014 (R 2014-1) TEFs recommended
by EFSA [6] were prescribed in the protocol (Table 1-1).
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Table 6-2: List of materials used in each exercise, assigned codes, predominant toxins present, matrices studied and homogeneity results.
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The format of the data submitted by participants is dependent upon the method employed for
material testing. All participants are required to submit a total toxicity result for each sample,
enabling the assessment and comparison of all methodologies. Participants using either the
preCOX, PCOX or LC-MS/MS methods were able to submit concentration data for
individual analogues, thereby enabling the assessment of performance for each individual
toxin, or epimeric pair, in addition to total toxicity. This allows participants receiving less
than satisfactory z-scores to pinpoint potential causes of method failure or operator error, if
they relate to the determination of a particular analogue.

6.3

INTERCOMPARISON RESULTS

Up to 23 laboratories submitted data over the six exercises and Table 6-3 summarises these
results. The table contains assigned values for each determinand and/or total toxicity, the
number of observations or participant submissions for each determinand as well as betweenlaboratory CV (%) and percentage of participants receiving satisfactory z-scores. The
performance of laboratories was not assessed in cases where an assigned value could not be
calculated. In these cases an indicative value was generated and no z-scores were calculated.
Only materials where assigned values could be calculated are listed in Table 6-3. The criteria
set out in calculating an assigned value and z-scores are contained in the QUASIMEME
manual [159].
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Table 6-3: Summary data 2009-2014

N.B. Codes used in table. Assigned Value, Numbers of Observations / Coefficient of Variation % (CV%), % z-scores satisfactory (|z| < 2).
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Figure 6-3 and Figure 6-5 graphically represent z-scores generated over the last six exercises
with calculated upper and lower z-score limits for satisfactory (z ≤ |2|), questionable (z > |2| ≤
|3|) and unsatisfactory (z ≥ |3|) data.
A list of the methods used by participants since 2009, including references where possible, is
detailed in Table 6-4. It should be noted that participants 3 and 8 changed from using the
MBA as their method of analysis in R57 (2009) to using preCOX and PCOX methods
respectively, when they next participated in 2010 and 2011.

6.3.1 TISSUE A
This tissue was prepared at approximately half the EU regulatory limit, which is just above
the limit of detection for the MBA and was designed to test participants at a low
concentration level with a relatively simple toxin profile containing 3 predominant analogues.
From the data contained in Table 6-3, 14-22 labs submitted total toxicity results in the four
rounds this material has been used, R57, 61, 69 and 2014-1. Only total toxicity results were
submitted in R57, while in R61, 69 and 2014-1 toxin concentrations were also requested. The
assigned values for total toxicity showed some variability over the four rounds with
concentrations of 461, 400, 629 and 750 µg STX diHCl-eq./kg being assigned respectively.
This variability can mainly be attributed to changes made to the protocol which prescribed
the use of Oshima TEFs in R57 and 61 and the use of EFSA recommended TEFs in R69 and
2014-1. DcSTX is the predominant toxin present in this tissue so the increased TEF value
significantly affected total toxicity results submitted, which can be clearly seen from Figure
6-4. The precision of the participants, expressed by the between laboratory CV% has
exhibited variability over the four rounds with values of 34.7, 44.4, 18.3 and 32.5%
respectively.
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Figure 6-3: Distribution of participants’ z-scores for Tissues A-C used in various rounds from 2009-2014.
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Table 6-4: Overview of methods used from 2009-2014 with references where applicable.

Lab Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Codes:

2009
1
1
2
2
3
1
1
2
1
1
1
4
2
4
-

2010
1
1
2
3
1
1
4
1
1
1
2
1
4
4
1
4
-

Method Used
2011
2012
1
1
1
1
1
1
2
2
3
1
1
1
1
4
4
1
1
1
1
1
2
4
4
1
1
4
4
4
4
4
5
2
2
2
5
-

1. OMA AOAC 2005.06
2. OMA AOAC 959.08
3. Oshima (PCOX)
4. OMA AOAC 2011.02
5. ELISA (Ridascreen)
6. LC-MS-MS Internal method
7. DIN EN 14526
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2013
1
1
1
2
1
1
4
1
1
1
4
4
1
4
4
1
6
-

2014
1
1
1
2
4
1
1
4
1
4
4
1
4
1
6
6
1
6
1
7
1
1
2
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6.3.2 TISSUE B
This material was prepared at approximately 1.2 times the EU regulatory limit and had a
more complicated toxin profile than tissue A containing 9 predominant PSP analogues.
14-15 labs submitted total toxicity results for this material in R57, 61 and 69 with assigned
values in each round of 977, 950 and 986 µgSTXdiHCl-eq./kg respectively. The assigned
values for the three rounds were consistent, even with the change to the prescribed TEFs
made for R69. This is due to dcSTX being present in much lower quantities in this material
compared to Tissue A which therefore has a lower overall effect on the assigned value. The
improvement of participants over the three rounds was evident from the laboratory precision
values of 43.8, 36.0 and 31.7 CV% respectively.
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Figure 6-4: Assigned values determined in multiple rounds for Tissues A-E and in single rounds for Tissues F-H.

6.3.3 TISSUE C
This material was prepared at approximately 3 times the EU regulatory limit and although
only containing 4 predominant analogues it represented a significantly more challenging
toxin profile for participants using chemical based methods of analysis due to the presence of
dcNEO and other decarbamoyl toxins.
Up to 22 labs submitted total toxicity results for this material in R61, 65, 69 and 2014-1 with
assigned values of 1886, 2670, 2734 and 3045 µgSTXdiHCl-eq./kg respectively. The
increase in the assigned value from R61 to those calculated in R65, 69 and 2014-1 can, as in
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the case of Tissue A, be attributed to the change in TEF values prescribed in these later
rounds. The between lab %CVs over these four rounds were 45.4, 19.4, 19.0 and 22.1%
which showed significant improvements from this materials early use.
It is interesting to note that in R2014-1 (Table 6-3) the assigned values for dcGTX2 (11.20
µmol/kg) and dcGTX3 (3.07 µmol/kg), generated from PCOX users data produces a
significantly higher result if summed together (14.27 µmol/kg) when compared to the
assigned value for dcGTX2,3 together (10.20µmol/kg) which was generated from preCOX
users only. This along with the data for GTX2 and GTX3 (see Tissues D, E, G & H) suggest
that both LC-FLD methods are not comparable when determining these epimer pairs.
Previous studies carried out by the EU-RLMB to extend the validation of AOAC 2005.06 to
include dcGTX2,3 found low mean recoveries (53 – 59%) from spiked mussel and clam
tissues using this method [139]. A single laboratory validation to refine and extend the
preCOX AOAC 2005.06 method to include additional toxins also showed differences
between both LC-FLD methods in determining dcGTX2,3 [120]. This may explain some of
the differences found between the dcGTX2,3 results generated by both LC-FLD methods
above. An interlaboratory ring trial organised by CEFAS in 2011/2012 showed statistically
significant differences between both methods in determining GTX2,3 with results generated
by PCOX LC-FLD ~50% higher than those determined by preCOX LC-FLD [151]. This
study did not include the toxins dcGTX2,3.
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Figure 6-5: Distribution of participants’ z-scores for Tissues D-F used in various rounds from 2011-2014.
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6.3.4 TISSUE D
The material was prepared at approximately 1.5 times the EU regulatory limit and
represented a simple toxin profile for the participants, containing just STX and GTX2,3.
Up to 21 labs submitted total toxicity results for this material in R65, 72 and 2014-1 with
values of 1139, 1245 and 1289 µgSTXdiHCl-eq./kg assigned in each round respectively. The
improvement in laboratory precision was again evidenced by the decrease in between
laboratory CV% of 29.8, 10.6 and 16.6% observed over the three rounds.
As in the case of Tissue C the individual assigned values for GTX2 and GTX3 in 2013 and
2014 were significantly higher than those for GTX2,3 together submitted by preCOX users
only.

6.3.5 TISSUE E
This material was prepared at approximately 1.5 times the EU regulatory limit and again
represented a relatively simple toxin profile of only 4 predominant analogues (STX, dcSTX
and GTX2,3).
Up to 19 labs submitted total toxicity results for this material in R65 and 72 with assigned
values in each round of 1187 and 1246 µgSTXdiHCl-eq./kg respectively. Improvement in
laboratory performance was again evidenced in the CV% decreasing from 27.0% to 16.9%
over the two year period.
In 2013, where enough data was available to enable the generation of assigned values for
GTX2 and GTX3 separately, these results were significantly higher than the total GTX2,3
concentrations generated by preCOX users.
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6.3.6 TISSUES F, G & H
Tissues F and G were both prepared around the EU regulatory limit and Tissue H was
prepared at approximately twice this level. All three tissues contained 6 predominant
analogues (STX, dcSTX, GTX2,3, GTX4, NEO).
15 labs submitted data for Tissue F in R69, 17 labs submitted data for Tissue G in R72 and 22
labs submitted data for Tissue H in R2014-1. Values of 789, 742 and 1569 µgSTXdiHCleq./kg were assigned to each material respectively in the three rounds with between lab CV%
of 38.0, 18.6 and 15.3%.
As previously seen in Tissue E the assigned values for GTX2 & GTX3 in Tissues G & H
were significantly higher when summed together, than those determined as GTX2,3 together
from participants reporting preCOX data.

6.4

DISCUSSION

6.4.1 IDENTIFICATION OF POOR PERFORMANCE
The source or sources of poor performance in PT schemes can be difficult to pinpoint for
both the participant and organiser. While it is possible to see where an inappropriate method
has been used or the application of the method has not been carried out correctly, for example
ELISA determination of Tissues D and E significantly overestimating total toxicity (Figure
6-5), finding correlations between method choice and analytical performance is very difficult
even with the large amount of data submitted by participants over the last six years. This is
mainly due to the large number of variabilities potentially influencing PST analysis and
results, for example changes to staff and associated training, reagents used, slight variations
in the oxidation of toxins, and a range of other factors.
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The majority of extreme z-scores (z ≥|6|) achieved by participants can be traced back to either
gross calculation errors made during the conversion of concentration data into total sample
toxicities (in some cases 2-3 orders of magnitude difference) or the misidentification of
toxins present in chromatographic data. Adequate training of personnel, particularly new
employees, in-house validation of methods and a comprehensive review process prior to
submission of PT results is therefore of huge importance and would minimise, if not
eliminate these extreme results. Experienced laboratories can also suffer from variable
performance levels due to the recruitment of new staff requiring training or the
implementation of new methodologies and instrumentation.
While the causes of extreme z-scores are in general easier for participants to trace and
remedy, unsatisfactory z-scores (z >|3 |<|6|) are a lot more difficult to account for. New
participants to these schemes typically take two to three exercises before receiving
satisfactory z-scores, the exact causes of which are unknown but are most likely because of
their unfamiliarity with the submission process, reporting units requested, and analysing toxin
profiles atypical of the participant’s geographical location. This can be seen in Figure 6-3,
particularly for laboratories 1, 2 and 4 where initial unsatisfactory z-scores received in the
first round were improved in subsequent exercises. The opposite of this can also be the case
however (see laboratory 5 in Figure 6-3) therefore participants have to be continually vigilant
to ensure satisfactory performances are maintained.

6.4.2 FACTORS AFFECTING POOR PERFORMANCE
Previous PT schemes, ring trials and interlaboratory studies for PSP toxins have highlighted
issues related to each of the methods used [151,160–162]. The MBA is known to suffer from
recovery issues caused by “salt” effects [160] and the presence of some metals, particularly
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zinc can have a large suppressive effect on the bioassay [77] with underestimation of total
toxicity particularly in samples close to the EU regulatory limit. These observations could
explain some of the MBA results returned by participants in particular Tissues B-E where
results were consistently below the assigned value (24 of 27 in total) with some results ~60%
below the assigned value.
The choice of extraction method can also have a fundamental influence on results, with
previous studies showing that under boiling HCl conditions (MBA & PCOX methods),
partial hydrolysis of the N-sulfocarbamoyl toxins, GTX-5 and C-1,2 transformed them into
their carbamoyl counterparts, STX and GTX-2,3 respectively [162]. It was noted however
that the N-sulfocarbamoyl toxins were not present at concentrations high enough to
significantly contribute to the variability associated with the dataset.
Other factors which may cause poor performance could include but are not limited to the use
of inappropriate consumables, inter-batch performance of SPE cartridges or batch to batch
issues with chromatographic columns which may cause retention and matrix issues.

6.4.3 CRMS
The lack of certified reference materials (CRMs), both solvent and matrix for all the PSP
toxins is a problem consistently highlighted in the area, although a matrix CRM has recently
been produced by CEFAS [152]. This lack of CRMs, particularly for the toxins GTX6 and
C3,4, although not present in any QUASIMEME samples to date, has highlighted problems
in the PT schemes delivered by the EU Reference Laboratory for Marine Biotoxins (EURLMB) [163,164]. Participants using preCOX methods can perform a hydrolysis step converting
GTX6 into NEO and C3,4 into GTX1,4 which allows an indirect means of quantification for
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those toxins. Although the toxicity of GTX6 is relatively low it can still contribute
significantly to the overall toxicity of some samples [87].

6.4.4 MISIDENTIFICATION OF TOXINS
The misidentification of toxins, particularly dcNEO, has been an issue for some participants
and has been a source of poor performance in these exercises (see Tissue C in Figure 6-3).
The dcNEO misidentification was particularly highlighted in the analysis of Tissue C. Users
of PCOX methods of analysis identify this toxin as NEO due to the methods inability to
separate both toxins unless a very long run time is utilised (>60mins). This is an accepted
limitation of the PCOX method and presents no consumer risk in a real sample scenario
owing to the 10-fold difference in TEF values between the two toxins. It can potentially lead
to a significant over estimation of total toxicity owing to the differences in TEF however, and
for the most part resulted in participants receiving unsatisfactory or extreme z-scores. This
was not always the case however as some laboratories received satisfactory z-scores even
with dcNEO misidentified, (see Lab 8 & 15 in 2011, 2012 and 2014 for Tissue C, Figure
6-3). The analysis of dcNEO can also pose problems to preCOX participants as this toxin coelutes with dcSTX, requiring a back calculation in order to estimate toxicity. Only two
preCOX participants (Lab 11 & 14) have failed to correctly identify dcNEO as being present
in Tissue C. Lab 11 received an unsatisfactory z-score for this sample while Lab 14 received
a satisfactory z-score as they significantly overestimated the dcSTX content in the sample,
negating the fact that dcNEO was not quantified. In subsequent rounds Lab 11 correctly
identified dcNEO in this sample and received satisfactory z-scores. Lab 14 did not participate
in subsequent rounds. As no data is removed by QUASIMEME before assigned values and zscores are calculated, the onus is on participants to have a comprehensive review process of
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final reports and z-score results to ensure that correct identification of all toxins present in the
materials has been achieved.

6.4.5 RECOVERY CORRECTION FACTORS
The application of method recovery correction factors to results generated from preCOX
analysis is an important issue and has been high on the agenda of the EURL-MB Working
Group for PSP toxins over the last number of years. Only one QUASIMEME participant has
submitted both non-recovery corrected (Lab 10) and recovery corrected (Lab 26) results in
2013 and 2014 (Figure 6-3 & Figure 6-4), with none of the recovery corrected results
receiving satisfactory z-scores in either round. This observation is not surprising as the
assigned values (from which z-scores are calculated) generated for each tissue are calculated
from the group which is weighted more heavily by non-recovery correcting participants.
Applying recovery correction factors prior to submission of results would need to be
stipulated in future protocols in order to ensure all participants carry out this procedure.

6.4.6 METHOD DEPENDENCY AND INDIVIDUAL ANALOGUES
Finding correlations between proficiency test performance and method choice or between
performance and the presence of specific analogues in test samples is difficult. For instance
the plot of the population density functions in Figure 6-6 (left) clearly shows a bi-modal
distribution of the data in the determination of dcSTX in sample QST132BT with the smaller
mode PMF2 (circled red) resulting from PCOX users (3 Labs). The main mode of data
(PMF1) was shown to arise from the remaining preCOX users, although one PCOX
participant is also contained in this main mode of data. Another sample, QST133BT used in
the same round also showed a bimodal distribution in the determination of dcSTX (data not
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shown). It might be easy to deduce from this and the Kilt plot (Figure 6-6 right) that there is a
method dependency issue between both LC-FLD methods relating to the analysis of dcSTX.
This trend however, is not consistent, as the analysis of the same two samples in 2009 and
2010 showed no bi-modality for this toxin with the entire data set fitting a Gaussian
distribution and results from PCOX users randomly spread throughout the entire series.
Furthermore other samples used in these exercises that contained dcSTX showed no bimodality in their distributions.
ELISA results showed variable performance levels with the only analysis of Tissue C (Lab
24, Figure 6-3) by this method producing a satisfactory z-score, whereas ELISA analysis
carried out on Tissues D and E (Lab 21 & 24, Figure 6-5) produced all extreme z-scores (>6).
Tissues D and E contain the toxins GTX2,3 and STX, with Tissue E also containing dcSTX.
This profile is relatively simple and would represent a fairly standard North European profile
so the ELISA results if not pertaining to analyst or submission errors should be further
investigated.
Although LC-MS/MS has not been used extensively in PSP PT schemes to date, results
generated by this method are encouraging with only one unsatisfactory result submitted to
date with most receiving satisfactory z-scores. LC-MS/MS participants have also
demonstrated the applicability of their methods to cover a variety of different toxin profiles
with satisfactory results received from a range of different samples [165].
Although we have attempted to look for correlations between method choice and
performance, no obvious or consistent patterns could be discerned from any of the PSP PT
rounds completed to date.
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Figure 6-6: Graphical output from the Cofino model with population measurement function (left) and kilt plot (right)
showing two modes of data in the analysis of dcSTX in 2012.

6.4.7 PERFORMANCE IMPROVEMENTS
Overall, the development of this exercise and the performance of participating laboratories
have improved since its inception in 2009. The numbers of participants has increased each
year (apart from 2012) which highlights the strengthening of the exercise and its economic
sustainability going forward. The performance of laboratories has mostly improved and this
is clearly evidenced from Figure 6-7 which displays the averages of both the coefficient of
variation for all samples in each round and the percentage of participants receiving
satisfactory z-scores. The percentage of participants receiving satisfactory z-scores has
increased most years as laboratories gain experience in these exercises and in determining
potentially atypical toxin profiles. The precision of the laboratories as expressed by the
coefficient of variation has also showed signs of significant improvement from the early
exercises in 2009 and 2010. The coefficients of variations are also comparable to other more
established shellfish biotoxin exercises organised by QUASIMEME, such as exercise BT-11
for lipophilic marine biotoxins. Datasets in 2014 for BT-11 produced %CVs in the range 20 38%, which equated to between 45 – 80% of participants receiving satisfactory z-scores. In
the same year, the PSP development exercise generated %CVs in the range 15 – 33% with 55
-71% of participants receiving satisfactory z-scores. Through adding PSP toxins to their
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scope, QUASIMEME have established a comprehensive PT scheme for all EU regulated
shellfish biotoxins.

Figure 6-7: Improvements made over the duration of the PSP development exercise 2009-2014 with trend lines showing the
average decrease in %CVs observed and the increase in the percentage of participants receiving satisfactory z-scores..

6.4.8 SUMMARY RESULTS FOR INDIVIDUAL TOXINS
The graphs contained in Figure 6-8 present the data generated for the toxins STX, dcSTX and
GTX2,3 and represent all results supplied for these toxins by participants. In R57, 2009,
participants were requested to only submit total toxicity results so no concentrations of these
analogues were available. The concentrations submitted by participants were normalised to
the assigned value in that particular round such that all results could be presented in one
figure.
Results for all determinants, where an assigned value was calculated, were normalised in this
way and the data was further assessed as follows. The normalised data was divided into those
participants using preCOX or PCOX methods of analysis and some non-valid data was
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removed where participants made gross reporting errors in calculating concentration or
during submission. To minimise the influence of extreme results in this further statistical
evaluation, outliers were identified and removed prior to assessment (note that non-valid or
extreme results are not removed in the general QUASIMEME assessment as the Cofino
model is specifically designed to cope with these scenarios). The identification of outliers
was carried out by applying a Dixon’s test (α = 0.05), with a maximum of one result removed
from each data set.
In the case of the epimers, GTX2 & 3, PCOX participants submitted results for each
individual analogue, while preCOX participants, where epimeric separation is not possible,
submitted a result for the sum of the epimeric pair only. To compare the two methods, it was
therefore necessary to sum the individual analogue concentrations from PCOX participants
and normalise this concentration to the assigned value for the combined pair of epimers,
generated from preCOX participant results only.
Comparison of both methods was only carried out on the toxins dcSTX, STX and GTX2,3 as
there was insufficient data submitted by participants for other toxins present in the samples.
After the removal of non-valid data and outliers, the normalised mean and standard
deviations were calculated for each method and all determinants. A paired t-test (two tailed,
α=0.05) was then performed on the data to observe if there was a statistical difference
between the two LC-FLD methods in determining the concentrations of those toxins.
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Figure 6-8: Summary data of all determinations for STX, dcSTX and GTX2,3 normalised to the assigned values in each round.
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The results of the paired t-test showed there to be a statistical difference between both data
sets in the case of dcSTX and GTX2,3 but not for STX. The statistical differences observed
could be partially explained through the extraction techniques of both methods. As discussed
earlier, partial hydrolysis of the N-sulfocarbamoyl toxins to their carbamoyl counterparts may
explain the higher mean values observed from PCOX participants for the toxins GTX2,3,
although C1,2 were not present in very high concentrations. If however, hydrolysis of the Nsulfocarbamoyl toxins statistically differentiates both methods for GTX2,3 determination
then these differences would be expected for STX as well. Hydrolysis of GTX5 to STX
would also be expected to take place, and although GTX5 was not present in high levels in
these tissues, it was present at similar levels to the C-toxins.
Another major difference between the PCOX and preCOX extraction methods is the cleanup
method employed. Samples extracted by the preCOX method are subjected to a minimum of
SPE cleanup using C18 cartridges and depending on the toxin profile present may also require
further SPE cleanup with carboxylic acid cartridges. This cleanup step is not carried out in
the PCOX extraction method, where samples, after initial extraction, follow a
deproteinisation step using trichloro-acetic acid and centrifugation. The application of the
SPE cleanup steps in the preCOX method would, unless recovery factors are determined and
applied, underestimate results generated using this method, owing to losses during the
process. Differences between both of these methods have also been highlighted in results
from previous studies by Turner et al. [151] and in PT schemes operated by the EU-RLMB
[163,164,166].

6.5

CONCLUSIONS

Six development exercises for PSTs have been delivered since 2009 by QUASIMEME, with
global participation from laboratories using a range of different methods of analysis based on
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LC-FLD, LC-MS/MS, animal toxicity and immuno-based assays. Whilst no specific and
consistent method dependency issues could be detected from the datasets, factors affecting
poor performance were highlighted with suggestions made on how improvements could be
made. Data is continually monitored by QUASIMEME through their Scientific Advisory
Board (SAB) to determine issues contributing to poor performance and any method related
issues. Personalised feedback to participants, particularly those with unsatisfactory
performances is not carried out by QUASIMEME owing to the large scope of determinants
within their remit and the practicalities of extensively reviewing so many datasets.
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CONCLUSIONS AND FURTHER WORK
7.1

CONCLUSIONS

The research detailed in this thesis describes investigations of various RM preparation
techniques evaluated for their stabilising effects on PSTs and their applications in various
internal and external QA/QC programmes.
The research began similarly to any planned RM preparation, by sourcing materials
contaminated with PSTs necessary to complete the studies. Shortly after the commencement
of these studies a large PSP event took place in Iceland. Large quantities of contaminated
materials were harvested and used in the RM experiments but samples were also taken
throughout the toxic period and analysed at the MI using various methods. As PSTs had not
been previously reported from Icelandic waters the data was compiled, including
phytoplankton data, and presented as a first report (Chapter 3). Shellfish tissues were also
sourced from other MI collaborators which provided samples of various shellfish species
containing an assortment of toxin profiles. Once adequate quantities of tissues had been
sourced, various stabilisation techniques were evaluated to observe their effects on PST and
matrix stability.
Freeze drying proved to be the most effective technique investigated, with the greatest level
of PST stability demonstrated in materials prepared in this way (Chapter 5). Freeze drying
had not previously been carried out within MI facilities so it was necessary to initially carry
out a feasibility study on the technique to evaluate MI capabilities as well as confirming the
stability advantages of the technique. Once the feasibility of carrying out this technique at the
MI was demonstrated, all associated processing and dispensing steps were optimised. This
was carried out through a series of experiments aimed firstly at gaining experience in
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preparing materials in this way and secondly to confirm the equipment at the MI was suitable
to prepare materials at MCs close to ~5%. Further experiments, using the optimised
conditions, were then conducted, specifically to investigate issues arising from the feasibility
study which related to toxin biotransformations and epimerization. Through sterilization of
the source tissues prior to freeze drying these reactions were minimised. A final, relatively
large scale material (>1000 aliquots), was then prepared using all the experimentally
determined conditions to produce a material as a candidate CRM in collaboration with
CEFAS. This material is awaiting certification and characterisation studies due to funding
issues and the current availability of another PST CRM from CEFAS.
The use of preserving additives, both separately and combined were also evaluated for their
stabilisation effects and both were proven to be effective in RM preparation for various PSTs,
specifically GTX1,4 (Chapter 4). The heat treatment of tissues was also evaluated in parallel
with the additives study and this technique provided excellent matrix and toxin stability for
the remaining PSTs investigated in that section, namely dcSTX, STX, GTX5 and GTX2,3.
The results from this study indicated that combining both techniques would produce a
material with excellent stability for all the toxins studied. Materials were prepared in this way
and used internally at the MI in the routine QC/QA of the NMP for PSP toxins and in a
development exercise for international PT schemes operated by QUASIMEME and
VEREFIN. The short-term stability, demonstrated sufficiently in these materials, was an
important prerequisite for these PT materials.
The novel application of HPP in RM preparation was also investigated for the stabilising
effects this technique provided (Chapter 4). The technique provided excellent matrix and
toxin stability and was the only other technique, other than freeze drying, which could be
considered for a feasibility study into CRM production. The HPP equipment used in this
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section is expensive although it is available as a commercial service to paying customers.
This may limit its’ applicability in LRM or ILRM preparation as other techniques such as
thermal treatment or the use of preserving additives provide more cost effective stabilisation
techniques.
The final part of this research concerned a specific application of materials prepared through
thermal treatment and spiking with preserving additives. The first commercially available
PST PT scheme was operated by QUASIMEME using materials prepared using these
techniques and results from these exercises were presented (Chapter 6). Participants used a
range of different methodologies from animal based assays to instrument based methods of
analysis. Participants’ results were evaluated specifically to determine if trends existed in the
datasets and if they related to specific methods or analogues being determined. Results
suggested many factors influence participant performance and therefore z-scores so specific
method or analogue dependency issues could not be definitively determined.
The studies contained in this thesis provided PST RM preparation techniques for multiple
uses in LRM, ILRM and potential CRM production. Materials were used in the daily QC/QA
of produce from Irish shellfish farmers and provided an excellent material for method
development and validation studies. These studies were crucial in the movement away from
the use of animal based assays to instrumental based methods of analysis in Ireland. The use
of preserving additives or thermal treatment provides an extremely cost effective means for
PST RM preparation and should be within the capacity of most monitoring or research
laboratories.
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7.2

FURTHER WORK

The research contained in this thesis focused on tools that can be used in statutory monitoring
of PSP toxins in shellfish. The research sought to gain further understanding on the
mechanisms of PST degradation, epimerization or biotransformations taking place in
shellfish tissue matrices and to highlight the advantages of each technique for various RM
uses. One use for these materials is in PT development exercises and participant data was
evaluated over a 6 year period from schemes operated by QUASIMEME.
The findings from this research have raised some questions and have highlighted some areas
that warrant further investigation such as the following.


The continued monitoring of Icelandic shellfish for marine biotoxins including
causative organisms in water samples. This is in order to produce a thorough risk
assessment for the occurrence of not only PSP toxins but other toxin groups present in
Icelandic waters. Data on the timing and intensity of these algal blooms will provide a
more comprehensive picture on toxin accumulation in Icelandic shellfish which will
aid in setting up an Icelandic monitoring programme.



HPP treatment of different tissue matrices, particularly mussel, could be investigated
to observe if the same level of stability as seen in oysters tissues is evident.



The certification studies should be carried out on the large scale freeze dried material
prepared at the end of Chapter 5. The stability and homogeneity of this material could
be determined after which the material could be made commercially available. The
certification, if not carried out using a multi method approach, could be achieved
through an interlaboratory exercise (consensus of expert laboratories).



Expand the QUASIMEME PSP exercise to include more shellfish species and toxin
profiles in the programme. This will specifically involve sourcing various species

270

Chapter 7
from third party suppliers or alternatively, shellfish could be fed with various species
of phytoplankton to produce the different profiles required. The inclusion of toxins
not covered so far in these exercises such as those predominating in shellfish from the
South of Europe for example GTX6 and C3,4 should also be considered. The
inclusion of these toxins could be problematic however as there are currently no
CRMs available.
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